Title
stringlengths 1
395
⌀ | abstractText
stringlengths 57
5.98k
| meshMajor
stringlengths 14
1.03k
| pmid
int64 22
33.2M
| meshid
stringlengths 2
3.14k
| meshroot
stringlengths 2
421
| A
int64 0
1
| B
int64 0
1
| C
int64 0
1
| D
int64 0
1
| E
int64 0
1
| F
int64 0
1
| G
int64 0
1
| H
int64 0
1
| I
int64 0
1
| J
int64 0
1
| L
int64 0
1
| M
int64 0
1
| N
int64 0
1
| Z
int64 0
1
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ghrelin levels in children with constitutional delay of growth and puberty.
|
OBJECTIVE: In this study, we aimed to show the role of ghrelin in growth delay in children with constitutional delay of growth and puberty (CDGP).METHODS: Thirty male children with CDGP constituted the study group and fifteen healthy children with normal growth of similar ages-the control group. In both groups, fasting and postprandial plasma ghrelin levels, serum insulin-like growth factor-1 (IGF-1) and IGF-binding protein-3 (IGFBP-3) levels were determined.RESULTS: There were no differences in fasting and postprandial ghrelin levels (824.23±523.46 pg/mL and 447.26±259.92 pg/mL, respectively) in children with CDGP compared to the levels in the control group (687.38±481.43 pg/mL and 365.59±260.43 pg/mL, respectively; p>0.05). Differences in fasting and postprandial ghrelin levels were also similar in the two groups (394.44±369.10 pg/mL and 346.55±338.67 pg/mL, respectively; p>0.05). Serum IGF-1 levels were significantly depressed in children with CDGP compared to those in the control group (239.5±83.95 ng/mL and 339.20±63.08 ng/mL, respectively; p<0.05).CONCLUSION: Decreased appetite and feeding problems in children with CDGP were not related to depressed ghrelin levels. In addition, ghrelin levels did not increase to compensate for the decreased appetite and feeding problems in CDGP.
|
['Adolescent', 'Age Determination by Skeleton', 'Body Height', 'Body Mass Index', 'Body Weight', 'Child', 'Dietary Proteins', 'Energy Intake', 'Enzyme-Linked Immunosorbent Assay', 'Fasting', 'Ghrelin', 'Growth Disorders', 'Humans', 'Insulin-Like Growth Factor Binding Protein 3', 'Insulin-Like Growth Factor I', 'Male', 'Postprandial Period', 'Puberty, Delayed', 'Turkey']
| 21,274,325
|
[['M01.060.057'], ['E01.370.049', 'E01.370.350.700.050'], ['E01.370.600.115.100.160.100', 'E05.041.124.160.500', 'G07.100.100.160.100', 'G07.345.249.314.100'], ['E01.370.600.115.100.125', 'E05.041.124.125', 'G07.100.100.125', 'N06.850.505.200.100.175'], ['C23.888.144', 'E01.370.600.115.100.160.120', 'E05.041.124.160.750', 'G07.100.100.160.120', 'G07.345.249.314.120'], ['M01.060.406'], ['D12.776.256', 'G07.203.300.428', 'J02.500.428'], ['G07.203.650.240.340'], ['E05.478.566.350.170', 'E05.478.566.380.360', 'E05.478.583.400.170', 'E05.601.470.350.170', 'E05.601.470.380.360'], ['F01.145.407.400', 'G07.203.650.240.587', 'G07.203.650.353.400'], ['D06.472.699.301', 'D12.644.548.322'], ['C23.550.393'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['D12.776.157.420.270'], ['D12.644.276.937.400', 'D12.776.124.862.400', 'D12.776.467.937.400', 'D23.529.937.400'], ['G10.261.700'], ['C19.391.690'], ['Z01.252.245.500.850']]
|
['Named Groups [M]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Phenomena and Processes [G]', 'Health Care [N]', 'Diseases [C]', 'Chemicals and Drugs [D]', 'Technology, Industry, and Agriculture [J]', 'Psychiatry and Psychology [F]', 'Organisms [B]', 'Geographicals [Z]']
| 0
| 1
| 1
| 1
| 1
| 1
| 1
| 0
| 0
| 1
| 0
| 1
| 1
| 1
|
A selective peroxisome proliferator-activated receptor alpha agonist, CP-900691, improves plasma lipids, lipoproteins, and glycemic control in diabetic monkeys.
|
Peroxisome proliferator-activated receptors (PPARs) are involved in the regulation of lipid and glucose metabolism. PPARgamma agonists improve insulin sensitivity and hyperglycemia and are effective in treating type 2 diabetes mellitus (T2DM), whereas PPARalpha agonists are used to treat dyslipidemia and atherosclerosis. The goal here was to examine the efficacy of a selective PPARalpha agonist {(S)-3-[3-(1-carboxy-1-methyl-ethoxy)-phenyl]-piperidine-1-carboxylic acid 4-trifluoromethyl-benzyl ester; CP-900691} on lipid, glycemic, and inflammation indices in 14 cynomolgus monkeys with spontaneous T2DM maintained on daily insulin therapy. Monkeys were dosed orally with either vehicle (n = 7) or CP-900691 (3 mg/kg, n = 7) daily for 6 weeks. CP-900691 treatment increased plasma high-density lipoprotein cholesterol (HDLC) (33 +/- 3 to 60 +/- 4 mg/dL, p < 0.001) and apolipoprotein A1 (96 +/- 5 to 157 +/- 5 mg/dL, p < 0.001), reduced plasma triglycerides (547 +/- 102 to 356 +/- 90 mg/dL, p < 0.01), and apolipoprotein B (62 +/- 3 to 45 +/- 3 mg/dL, p < 0.01), improved the lipoprotein index (HDL to non-HDLC ratio; 0.28 +/- 0.06 to 0.79 +/- 0.16, p < 0.001), decreased body weight (p < 0.01) and C-reactive protein (CRP) (1700 +/- 382 to 304 +/- 102 ng/ml, p < 0.01), and increased adiponectin (1697 +/- 542 to 4242 +/- 1070 ng/ml, p < 0.001) compared with baseline. CP-900691 treatment reduced exogenous insulin requirements by approximately 25% (p < 0.04) while lowering plasma fructosamine from 2.87 +/- 0.09 to 2.22 +/- 0.17 mM (p < 0.05), indicative of improved glycemic control. There were no changes in any of the aforementioned parameters in the vehicle group. Because low HDLC and high triglycerides are well established risk factors for cardiovascular disease, the marked improvements in these parameters, and in glycemic control, body weight, and CRP, suggest that CP-900691 may be of benefit in diabetic and obese or hyperlipidemic populations.
|
['Adiponectin', 'Animals', 'Area Under Curve', 'Blood Glucose', 'C-Reactive Protein', 'Diabetes Mellitus, Type 2', 'Dose-Response Relationship, Drug', 'Glucose Tolerance Test', 'Hypoglycemic Agents', 'Hypolipidemic Agents', 'Insulin Resistance', 'Lipids', 'Lipoproteins', 'Macaca fascicularis', 'PPAR alpha', 'Piperidines', 'Propionates', 'Weight Loss']
| 20,190,014
|
[['D06.472.699.042.249', 'D12.644.276.024.249', 'D12.644.548.011.249', 'D12.776.467.024.249', 'D23.529.024.249'], ['B01.050'], ['E05.318.740.200', 'G03.787.101', 'G07.690.725.064', 'N06.850.520.830.200'], ['D09.947.875.359.448.500'], ['D12.776.034.145', 'D12.776.124.050.120', 'D12.776.124.486.157'], ['C18.452.394.750.149', 'C19.246.300'], ['G07.690.773.875', 'G07.690.936.500'], ['E01.370.225.124.100.355', 'E01.370.374.355', 'E05.200.124.100.355'], ['D27.505.696.422'], ['D27.505.519.186.071', 'D27.505.954.557.500'], ['C18.452.394.968.500', 'G07.690.773.984.617'], ['D10'], ['D10.532', 'D12.776.521'], ['B01.050.150.900.649.313.988.400.112.199.120.510.520'], ['D12.776.826.239.500'], ['D03.383.621'], ['D02.241.081.751', 'D10.251.400.706'], ['C23.888.144.243.963', 'G07.345.249.314.120.200.963']]
|
['Chemicals and Drugs [D]', 'Organisms [B]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Phenomena and Processes [G]', 'Health Care [N]', 'Diseases [C]']
| 0
| 1
| 1
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 0
| 1
| 0
|
Clinical features and treatment outcomes of vancomycin-intermediate Staphylococcus aureus (VISA) and heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) in a tertiary care institution in Singapore.
|
This retrospective case-control study was undertaken to review the clinical features associated with heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) and vancomycin-intermediate S. aureus (VISA) infections and the local impact they have on clinical outcome. Compared with vancomycin-susceptible S. aureus (n = 30), hVISA and VISA infections (n = 10) are found to be associated with a longer period of prior glycopeptide use (P = 0.01), bone/joint (P < 0.01) and prosthetic infections (P = 0.04), as well as treatment failure, as evidenced by longer bacteremic (P < 0.01) and culture positivity (P < 0.01) periods. This was observed to have resulted in longer hospital length of stay (P < 0.01) and total antibiotic therapy duration (P = 0.01). There was, however, no significant difference in the overall patient mortality or the hospitalization cost (P = 0.12) in both groups. Clinicians should be cognizant of the association between hVISA/VISA with high bacterial load deep-seated infections. We recommend targeted and even universal screening for hVISA/VISA in methicillin-resistant S. aureus (MRSA) infections.
|
['Adult', 'Aged', 'Anti-Bacterial Agents', 'Case-Control Studies', 'Female', 'Health Care Costs', 'Hospitals', 'Humans', 'Length of Stay', 'Male', 'Middle Aged', 'Retrospective Studies', 'Singapore', 'Staphylococcal Infections', 'Staphylococcus aureus', 'Treatment Failure', 'Treatment Outcome', 'Vancomycin Resistance']
| 19,387,707
|
[['M01.060.116'], ['M01.060.116.100'], ['D27.505.954.122.085'], ['E05.318.372.500.500', 'N05.715.360.330.500.500', 'N06.850.520.450.500.500'], ['N03.219.151.400', 'N05.300.375'], ['N02.278.421'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['E02.760.400.480', 'N02.421.585.400.480'], ['M01.060.116.630'], ['E05.318.372.500.500.500', 'E05.318.372.500.750.750', 'N05.715.360.330.500.500.500', 'N05.715.360.330.500.750.825', 'N06.850.520.450.500.500.500', 'N06.850.520.450.500.750.825'], ['Z01.252.145.774'], ['C01.150.252.410.868'], ['B03.300.390.400.800.750.100', 'B03.353.500.750.750.100', 'B03.510.100.750.750.100', 'B03.510.400.790.750.100'], ['E01.789.800.760', 'N04.761.559.590.800.760', 'N05.715.360.575.575.800.760'], ['E01.789.800', 'N04.761.559.590.800', 'N05.715.360.575.575.800'], ['G06.099.225.984', 'G06.225.347.984', 'G07.690.773.984.269.347.984']]
|
['Named Groups [M]', 'Chemicals and Drugs [D]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Health Care [N]', 'Organisms [B]', 'Geographicals [Z]', 'Diseases [C]', 'Phenomena and Processes [G]']
| 0
| 1
| 1
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 1
| 1
| 1
|
Humoral hyporesponsiveness to a conjugate contraceptive vaccine and its bypass by diverse carriers using permissible adjuvant.
|
A contraceptive vaccine directed against human chorionic gonadotropin (hCG) has previously undergone clinical testing that demonstrated the feasibility of the approach in preventing pregnancy in women. Some immunized volunteers however, did not respond with an adequate anti-hCG antibody response despite employing highly immunogenic bacterial toxoids as carriers. Since there is some evidence that T cell responses to a complex protein typically focus on a few immunodominant epitopes, we investigated the responsiveness to hCG in mice of different haplotypes using the protein carrier diphtheria toxoid (DT). Our data showed a differential carrier effect of DT. With the aim of making a more potent immunogen employing promiscuous pathogen-derived Th peptides as carriers, peptide:antigen stoichiometric ratios were optimized. When tested individually using alum as the adjuvant, three such peptide conjugates improved the anti-hCG response, though not consistently to levels higher than the DT conjugate. Immunization with a combination of these synthetic epitopes generated anti-hCG responses higher than those achieved with DT or with the individual peptides. Antibodies were of high affinity and capable of neutralizing the bioactivity of hCG, but were devoid of anti-peptide reactivity. These results support our view that differential hyporesponsiveness in a diverse population may arise from inadequate carrier effect and that it can be overcome by use of pathogen-derived broadly reactive non-B Th epitopes employing only alum, a permissible adjuvant.
|
['Adjuvants, Immunologic', 'Amino Acid Sequence', 'Animals', 'Antibody Formation', 'Antigens, Bacterial', 'Cell Division', 'Chorionic Gonadotropin', 'Contraceptive Agents, Female', 'Diphtheria Toxoid', 'Female', 'Humans', 'Lipoproteins', 'Mice', 'Mice, Inbred BALB C', 'Mice, Inbred C57BL', 'Mice, Inbred CBA', 'Molecular Sequence Data', 'Peptides', 'Protozoan Proteins', 'Respiratory Syncytial Viruses', 'T-Lymphocytes', 'Vaccines, Conjugate', 'Viral Proteins']
| 11,012,625
|
[['D27.505.696.477.067'], ['G02.111.570.060', 'L01.453.245.667.060'], ['B01.050'], ['G12.450.050.370.250'], ['D23.050.161'], ['G04.144.220', 'G04.161.750.500', 'G05.113', 'G07.345.249.410.750.500'], ['D06.472.699.322.326', 'D06.472.699.649.367', 'D12.644.548.726.367', 'D12.776.780.400'], ['D27.505.696.875.360.276', 'D27.505.954.705.360.276'], ['D20.215.894.691.263'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['D10.532', 'D12.776.521'], ['B01.050.150.900.649.313.992.635.505.500'], ['B01.050.050.199.520.520.338', 'B01.050.150.900.649.313.992.635.505.500.400.338'], ['B01.050.050.199.520.520.420', 'B01.050.150.900.649.313.992.635.505.500.400.420'], ['B01.050.050.199.520.520.440', 'B01.050.150.900.649.313.992.635.505.500.400.440'], ['L01.453.245.667'], ['D12.644'], ['D12.776.820'], ['B04.820.480.937.600.670.600.750'], ['A11.118.637.555.567.569', 'A15.145.229.637.555.567.569', 'A15.382.490.555.567.569'], ['D20.215.894.865.900', 'D23.050.865.900'], ['D12.776.964']]
|
['Chemicals and Drugs [D]', 'Phenomena and Processes [G]', 'Information Science [L]', 'Organisms [B]', 'Anatomy [A]']
| 1
| 1
| 0
| 1
| 0
| 0
| 1
| 0
| 0
| 0
| 1
| 0
| 0
| 0
|
Trends in blood pressure control in hypertensive patients with diabetes mellitus in Japan.
|
Hypertension is often accompanied by type 2 diabetes mellitus. Recently, the American Diabetes Association (ADA) published guidelines on the treatment of hypertension in adult patients with diabetes mellitus. However, the views of general physicians on how to control blood pressure (BP) in diabetic patients and the impact of the ADA guidelines in Japan are still not known. We conducted an internet survey in May 2002: Questionnaires were e-mailed to a total of 3,616 medical doctors, of whom 441 (12.2%) properly responded. About half of the respondents (48.3%) had already read the ADA guidelines. Before being given an outline of the guidelines, the respondents' average BP level for starting medication was 152/94 mmHg, and the BP goal 133/83 mmHg; after reading the outline, these values were 149/92 and 132/82 mmHg, respectively. The goal BP decreased more after reading the guidelines in doctors who had not previously read the ADA guidelines than in those who had already read. After being given an outline of the ADA guidelines, 40.3% of respondents reported that they would select, as a first-line agent, an angiotensin II receptor antagonist (ARB), 35.6% an angiotensin-converting enzyme inhibitor (ACEI), and 18.6% a calcium channel blocker (CCB); as a second-line medication, 39.7% of the respondents would select a CCB. Seventy percent of doctors reported having at least one patient receiving CCB monotherapy; after reading the guidelines, 41.5% of these doctors said they would continue CCB monotherapy, 36.6% said they would add an ACEI or ARB, and 29.7% planned to change to an ACEI or ARB. In conclusion, our data suggest the impact of the ADA guidelines on the target BP and the first choice of antihypertensive medication in diabetic patients. ARBs and ACEIs became first-line medications, and CCBs became second-line medications to achieve the BP goal and prevent organ damage.
|
['Adult', 'Angiotensin Receptor Antagonists', 'Angiotensin-Converting Enzyme Inhibitors', 'Antihypertensive Agents', 'Calcium Channel Blockers', 'Diabetes Mellitus, Type 2', 'Female', 'Guideline Adherence', 'Humans', 'Hypertension', 'Japan', 'Male', 'Middle Aged', 'Practice Guidelines as Topic', 'Surveys and Questionnaires']
| 14,620,927
|
[['M01.060.116'], ['D27.505.519.162'], ['D27.505.519.389.745.085'], ['D27.505.954.411.162'], ['D27.505.519.562.249', 'D27.505.696.260.500', 'D27.505.954.411.192'], ['C18.452.394.750.149', 'C19.246.300'], ['N04.761.337', 'N05.715.360.395'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['C14.907.489'], ['Z01.252.474.463', 'Z01.639.595'], ['M01.060.116.630'], ['N04.761.700.350.650', 'N05.700.350.650'], ['E05.318.308.980', 'N05.715.360.300.800', 'N06.850.520.308.980']]
|
['Named Groups [M]', 'Chemicals and Drugs [D]', 'Diseases [C]', 'Health Care [N]', 'Organisms [B]', 'Geographicals [Z]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]']
| 0
| 1
| 1
| 1
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 1
| 1
| 1
|
Two evolutionary histories in the genome of rice: the roles of domestication genes.
|
Genealogical patterns in different genomic regions may be different due to the joint influence of gene flow and selection. The existence of two subspecies of cultivated rice provides a unique opportunity for analyzing these effects during domestication. We chose 66 accessions from the three rice taxa (about 22 each from Oryza sativa indica, O. sativa japonica, and O. rufipogon) for whole-genome sequencing. In the search for the signature of selection, we focus on low diversity regions (LDRs) shared by both cultivars. We found that the genealogical histories of these overlapping LDRs are distinct from the genomic background. While indica and japonica genomes generally appear to be of independent origin, many overlapping LDRs may have originated only once, as a result of selection and subsequent introgression. Interestingly, many such LDRs contain only one candidate gene of rice domestication, and several known domestication genes have indeed been "rediscovered" by this approach. In summary, we identified 13 additional candidate genes of domestication.
|
['Crops, Agricultural', 'Evolution, Molecular', 'Gene Flow', 'Genetic Variation', 'Genome, Plant', 'Oryza']
| 21,695,282
|
[['B01.650.160', 'G07.203.300.300', 'J02.500.300'], ['G05.045.250', 'G16.075.250'], ['G05.330.159'], ['G05.365'], ['G05.360.340.365'], ['B01.650.940.800.575.912.250.822.616']]
|
['Organisms [B]', 'Phenomena and Processes [G]', 'Technology, Industry, and Agriculture [J]']
| 0
| 1
| 0
| 0
| 0
| 0
| 1
| 0
| 0
| 1
| 0
| 0
| 0
| 0
|
In vitro dual perfusion of human placental lobules as a flow phantom to investigate the relationship between fetoplacental flow and quantitative 3D power doppler angiography.
|
Flow phantoms have been used to investigate and quantify three-dimensional power Doppler data but this is the first study to use the in vitro, dual perfused, placental perfusion model. We used this model to investigate and quantify the effect of variation in fetal-side flow rates and attenuation on 3D power Doppler angiography. Perfusion of a placental lobule was commenced within 30 min of delivery and experimentation was successful in 8 of the 18 placenta obtained. Fetal and maternal perfusate was modified Earle's bicarbonate buffer which, following equilibration, was supplemented on the fetal side with whole heparinised cord blood. Imaging was performed with a Voluson-i ultrasound machine. A 'vascular biopsy' the thickness of the placental lobule was defined and signal quantified within using VOCAL (GE Medical Systems, Zipf, Austria). Three vascular indices are generated: vascularisation index (VI) defined as the percentage of power Doppler data within a volume of interest; flow index (FI), the mean signal intensity of the power Doppler information; and vascularisation flow index (VFI), a combination of both factors derived through their multiplication. Attenuation was investigated in this model with the addition of tissue mimic blocks. Our results showed a predictable relationship between flow rates and the vascular indices VI and VFI. However the FI was a less reliable predictor of flow; thus it should be interpreted with caution. The power Doppler signal was markedly affected by attenuation leading to a complete loss of information at a depth of 6 cm in the model used. In conclusion this model can be adapted to provide a phantom to analyse and quantify 3D power Doppler signals and demonstrates that vascular indices within a tissue remain related to volume flow. This model provides further evidence that depth dependent attenuation of signal needs to be accounted for in any in vivo work where the probe is not in direct contact with the tissue of interest.
|
['Adult', 'Female', 'Fetus', 'Humans', 'Image Interpretation, Computer-Assisted', 'Maternal-Fetal Exchange', 'Organ Culture Techniques', 'Perfusion', 'Placental Circulation', 'Pregnancy', 'Regional Blood Flow', 'Ultrasonography, Doppler', 'Young Adult']
| 19,059,643
|
[['M01.060.116'], ['A16.378'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['E01.158.600', 'E01.370.350.350', 'L01.313.500.750.100.158.600'], ['G08.686.784.769.455'], ['E05.481.500.484'], ['E05.680'], ['G09.330.100.749'], ['G08.686.784.769'], ['G09.330.100.780'], ['E01.370.350.850.850'], ['M01.060.116.815']]
|
['Named Groups [M]', 'Anatomy [A]', 'Organisms [B]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Information Science [L]', 'Phenomena and Processes [G]']
| 1
| 1
| 0
| 0
| 1
| 0
| 1
| 0
| 0
| 0
| 1
| 1
| 0
| 0
|
Examining the influence of perceived and objective time constraints on the quality of household food purchases.
|
BACKGROUND: Obesity is a major public health concern in the United States. From the late 1970s through the mid-1990s, the reduction in the amount of time individuals spent preparing food coincided with changes in the food environment. This led to increased consumption of energy and contributed to the dramatic rise in obesity rates over the same period. Research and policy aimed at improving American diets has largely focused on ensuring that healthy foods are accessible and affordable. Although these are important determinants of food choice, time constraints also factors into purchasing decisions.PURPOSE: To examine the relationship between time constraints, both perceived and objective, and the quality of Americans' food purchases by income level.METHODS: USDA's National Household Food Acquisition and Purchase Survey was used to examine the relationship between time constraints (objective and perceived) and HEI-2010 score of food purchases and examines this relationship by income. It estimates an econometric model that controls for other factors that influence time resources and food choice.RESULTS: The relationship between the perceived time constraint and estimated HEI score of food purchases varied by income level, though the relationship was only significant for higher-income households, or those between 400% and 600% of the poverty line. There was no significant relationship between the objective time constraint and HEI score of food purchases.CONCLUSIONS: Nutrition education and interventions aimed at improving household food purchasing decisions may benefit from focusing on improving time management skills and emphasizing healthier convenience food substitutions when consumers feel time-constrained. Higher-income consumers eat out more frequently than lower-income consumers, so menu labeling aimed at nudging higher-income individuals to purchase healthier options could help improve food choice in these settings.
|
['Adult', 'Consumer Behavior', 'Family Characteristics', 'Fast Foods', 'Female', 'Food Preferences', 'Humans', 'Income', 'Male', 'Middle Aged', 'Surveys and Questionnaires', 'Time Factors', 'United States']
| 30,142,374
|
[['M01.060.116'], ['F01.145.236'], ['F01.829.263.315', 'I01.240.361', 'I01.880.853.150.423', 'N01.224.361', 'N01.824.308', 'N06.850.505.400.400'], ['G07.203.300.477', 'J02.500.477'], ['F01.145.407.516', 'G07.203.650.353.516'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['N01.824.417'], ['M01.060.116.630'], ['E05.318.308.980', 'N05.715.360.300.800', 'N06.850.520.308.980'], ['G01.910.857'], ['Z01.107.567.875']]
|
['Named Groups [M]', 'Psychiatry and Psychology [F]', 'Anthropology, Education, Sociology, and Social Phenomena [I]', 'Health Care [N]', 'Phenomena and Processes [G]', 'Technology, Industry, and Agriculture [J]', 'Organisms [B]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Geographicals [Z]']
| 0
| 1
| 0
| 0
| 1
| 1
| 1
| 0
| 1
| 1
| 0
| 1
| 1
| 1
|
[Anatomical education in the late Meiji era --Lu Xun, doctor Fujino and their comtemporaries].
|
Lu Xun studied medicine at Sendai Medical School for 1 and a half years and then changed his course to Literature. In his novel "Doctor Fujino", Lu Xun told his memory on the anatomical notes in which Professor Fujino made numerous corrections. I analyzed the anatomical notes by Lu Xun and his classmates, and revealed the situation of lectures at that time. The teachers drew many anatomical illustrations on the black board with colored chalks. The lecture notes of students may be either clean copies rewritten after lectures or crude notes written during the lectures. When making clean copies, they copied anatomical illustrations in the anatomical textbooks at hand. The anatomical textbooks by Gegenbaur, Rauber and Ishikawa were utilized. Lu Xun made clean copies in the first two months after matriculation, and made crude notes after then. Corrections by Professor Fujino were found in the crude notes for his lectures.
|
['Anatomy', 'Anatomy, Artistic', 'Education, Medical', 'History, 19th Century', 'History, 20th Century', 'Humans', 'Japan', 'Medical Illustration']
| 17,396,567
|
[['H01.158.100'], ['H01.158.100.091', 'K01.093.410.100'], ['I02.358.399'], ['K01.400.504.937'], ['K01.400.504.968'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['Z01.252.474.463', 'Z01.639.595'], ['H02.385', 'J01.897.280.500.480', 'K01.093.410', 'L01.178.820.090.480']]
|
['Disciplines and Occupations [H]', 'Humanities [K]', 'Anthropology, Education, Sociology, and Social Phenomena [I]', 'Organisms [B]', 'Geographicals [Z]', 'Technology, Industry, and Agriculture [J]', 'Information Science [L]']
| 0
| 1
| 0
| 0
| 0
| 0
| 0
| 1
| 1
| 1
| 1
| 0
| 0
| 1
|
A fatal case of malignant hyperthermia complicated by generalized compartment syndrome and rhabdomyolysis.
|
A healthy 21-year-old male who had previously been anaesthetized without complications underwent a laparotomy following a skiing accident. He developed severe malignant hyperthermia. The initial reaction was successfully treated with dantrolene, but during the following days the patient developed several compartment syndromes requiring fasciotomies. The patient died of hyperkalaemia in spite of continuous dialysis. We present a detailed description of the case and also discuss the role of propofol and rhabdomyolysis.
|
['Adult', 'Anesthetics, Intravenous', 'Compartment Syndromes', 'Dantrolene', 'Fatal Outcome', 'Hemorrhage', 'Humans', 'Hyperkalemia', 'Laparotomy', 'Male', 'Malignant Hyperthermia', 'Muscle Relaxants, Central', 'Propofol', 'Renal Dialysis', 'Rhabdomyolysis']
| 12,699,524
|
[['M01.060.116'], ['D27.505.696.277.100.035.075', 'D27.505.954.427.210.100.035.075'], ['C05.651.180', 'C14.907.303'], ['D03.383.129.308.432.555.287'], ['E05.318.308.985.550.325', 'N01.224.935.698.201', 'N06.850.505.400.975.550.325', 'N06.850.520.308.985.550.325'], ['C23.550.414'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['C18.452.950.396'], ['E04.406'], ['C23.550.505.700', 'C23.550.767.600'], ['D27.505.696.510', 'D27.505.696.663.700.600', 'D27.505.954.427.525'], ['D02.455.426.559.389.657.773'], ['E02.870.300', 'E02.912.800'], ['C05.651.807']]
|
['Named Groups [M]', 'Chemicals and Drugs [D]', 'Diseases [C]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Health Care [N]', 'Organisms [B]']
| 0
| 1
| 1
| 1
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 1
| 1
| 0
|
Pseudolinear C4d deposits in a hereditary glomerulopathy caused by a rare NC1 collagen-4-alpha-5 missense mutation: a "new disease entity"?
|
C4d positive glomerulopathies with pseudolinear capillary wall deposits caused by basement membrane (GBM) remodeling have sporadically been reported in renal transplants. Here we describe the case of a hypertensive 60 year-old male with a 5 month history of nephrotic range proteinuria in the setting of normal serum creatinine, complement and ANA levels. Work-up showed MGUS (IgG/kappa restricted). A diagnostic renal biopsy to search for monoclonal gammopathy of renal significance demonstrated thickened glomerular capillary walls with strong pseudolinear complement factor C4d deposits by immunofluorescence microscopy (IF); all other IF studies including stains for Col4A3 were unrevealing with only minor abnormalities seen for Col4A5. The strong and unusual C4d staining of undetermined direct diagnostic significance triggered additional electron microscopic studies uncovering marked structural GBM changes suggestive of a hereditary nephropathy. Further genetic testing revealed a very rare X-linked single missense mutation in the NC1 domain of Col4A5 (exon 51) with a single amino acid substitution (COL4A5 p.A1581S) that has thus far not been reported in hereditary nephropathies. Our case provides further support for pseudolinear glomerular C4d deposits as general markers of GBM remodeling, in our case an unexpected hereditary nephropathy in an older male. Pseudolinear C4d: a general signpost for architectural GBM disturbance and a stimulus for in-depth studies including electron microscopy.
|
['Collagen Type IV', 'Complement C4b', 'Glomerulonephritis, Membranous', 'Humans', 'Male', 'Middle Aged', 'Mutation, Missense', 'Peptide Fragments']
| 31,682,783
|
[['D12.776.860.300.250.400.100'], ['D12.776.124.486.274.350.260'], ['C12.777.419.570.363.625', 'C13.351.968.419.570.363.625', 'C20.111.535'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['M01.060.116.630'], ['G05.365.590.650'], ['D12.644.541']]
|
['Chemicals and Drugs [D]', 'Diseases [C]', 'Organisms [B]', 'Named Groups [M]', 'Phenomena and Processes [G]']
| 0
| 1
| 1
| 1
| 0
| 0
| 1
| 0
| 0
| 0
| 0
| 1
| 0
| 0
|
A highly sensitive immunoassay for atrazine based on covalently linking the small molecule hapten to a urea-glutaraldehyde network on a polystyrene surface.
|
A new enzyme-linked immunosorbent assay (ELISA) for atrazine was developed based on covalent bonding of the small molecule hapten, 2-mercaptopropionic acid-4-ethylamino-6-isopropylamino-1,3,5-triazine (MPA-atrazine), to urea-glutaraldehyde (UGA)-treated microtiter plates. In this assay, the microtiter plate surface was treated with the UGA network to both introduce amino groups, which were used to cross-link with the hapten carboxylate groups, and efficiently prevent non-specific adsorption of antibodies, which successfully eliminated the time-consuming routine blocking step. Compared with HNO3-H2SO4-APTES-hapten coated ELISA (modified with a HNO3-H2SO4-APTES mixture and covalent-linked hapten) and conventional ELISA (coated with hapten-carrier protein conjugates), the novel ELISA format increased the sensitivity by approximately 3.5-fold and 7.5-fold, respectively, and saved 2.5h and 34h of coating hapten time, respectively. The method's 50% inhibition concentration for atrazine was 5.54ngmL-1, and the limit of detection was 0.16ngmL-1 after optimization of reaction conditions. Furthermore, the ELISA was adapted for analysis of atrazine in corn, rice, and water samples, demonstrating recoveries of 90%-108%. Thus, the assay provides a convenient alternative to conventional, laborious immunoassays for routine supervision of residue detection in food and the environment.
|
['Atrazine', 'Environmental Pollutants', 'Enzyme-Linked Immunosorbent Assay', 'Glutaral', 'Haptens', 'Herbicides', 'Humans', 'Oryza', 'Polystyrenes', 'Reference Values', 'Sensitivity and Specificity', 'Sulfhydryl Compounds', 'Urea', 'Water', 'Zea mays']
| 27,743,554
|
[['D03.383.931.247'], ['D27.888.284'], ['E05.478.566.350.170', 'E05.478.566.380.360', 'E05.478.583.400.170', 'E05.601.470.350.170', 'E05.601.470.380.360'], ['D02.047.532'], ['D23.050.550.480'], ['D27.720.031.700.366', 'D27.888.723.366'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['B01.650.940.800.575.912.250.822.616'], ['D02.455.426.559.389.150.750.800.830', 'D05.750.716.579', 'D25.720.716.579', 'J01.637.051.720.716.579'], ['E05.978.810'], ['E05.318.370.800', 'E05.318.740.872', 'G17.800', 'N05.715.360.325.700', 'N05.715.360.750.725', 'N06.850.520.445.800', 'N06.850.520.830.872'], ['D02.886.489'], ['D02.065.950'], ['D01.045.250.875', 'D01.248.497.158.459.650', 'D01.650.550.925'], ['B01.650.940.800.575.912.250.822.966']]
|
['Chemicals and Drugs [D]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Organisms [B]', 'Technology, Industry, and Agriculture [J]', 'Phenomena and Processes [G]', 'Health Care [N]']
| 0
| 1
| 0
| 1
| 1
| 0
| 1
| 0
| 0
| 1
| 0
| 0
| 1
| 0
|
Pediatric generalized joint hypermobility with and without musculoskeletal complaints: a localized or systemic disorder?
|
OBJECTIVES: Children with generalized hypermobility of the joints and musculoskeletal complaints frequently visit pediatric clinics, but many show no currently known collagen or other possibly related diseases. Whether the symptoms are confined to the musculoskeletal system is unknown. We assessed whether such children have detectable differences in laxity of connective tissue present in organ systems other than joints. We also assessed whether children with generalized joint hypermobility and musculoskeletal complaints have more profound systemic changes in connective tissue of various organ systems as compared with children with generalized joint hypermobility without musculoskeletal complaints.METHODS: Anthropometrics, range of joint motion, muscle strength, skin extensibility, blood pressure, quantitative ultrasound measurements of bone, and degradation products of collagen were studied in 15 prepubertal children with generalized joint hypermobility and musculoskeletal complaints and compared with a population-based reference group of 95 nonsymptomatic prepubertal children. Symptomatic hypermobile children were also compared with children of the population-based reference group who had asymptomatic hypermobility of the joints (n = 16).RESULTS: Children with symptomatic generalized joint hypermobility had significantly higher skin extensibility (5.6 mm/15 kPa, 95% confidence interval [CI]: 4.0-7.1), lower quantitative ultrasound measurements (speed of sound: -26.8 m/s; 95% CI: -41.1 to -12.6) in bone, and lower systolic and diastolic blood pressure (-8.0 mmHg, 95% CI: -13.3 to -2.8; and -6.0 mmHg, 95% CI: -10.0 to -2.2, respectively) as compared with the total reference group. Also, they had significantly lower excretion of urinary hydroxylysylpyridinoline cross-links (mean difference: -51.3 micro mol/mmol; 95% CI: -92.2 to -10.4) as well as lysylpyridinoline cross-links (-18.7 micro mol/mmol; 95% CI: -36.9 to -0.5). Age, gender, body weight, height, and particularly cross-links excretion did not explain group differences in clinical and bone characteristics. After adjustment for age, gender, body weight, and height, children with symptomatic generalized joint hypermobility (n = 15) had significantly higher total range of joint motion (117.8 degrees; 95% CI: 77.7-158.0), skin extensibility (3.5 mm/15 kPa; 95% CI: 1.6-5.3), lower quantitative ultrasound measurements in bone (speed of sound: -27.9 m/s; 95% CI: -48.4 to -7.5), borderline lower diastolic blood pressure (-4.9 mmHg; 95% CI: -10.7-0.9), and significantly higher degradation products in urine (hydroxyproline/creatinine: 21.2 micro mol/mmol; 95% CI: 2.3-40.1) as compared with asymptomatic hypermobile children of the total reference group (n = 16). After adjustment for possible confounders, children with generalized joint hypermobility without musculoskeletal complaints had a significantly higher total range of joint motion and more profound skin extensibility, as compared with the reference group (n = 79).CONCLUSIONS: Clinically manifested symptoms in otherwise healthy children with generalized joint hypermobility are accompanied by increases in the laxity of other body tissues. Thus, generalized joint hypermobility with musculoskeletal symptoms does not seem to be restricted to joint tissues. In symptomatic hypermobile children, a more systemic derangement was also present as compared with asymptomatic hypermobile children.
|
['Anthropometry', 'Biomechanical Phenomena', 'Bone Density', 'Bone Diseases', 'Bone and Bones', 'Child', 'Comorbidity', 'Connective Tissue Diseases', 'Diagnosis, Differential', 'Diastole', 'Humans', 'Joint Instability', 'Muscle Contraction', 'Muscle, Skeletal', 'Muscular Diseases', 'Musculoskeletal Diseases', 'Physical Exertion', 'Range of Motion, Articular', 'Skin Physiological Phenomena', 'Ultrasonography']
| 12,612,280
|
[['E01.370.600.024', 'E05.041', 'N06.850.505.200.100'], ['G01.154.090', 'G01.374.089'], ['G11.427.100'], ['C05.116'], ['A02.835.232', 'A10.165.265'], ['M01.060.406'], ['N05.715.350.225', 'N06.850.490.687'], ['C17.300'], ['E01.171'], ['G09.330.580.295', 'G11.427.494.554.250', 'G11.427.494.570.295'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['C05.550.521'], ['G11.427.494'], ['A02.633.567', 'A10.690.552.500'], ['C05.651', 'C10.668.491'], ['C05'], ['G11.427.683'], ['E01.370.600.700', 'G11.427.760'], ['G13.750'], ['E01.370.350.850']]
|
['Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Health Care [N]', 'Phenomena and Processes [G]', 'Diseases [C]', 'Anatomy [A]', 'Named Groups [M]', 'Organisms [B]']
| 1
| 1
| 1
| 0
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 1
| 1
| 0
|
In vitro biomechanical study of female geriatric cervical vertebral bodies.
|
Compressive strength tests were conducted on fresh human geriatric female cervical vertebral bodies. Nineteen specimens were compressed to 50% of their initial height using an electrohydraulic testing device. The mechanical force-deflection response was sigmoidal with continuously changing resistance. The mean cross-sectional area and bone mineral content (BMC) of the vertebral bodies progressively increased from C3 (area: 333.8 mm2, BMC: 1.56 g) to C6 (area: 499.7 mm2, BMC: 2.18 g). The maximum compressive force increased from 1060 N at C3 to 1787 N at C6. The stiffness and the energy absorbed at failure also increased from C3 to C6 (stiffness: 279.95 to 556.41 N mm-1, energy: 2.45 to 4.16 J). These parameters demonstrated a decreasing tendency from C6 to C7. The relatively higher biomechanical parameters at the sixth vertebral level compared with its caudad and cephalad counterparts may be due to the fact the transition of the cervical lordosis to thoracic kyphosis begins at this level. Furthermore, the change in the anatomy of the unicinate processes in the cervical column around this region may also be a contributing factor.
|
['Aged', 'Aged, 80 and over', 'Aging', 'Biomechanical Phenomena', 'Bone Density', 'Cervical Vertebrae', 'Female', 'Humans', 'Reference Values']
| 2,319,771
|
[['M01.060.116.100'], ['M01.060.116.100.080'], ['G07.345.124'], ['G01.154.090', 'G01.374.089'], ['G11.427.100'], ['A02.835.232.834.151'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['E05.978.810']]
|
['Named Groups [M]', 'Phenomena and Processes [G]', 'Anatomy [A]', 'Organisms [B]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]']
| 1
| 1
| 0
| 0
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 1
| 0
| 0
|
The daughter as the principal "double" in a Capgras' syndrome: psychodynamic correlates.
|
In a case of Capgras' syndrome the primary double is usually the spouse. In the described case, the patient chose as a double her pregnant 15-year-old daughter even though her spouse and four other children lived with her. A psychodynamic explanation for this choice is offered within the mechanism of the "ambivalence theory."
|
['Adolescent', 'Adult', 'Aggression', 'Capgras Syndrome', 'Combined Modality Therapy', 'Female', 'Haloperidol', 'Humans', 'Mother-Child Relations', 'Pregnancy', 'Psychotherapy', 'Psychotic Disorders', 'Violence']
| 3,812,829
|
[['M01.060.057'], ['M01.060.116'], ['F01.145.126.125', 'F01.145.813.045'], ['F03.700.300'], ['E02.186'], ['D02.522.352.506'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['F01.829.263.370.290.170'], ['G08.686.784.769'], ['F04.754'], ['F03.700.675'], ['I01.198.240.856', 'I01.880.735.900']]
|
['Named Groups [M]', 'Psychiatry and Psychology [F]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Chemicals and Drugs [D]', 'Organisms [B]', 'Phenomena and Processes [G]', 'Anthropology, Education, Sociology, and Social Phenomena [I]']
| 0
| 1
| 0
| 1
| 1
| 1
| 1
| 0
| 1
| 0
| 0
| 1
| 0
| 0
|
Effect of M4-cholinoceptor blockade on haloperidol-produced catatonic syndrome in rats.
|
We studied the relationship between the efficiency of muscarinic receptor antagonists in preventing haloperidol-induced catatonia and their activity in tests for the interaction of ligands with various subtypes of muscarinic receptors (M1-M4) in rats. Mathematical modeling showed that affinity of the ligand for M4 receptors positively affects its ability to correct extrapyramidal disorders (catatonic syndrome) produced by haloperidol, while affinity for M2 receptors had a negative effect on this characteristic.
|
['Animals', 'Basal Ganglia Diseases', 'Catatonia', 'Haloperidol', 'Kinetics', 'Ligands', 'Male', 'Models, Biological', 'Muscarinic Antagonists', 'Pilocarpine', 'Rats', 'Receptor, Muscarinic M4', 'Receptors, Muscarinic', 'Syndrome']
| 15,273,762
|
[['B01.050'], ['C10.228.140.079'], ['C10.597.606.115', 'C23.888.592.604.115', 'F01.145.126.156', 'F01.700.165'], ['D02.522.352.506'], ['G01.374.661', 'G02.111.490'], ['D27.720.470.480'], ['E05.599.395'], ['D27.505.519.625.120.200.500', 'D27.505.696.577.120.200.500'], ['D03.132.672'], ['B01.050.150.900.649.313.992.635.505.700'], ['D12.776.543.750.695.475.400', 'D12.776.543.750.720.360.500.400'], ['D12.776.543.750.695.475', 'D12.776.543.750.720.360.500'], ['C23.550.288.500']]
|
['Organisms [B]', 'Diseases [C]', 'Psychiatry and Psychology [F]', 'Chemicals and Drugs [D]', 'Phenomena and Processes [G]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]']
| 0
| 1
| 1
| 1
| 1
| 1
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 0
|
Reactive-electrospray-assisted laser desorption/ionization for characterization of peptides and proteins.
|
Electrospray-assisted laser desorption/ionization (ELDI) is a soft ionization method for mass spectrometry (MS) and combines features of both electrospray ionization (ESI) and matrix-assisted laser desorption/ionization to generate ESI-like multiply charged molecules. The ELDI process is based on merging ESI-generated, charged droplets with particles UV laser desorbed from dried or wet sample deposits. We previously reported that ELDI is amenable for MS-based protein identification of large peptides and small proteins using top-down and bottom-up techniques (Peng, I. X.; Shiea, J.; Ogorzalek Loo, R. R.; Loo, J. A. Rapid Commun. Mass Spectrom. 2007, 21, 2541-2546). We have extended our studies by applying collisionally activated dissociation and electron-transfer dissociation MS ( n ) to protein analysis and show that ELDI is capable of multistage MS to MS (4) for top-down characterization of large proteins such as 29 kDa carbonic anhydrase. Multiply charged proteins generated by the ELDI mechanism can be shifted to higher charge by increasing the organic content in the ESI solvent to denature the protein molecules, or by adding m-nitrobenzyl alcohol to the ESI solvent. Furthermore, we introduce "reactive-ELDI", which supports chemical reactions during the ELDI process. Preliminary data for online disulfide bond reduction using dithiothreitol on oxidized glutathione and insulin show reactive-ELDI to be effective. These data provide evidence that the laser-desorbed particles merge with the ESI-generated charge droplets to effect chemical reactions prior to online MS detection. This capability should allow other chemical and enzymatic reactions to be exploited as online protein characterization tools, as well as extending them to flexible, spatially resolved tissue screening and imaging. Also, these reactive-ELDI disulfide reduction experiments enable direct top-down protein identification for proteomic study, side stepping laborious, time-consuming sample preparation steps such as in-solution reduction and alkylation.
|
['Amino Acid Sequence', 'Animals', 'Cattle', 'Disulfides', 'Dithiothreitol', 'Electron Transport', 'Gases', 'Glutathione', 'Insulin', 'Molecular Weight', 'Organic Chemicals', 'Peptides', 'Protein Conformation', 'Proteins', 'Sequence Analysis, Protein', 'Solvents', 'Spectrometry, Mass, Electrospray Ionization', 'Tandem Mass Spectrometry']
| 18,683,952
|
[['G02.111.570.060', 'L01.453.245.667.060'], ['B01.050'], ['B01.050.150.900.649.313.500.380.271'], ['D01.248.497.158.874.390', 'D01.875.350.850.150', 'D02.886.520.150'], ['D02.033.800.196', 'D02.886.740.224', 'D09.853.196'], ['G02.111.248', 'G03.295.531.403', 'G03.493.350'], ['D01.362'], ['D12.644.456.448'], ['D06.472.699.587.200.500.625', 'D12.644.548.586.200.500.625'], ['G02.494'], ['D02'], ['D12.644'], ['G02.111.570.820.709'], ['D12.776'], ['E05.393.760.705'], ['D27.720.844'], ['E05.196.566.600'], ['E05.196.566.880']]
|
['Phenomena and Processes [G]', 'Information Science [L]', 'Organisms [B]', 'Chemicals and Drugs [D]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]']
| 0
| 1
| 0
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 1
| 0
| 0
| 0
|
Multiple-center study of reduced-concentration triamcinolone topical solution for the treatment of dogs with known or suspected allergic pruritus.
|
OBJECTIVE: To determine the efficacy of triamcinolone acetonide topical solution (TTS) in dogs for use in reduction of clinical signs of pruritic inflammatory skin diseases of a known or suspected allergic basis and to evaluate adverse effects associated with TTS administration.ANIMALS: 103 pruritic adult dogs with known or suspected allergic skin disease.PROCEDURE: Dogs were treated for 4 weeks with TTS or with vehicle solution (control dogs) in a multiple-center study. Clinical signs were scored by owners and by examining veterinarians before and after treatment. Blood samples obtained before and after treatment were subjected to routine hematologic and serum biochemical analyses.RESULTS: Treatment success, as defined by an improvement of at least 2 of 6 grades in overall clinical score, was evident in 35 of 52 (67%) TTS-treated dogs (mean improvement, 1.98) and 12 of 51 (24%) control dogs (mean improvement, 0.29). For several criteria, TTS was significantly more effective than vehicle in reducing clinical signs. Minor alterations in hematologic determinations in TTS-treated dogs were limited to slightly lower total leukocyte, lymphocyte, and eosinophil counts after treatment. Minor adverse effects were reported by owners in 6 of 52 (12%) TTS-treated and 9 of 51 (18%) control dogs.CONCLUSIONS AND CLINICAL RELEVANCE: Triamcinolone used as a spray solution at a concentration approximately one-sixth the concentration of triamcinolone topical preparations currently available for veterinary use is effective for short-term alleviation of allergic pruritus in dogs. Adverse effects are few and mild and, thus, do not preclude prolonged treatment with the solution.
|
['Administration, Topical', 'Animals', 'Blood Chemical Analysis', 'Dog Diseases', 'Dogs', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Female', 'Glucocorticoids', 'Leukocyte Count', 'Male', 'Pruritus', 'Treatment Outcome', 'Triamcinolone Acetonide']
| 11,911,576
|
[['E02.319.267.120'], ['B01.050'], ['E01.370.225.124.100', 'E05.200.124.100'], ['C22.268'], ['B01.050.150.900.649.313.750.250.216.200'], ['G07.690.773.875', 'G07.690.936.500'], ['E05.318.370.300', 'E05.581.500.300', 'N05.715.360.325.320', 'N06.850.520.445.300'], ['D06.472.040.543', 'D27.505.696.399.472.488'], ['E01.370.225.500.195.107.595', 'E01.370.225.625.107.595', 'E05.200.500.195.107.595', 'E05.200.625.107.595', 'E05.242.195.107.595', 'G04.140.107.595', 'G09.188.105.595'], ['C17.800.685', 'C23.888.885.625'], ['E01.789.800', 'N04.761.559.590.800', 'N05.715.360.575.575.800'], ['D04.210.500.745.432.915.715', 'D04.210.500.908.891.927']]
|
['Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Organisms [B]', 'Diseases [C]', 'Phenomena and Processes [G]', 'Health Care [N]', 'Chemicals and Drugs [D]']
| 0
| 1
| 1
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 0
| 1
| 0
|
Veterans have less age-related cognitive decline.
|
Military service involves exposure to a number of stresses, both psychological and physical. On the other hand, military personnel generally maintain excellent fitness, and veterans have increased access to education and health care. The overall effect on age-related cognitive decline, whether for good or ill, of having served in the armed forces has not been investigated previously. In this study, we examined a diverse population of 208 veterans and 1,216 civilians followed as part of the Epidemiologic Catchment Area Study in 1981, 1982, and 1993 to 1996. We examined change in Mini-Mental State Examination (MMSE) score after a median of 11.5 years. Veterans were found to have significantly less decrease in MMSE scores at follow-up even after sex, race, and education were taken into account. These results suggest an overall positive effect of military service on the rate of age-related cognitive decline.
|
['Aged', 'Baltimore', 'Catchment Area, Health', 'Cognition Disorders', 'Educational Status', 'Female', 'Humans', 'Male', 'Mental Status Schedule', 'Middle Aged', 'Socioeconomic Factors', 'Surveys and Questionnaires', 'Veterans']
| 10,957,857
|
[['M01.060.116.100'], ['Z01.107.567.875.500.500.100', 'Z01.433.100'], ['N01.224.791.200', 'N03.349.650.095', 'N06.850.505.400.800.200'], ['F03.615.250'], ['N01.824.196'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['F04.711.513.603.500', 'F04.711.513.653.574'], ['M01.060.116.630'], ['I01.880.853.996', 'N01.824'], ['E05.318.308.980', 'N05.715.360.300.800', 'N06.850.520.308.980'], ['M01.930']]
|
['Named Groups [M]', 'Geographicals [Z]', 'Health Care [N]', 'Psychiatry and Psychology [F]', 'Organisms [B]', 'Anthropology, Education, Sociology, and Social Phenomena [I]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]']
| 0
| 1
| 0
| 0
| 1
| 1
| 0
| 0
| 1
| 0
| 0
| 1
| 1
| 1
|
Singlet-Triplet Gaps of Cobalt Nitrosyls: Insights from Tropocoronand Complexes.
|
A density functional theory (DFT) study of {CoNO}(8) cobalt nitrosyl complexes containing the [n,n]tropocoronand ligand (TC-n,n) has revealed a sharp reduction of singlet-triplet gaps as the structures change from near-square-pyramidal (for n = 3) to trigonal-bipyramidal with an equatorial NO (for n = 5, 6). An experimental reinvestigation of [Co(TC-3,3)(NO)] has confirmed that it is not paramagnetic, as originally reported, but diamagnetic, like all other {CoNO}(8) complexes. Furthermore, DFT calculations indicate a substantial singlet-triplet gap of about half an eV or higher for this complex. At the other end of the series, low-energy, thermally accessible triplet states are predicted for [Co(TC-6,6)(NO)]. Enhanced triplet-state reactivity may well provide a partial explanation for the failure to isolate this compound as a stable species.
|
['Cobalt', 'Ligands', 'Macrocyclic Compounds', 'Models, Molecular', 'Molecular Conformation', 'Nitrogen', 'Organometallic Compounds', 'Quantum Theory']
| 26,203,786
|
[['D01.268.556.185', 'D01.268.956.155', 'D01.552.544.185'], ['D27.720.470.480'], ['D04.345'], ['E05.599.595'], ['G02.111.570.820'], ['D01.268.604', 'D01.362.625'], ['D02.691'], ['H01.671.579.800']]
|
['Chemicals and Drugs [D]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Phenomena and Processes [G]', 'Disciplines and Occupations [H]']
| 0
| 0
| 0
| 1
| 1
| 0
| 1
| 1
| 0
| 0
| 0
| 0
| 0
| 0
|
[Multiple fractures of the lower extremities (a propos of 50 patients)].
|
According to a study of 50 multiple fractures of the lower limbs, the frequency of associated lesions justifies the creation of new multiple injury units, well equipped in which may be found specialists of all branches of surgery. Although internal fixation in one stage as an emergency, is ideal in all fractures, one should in fact be circumspect for the danger of infection should lead one to avoid carrying out internal fixation if this is not absolutely necessary.
|
['Adult', 'Ankle Joint', 'Ankylosis', 'Arthritis', 'Female', 'Fracture Fixation', 'Fracture Fixation, Internal', 'Fracture Fixation, Intramedullary', 'Fractures, Bone', 'Humans', 'Knee Joint', 'Leg Injuries', 'Male', 'Middle Aged', 'Pseudarthrosis']
| 1,176,563
|
[['M01.060.116'], ['A02.835.583.378.062'], ['C05.550.069'], ['C05.550.114'], ['E04.555.300'], ['E04.555.300.300'], ['E04.555.300.300.300'], ['C26.404'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['A02.835.583.475'], ['C26.558'], ['M01.060.116.630'], ['C26.404.468.627']]
|
['Named Groups [M]', 'Anatomy [A]', 'Diseases [C]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Organisms [B]']
| 1
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 1
| 0
| 0
|
Histamine inhibits neutrophil NADPH oxidase activity triggered by the lipoxin A4 receptor-specific peptide agonist Trp-Lys-Tyr-Met-Val-Met.
|
The vasoactive amine histamine is found at high concentrations in the immune and inflammatory tissues. Earlier studies have revealed that histamine regulates the nicotinamide-adenine dinucleotide phosphate (NADPH) oxidase-dependent formation of oxygen radicals by phagocytic cells. However, the effects of histamine on intracellular signal transduction mechanisms of relevance to oxidase regulation remain controversial. For this study, we investigated the effects of histamine on NADPH oxidase activity in human neutrophil granulocytes triggered by a lipoxin A4 receptor agonist [the hexapeptide Trp-Lys-Tyr-Met-Val-Met (WKYMVM), a formyl peptide receptor (FPR) agonist (the chemotactic tripeptide formylmethionyl-leucyl-phenylalanine (fMLF)) and an activator of protein kinase C (phorbol myristate acetate (PMA)]. We report that histamine, acting via H2-type histamine receptors (H2R), suppresses NADPH oxidase-dependent formation of oxygen radicals induced by WKYMVM and fMLF but not that induced by PMA. Peptide-induced mobilization of granule-localized complement receptor 3 (CR3) was unaffected by histamine suggesting that the inhibition specifically affected NADPH oxidase activation. Our data suggest that histamine downregulates FPRL1- and FPR-induced NADPH oxidase activity upstream of protein kinase C (PKC) and downstream of the separation of the peptide-induced signal into granule secretion and oxidase activation.
|
['Chemotactic Factors', 'Cytoplasmic Granules', 'Down-Regulation', 'Enzyme Inhibitors', 'Histamine', 'Humans', 'N-Formylmethionine Leucyl-Phenylalanine', 'NADPH Oxidases', 'Neutrophils', 'Oligopeptides', 'Receptors, Cell Surface', 'Receptors, Formyl Peptide', 'Receptors, Lipoxin', 'Signal Transduction', 'Superoxides', 'Tetradecanoylphorbol Acetate']
| 12,950,678
|
[['D23.125'], ['A11.284.430.214.190.500', 'A11.284.430.214.190.875.190.190'], ['G02.111.240', 'G05.308.200', 'G07.690.773.937'], ['D27.505.519.389'], ['D02.092.211.215.501', 'D02.092.471.440', 'D03.383.129.308.373', 'D23.469.050.300'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['D02.886.030.676.450.440', 'D12.125.072.050.685.445', 'D12.125.142.666.500', 'D12.125.166.676.450.440', 'D12.644.456.400', 'D23.125.685'], ['D08.811.682.608.575', 'D12.776.331.894', 'D12.776.543.653'], ['A11.118.637.415.583', 'A11.627.340.583', 'A11.733.689', 'A15.145.229.637.415.583', 'A15.382.490.315.583', 'A15.382.680.689'], ['D12.644.456'], ['D12.776.543.750'], ['D12.776.543.750.695.235', 'D12.776.543.750.705.873', 'D12.776.543.750.750.340'], ['D12.776.543.750.695.200.575'], ['G02.111.820', 'G04.835'], ['D01.248.497.158.685.750.850', 'D01.339.431.374.850', 'D01.650.550.750.800', 'D02.389.338.732'], ['D02.455.849.291.500.510.850']]
|
['Chemicals and Drugs [D]', 'Anatomy [A]', 'Phenomena and Processes [G]', 'Organisms [B]']
| 1
| 1
| 0
| 1
| 0
| 0
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 0
|
In vivo Cre/loxP mediated recombination in mouse Clara cells.
|
In small airways, Clara cells are the main epithelial cell type and play an important physiological role in surfactant production, protection against environmental agents, regulation of inflammatory and immune responses in the respiratory system. Thus, Clara cells are involved in lung homeostasis and pathologies like asthma, Chronic Obstructive Pulmonary Diseases (COPD) or cancers. To date, Clara cells implication in these pathological processes remains largely enigmatic. The engineering of a transgenic strain mouse allowing specific gene invalidation in Clara cells may be of interest to improve our knowledge about the genes involved in these diseases. By using the Cre/loxP strategy we report the engineering of a transgenic mouse strain with expression of Cre recombinase under the control of the Clara Cell Secretory Protein (CCSP) promoter. Specific staining and immuno-histochemistry performed after breeding with reporter mice revealed that CCSP drives a functional Cre expression specifically in Clara cells. This mouse strain is a powerful tool for Cre-loxP-mediated conditional recombination in the lung and represents a new tool to study Clara cell physiology.
|
['Animals', 'Base Sequence', 'DNA, Recombinant', 'Epithelial Cells', 'Gene Expression', 'Genes, Reporter', 'Genetic Engineering', 'Integrases', 'Lung', 'Mice', 'Mice, Transgenic', 'Promoter Regions, Genetic', 'RNA, Messenger', 'Recombination, Genetic', 'Respiratory System', 'Reverse Transcriptase Polymerase Chain Reaction', 'Trachea', 'Uteroglobin']
| 16,245,155
|
[['B01.050'], ['G02.111.570.080', 'G05.360.080', 'L01.453.245.667.080'], ['D13.444.308.460'], ['A11.436'], ['G05.297'], ['G05.360.340.024.340.435'], ['E05.393.420'], ['D08.811.739.500'], ['A04.411'], ['B01.050.150.900.649.313.992.635.505.500'], ['B01.050.050.136.500', 'B01.050.150.900.649.313.992.635.505.500.800'], ['G02.111.570.080.689.675', 'G05.360.080.689.675', 'G05.360.340.024.340.137.750.680'], ['D13.444.735.544'], ['G05.728'], ['A04'], ['E05.393.620.500.725'], ['A04.889'], ['D12.776.861.500']]
|
['Organisms [B]', 'Phenomena and Processes [G]', 'Information Science [L]', 'Chemicals and Drugs [D]', 'Anatomy [A]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]']
| 1
| 1
| 0
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 1
| 0
| 0
| 0
|
Increased endothelial activation in recently symptomatic versus asymptomatic carotid artery stenosis and in cerebral microembolic-signal-negative patient subgroups.
|
BACKGROUND AND PURPOSE: von Willebrand factor propeptide (VWF:Ag II) is potentially a more sensitive marker of acute endothelial activation than von Willebrand factor antigen (VWF:Ag). These biomarkers have not been simultaneously assessed in asymptomatic versus symptomatic carotid stenosis patients. The relationship between endothelial activation and cerebral microembolic signals (MESs) detected on transcranial Doppler ultrasound is unknown.METHODS: In this multicentre observational analytical study, plasma VWF:Ag and VWF:Ag II levels in patients with ?50% asymptomatic carotid stenosis were compared with those from patients with ?50% symptomatic carotid stenosis in the 'early' (?4 weeks) and 'late' (?3 months) phases after transient ischaemic attack or ischaemic stroke. Endothelial activation was also longitudinally assessed in symptomatic patients during follow-up. Transcranial Doppler ultrasound monitoring classified patients as MES-positive or MES-negative.RESULTS: Data from 31 asymptomatic patients were compared with those from 46 early symptomatic and 35 late phase symptomatic carotid stenosis patients, 23 of whom had undergone carotid intervention. VWF:Ag II levels were higher in early (12.8 ìg/ml; P < 0.001), late (10.6 ìg/ml; P = 0.01) and late post-intervention (10.6 ìg/ml; P = 0.038) symptomatic patients than asymptomatic patients (8.9 ìg/ml). VWF:Ag levels decreased in symptomatic patients followed up from the early to late phase after symptom onset (P = 0.048). Early symptomatic MES-negative patients had higher VWF: Ag II levels (13.3 vs. 9.0 ìg/ml; P < 0.001) than asymptomatic MES-negative patients.CONCLUSIONS: Endothelial activation is enhanced in symptomatic versus asymptomatic carotid stenosis patients, in early symptomatic versus asymptomatic MES-negative patients, and decreases over time in symptomatic patients. VWF:Ag II levels are a more sensitive marker of endothelial activation than VWF:Ag levels in carotid stenosis. The potential value of endothelial biomarkers and concurrent cerebral MES detection at predicting stroke risk in carotid stenosis warrants further study.
|
['Aged', 'Biomarkers', 'Brain Ischemia', 'Carotid Stenosis', 'Endothelium', 'Humans', 'Intracranial Embolism', 'Ischemic Attack, Transient', 'Male', 'Middle Aged', 'Stroke', 'Ultrasonography', 'von Willebrand Factor']
| 24,712,648
|
[['M01.060.116.100'], ['D23.101'], ['C10.228.140.300.150', 'C14.907.253.092'], ['C10.228.140.300.200.360', 'C14.907.137.230', 'C14.907.253.123.360'], ['A10.272.491'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['C10.228.140.300.525.400', 'C14.907.253.566.300', 'C14.907.355.590.213.300'], ['C10.228.140.300.150.836', 'C14.907.253.092.836'], ['M01.060.116.630'], ['C10.228.140.300.775', 'C14.907.253.855'], ['E01.370.350.850'], ['D12.776.124.125.920', 'D23.119.985']]
|
['Named Groups [M]', 'Chemicals and Drugs [D]', 'Diseases [C]', 'Anatomy [A]', 'Organisms [B]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]']
| 1
| 1
| 1
| 1
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 1
| 0
| 0
|
Primary double pigtail stenting as a treatment of upper urinary tract leaks.
|
During a 5-year period 21 consecutive patients with iatrogenic or traumatic upper urinary tract leaks (nonmalignant) underwent treatment 5 to 28 days later with an indwelling double pigtail stent via an antegrade or retrograde approach. Six patients underwent initial nephrostomy drainage for relief of obstruction causing decreased renal function and/or septicemia. Stent placement was successful in 20 patients and complete healing occurred within 2 to 7 weeks in all 20. At followup 2 to 32 months later (median 3 months) no stricture formation or deterioration of kidney function was noted. There were no major complications and 85% of the patients were able to leave the hospital without any form of external drainage within 1 week after stent placement.
|
['Adult', 'Catheters, Indwelling', 'Female', 'Humans', 'Iatrogenic Disease', 'Kidney Diseases', 'Male', 'Nephrostomy, Percutaneous', 'Stents', 'Ureteral Diseases', 'Urinary Catheterization', 'Urinary Fistula']
| 2,299,709
|
[['M01.060.116'], ['E07.132.500'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['C23.550.291.875'], ['C12.777.419', 'C13.351.968.419'], ['E01.370.390.550', 'E04.579.642', 'E04.950.774.739.500', 'E04.950.774.852.642'], ['E07.695.750'], ['C12.777.725', 'C13.351.968.725'], ['E01.370.390.820', 'E02.148.947', 'E05.157.500'], ['C12.706.881', 'C13.351.875.881', 'C23.300.575.825']]
|
['Named Groups [M]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Organisms [B]', 'Diseases [C]']
| 0
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 1
| 0
| 0
|
Art in Alzheimer's care: promoting well-being in people with late-stage Alzheimer's disease.
|
The purpose of this qualitative study was to explore the responses of people with late-stage Alzheimer's disease (AD) to a creative bonding intervention (CBI). The CBI consisted of simple art activities. Guided by Reed's self-transcendence theory, research questions were "Will persons with late-stage AD show evidence of self-transcendence during the CBI?" and "Will persons with late-stage AD show evidence of well-being during the CBI?" Twelve CBI sessions, documented by videotape and field notes, were conducted with four participants. Themes emerged within two clusters: trusting/thirsting/following and choosing/connecting/reminiscing. An overarching category of "cocooning" described participants' world during the CBI as they displayed evidence of self-transcendence and well-being. The CBI is a strategy that can be implemented by staff families, and volunteers. Nurses are positioned to provide transformation leadership for implementation of creative approaches during care of people with late-stage AD, but administrative and financial support are needed.
|
['Aged', 'Alzheimer Disease', 'Humans', 'Models, Nursing', 'Qualitative Research', 'Rehabilitation Nursing']
| 21,473,563
|
[['M01.060.116.100'], ['C10.228.140.380.100', 'C10.574.945.249', 'F03.615.400.100'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['E05.599.645'], ['H01.770.644.241.850'], ['H02.478.676.789', 'N02.421.533.889']]
|
['Named Groups [M]', 'Diseases [C]', 'Psychiatry and Psychology [F]', 'Organisms [B]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Disciplines and Occupations [H]', 'Health Care [N]']
| 0
| 1
| 1
| 0
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 1
| 1
| 0
|
Exploration of CeO₂ nanoparticles as a chemi-sensor and photo-catalyst for environmental applications.
|
CeO₂ nanoparticles were synthesized hydrothermally and utilized as redox mediator for the fabrication of efficient ethanol chemi-sensor. The developed chemi-sensor showed an excellent performance for electrocatalytic oxidization of ethanol by exhibiting higher sensitivity (0.92 ìA?cm⁻²?mM⁻?) and lower limit of detection (0.124±0.010 mM) with the linear dynamic range of 0.17 mM-0.17 M. CeO₂ nanoparticles have been characterized by field emission scanning electron microscopy (FESEM), Energy dispersive spectroscopy (EDS), X-ray powder diffraction (XRD), Raman spectrum, Fourier transform infrared spectroscopy (FTIR), and UV-visible absorption spectrum which revealed that the synthesized CeO₂ is an aggregated form of optically active spherical nanoparticles with the range of 15-36 nm (average size of ~25±10 nm) and possessing well crystalline cubic phase. Additionally, CeO₂ performed well as a photo-catalyst by degrading amido black and acridine orange.
|
['Cerium', 'Environmental Monitoring', 'Environmental Pollutants', 'Nanoparticles', 'Photochemical Processes']
| 21,570,707
|
[['D01.268.558.362.249', 'D01.552.550.399.249'], ['N06.850.460.350.080', 'N06.850.780.375'], ['D27.888.284'], ['J01.637.512.600'], ['G02.740']]
|
['Chemicals and Drugs [D]', 'Health Care [N]', 'Technology, Industry, and Agriculture [J]', 'Phenomena and Processes [G]']
| 0
| 0
| 0
| 1
| 0
| 0
| 1
| 0
| 0
| 1
| 0
| 0
| 1
| 0
|
Expanding the infection control team: development of the infection control liaison position for the neonatal intensive care unit.
|
Neonatal survival has risen progressively during the past 30 years. As the limits of viability continue to decline, the challenges of providing care to infants at the lowest extremes of gestational age and birth weight continually increase. Nosocomial infections in this very fragile population can be devastating. The complexity of care of these premature infants requires specialized knowledge of the neonate, infectious disease processes, and methods to reduce infection risks in the neonatal intensive care unit. The role of infection control liaison has been established in our institution as an adjunct to meeting this challenge by providing a line of communication between staff, neonatologists, and the infection control team. This article describes the role of the infection control liaison and its overall impact on the infection control program in an 87-bed level II, III, and IV neonatal intensive care unit from 1995 to 1999.
|
['Cross Infection', 'Hospitals', 'Humans', 'Infant, Newborn', 'Infection Control', 'Intensive Care Units, Neonatal', 'Kentucky', 'Nursing Care', 'Patient Care Team', 'Risk Factors', 'Workforce']
| 11,988,713
|
[['C01.248', 'C23.550.291.875.500'], ['N02.278.421'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['M01.060.703.520'], ['N06.850.780.200.450'], ['N02.278.388.493.390.380'], ['Z01.107.567.875.075.400', 'Z01.107.567.875.510.400'], ['E02.760.611', 'N02.421.533'], ['N04.590.715'], ['E05.318.740.600.800.725', 'N05.715.350.200.700', 'N05.715.360.750.625.700.700', 'N06.850.490.625.750', 'N06.850.520.830.600.800.725'], ['N04.452.525']]
|
['Diseases [C]', 'Health Care [N]', 'Organisms [B]', 'Named Groups [M]', 'Geographicals [Z]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]']
| 0
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 1
| 1
| 1
|
Comparison of interventional outcomes according to preoperative indication: a single center analysis of 2,240 limb revascularizations.
|
BACKGROUND: Outcomes after lower extremity revascularization are usually reported according to the level of peripheral arterial disease (PAD, aortoiliac or infrainguinal) or the method of treatment (open or endovascular surgery). Outcomes stratified by indication, ie, claudication or critical limb ischemia (rest pain and tissue loss), have not been well studied. The purpose of this study was to compare postoperative outcomes according to the preoperative indications.STUDY DESIGN: Outcomes of 2,240 consecutive limb revascularizations in 1,732 patients from January 1998 through December 2005 were stratified and examined according to preoperative indication: claudication (n=999 limbs), ischemic rest pain (n=464 limbs), or tissue loss (n=777 limbs). End points measured included primary and secondary interventional or operative patency, limb salvage, survival, amputation-free survival, maintenance of ambulation, maintenance of independence, and resolution of presenting symptoms.RESULTS: The proportion of medical comorbidities and the severity of disease increased significantly by cohort from claudication to rest pain to tissue loss. With a mean followup of 1,089 days (range 0 to 3,689 days), overall outcomes performance declined consistently according to indication for all end points measured at 5 years (claudication, rest pain, tissue loss, p value): secondary reconstruction patency (93%, 80%, 66%, respectively; p < 0.001), limb salvage (99%, 81%, 68%, respectively; p < 0.001), survival (78%, 46%, 30%, respectively; p < 0.001), amputation-free survival (78%, 42%, 25%, respectively; p < 0.001), maintenance of ambulation (96%, 78%, 68%, respectively; p < 0.001), maintenance of independence (98%, 85%, 75%, respectively; p < 0.001), and resolution of presenting symptoms (79%, 61%, 42%, respectively; p < 0.001).CONCLUSIONS: There is a declining spectrum of outcomes performance from claudication to rest pain to tissue loss. These findings question the accuracy of all previously published data for critical limb ischemia, for which rest pain and tissue loss are usually blended and reported as a single outcomes value.
|
['Adult', 'Aged', 'Angioplasty, Balloon', 'Female', 'Humans', 'Intermittent Claudication', 'Ischemia', 'Leg', 'Limb Salvage', 'Male', 'Middle Aged', 'Peripheral Vascular Diseases', 'Recovery of Function', 'Treatment Outcome', 'Vascular Patency', 'Vascular Surgical Procedures']
| 19,476,835
|
[['M01.060.116'], ['M01.060.116.100'], ['E02.148.050.060', 'E04.100.814.529.124.060', 'E04.502.382.124.060', 'E05.157.016.060'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['C14.907.137.126.669', 'C23.888.531'], ['C23.550.513'], ['A01.378.610.500'], ['E04.100.814.603', 'E04.555.400', 'E04.680.350'], ['M01.060.116.630'], ['C14.907.617'], ['G16.757'], ['E01.789.800', 'N04.761.559.590.800', 'N05.715.360.575.575.800'], ['G09.330.920'], ['E04.100.814']]
|
['Named Groups [M]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Organisms [B]', 'Diseases [C]', 'Anatomy [A]', 'Phenomena and Processes [G]', 'Health Care [N]']
| 1
| 1
| 1
| 0
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 1
| 1
| 0
|
Effect of remifentanil for general anesthesia on parturients and newborns undergoing cesarean section: a meta-analysis.
|
INTRODUCTION: The results presented by studies investigating the effect of remifentanil on both parturients and newborns during cesarean section differed significantly. Therefore, we performed a meta-analysis to estimate the effect of remifentanil on these patients.EVIDENCE ACQUISITION: Potentially eligible studies published before 15 March 2016 were searched through four databases including PubMed, SCOPUS, ISI web of knowledge and EBSCO. Weighted mean difference (WMD) or odds ratios (ORs) and the corresponding 95% confidence interval (CI) were applied to estimate the strength of relationship.EVIDENCE SYNTHESIS: A total number of seven randomized-controlled trials were included in this meta-analysis. The results showed that Apgar values at 1 min and 5 min were significantly lower in the infants of remifentanil-treated mothers, with the WMD and corresponding 95% CI of -0.835 (-1.515, -0.154) and -0.296 (-0.570, -0.021), respectively. The pH value of umbilical artery was significantly higher in the remifentanil group (WMD: 0.014, 95% CI: 0.002, 0.025). The highest and lowest systolic blood pressures were significantly lower in remifentanil-treated mothers, with the WMD and corresponding 95% CI of -18.913 (-34.468, -3.359) and -12.982 (-21.479, -4.485), respectively.CONCLUSIONS: Remifentanil shows potential value of maternal circulation response during general anesthesia, which reduces maternal blood pressure in response to intubation and surgery. However, whether it is beneficial for the neonate is still controversial. More randomized-controlled trials with larger sample size are required to assess the adverse effects of remifentanil.
|
['Analgesics, Opioid', 'Anesthesia, General', 'Cesarean Section', 'Female', 'Humans', 'Infant, Newborn', 'Pregnancy', 'Randomized Controlled Trials as Topic', 'Remifentanil']
| 28,492,294
|
[['D27.505.696.277.600.500', 'D27.505.696.663.850.014.760.500', 'D27.505.954.427.040.550.500', 'D27.505.954.427.210.600.500'], ['E03.155.197'], ['E04.520.252.500'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['M01.060.703.520'], ['G08.686.784.769'], ['E05.318.372.250.250.365.500', 'N05.715.360.330.250.250.365.500', 'N06.850.520.450.250.250.365.500'], ['D02.241.081.751.756', 'D03.383.621.828']]
|
['Chemicals and Drugs [D]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Organisms [B]', 'Named Groups [M]', 'Phenomena and Processes [G]', 'Health Care [N]']
| 0
| 1
| 0
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 1
| 1
| 0
|
A single session of meditation reduces of physiological indices of anger in both experienced and novice meditators.
|
The goal of the present study was to explore how anger reduction via a single session of meditation might be measured using psychophysiological methodologies. To achieve this, 15 novice meditators (Experiment 1) and 12 practiced meditators (Experiment 2) completed autobiographical anger inductions prior to, and following, meditation training while respiration rate, heart rate, and blood pressure were measured. Participants also reported subjective anger via a visual analog scale. At both stages, the experienced meditators' physiological reaction to the anger induction reflected that of relaxation: slowed breathing and heart rate and decreased blood pressure. Na?ve meditators exhibited physiological reactions that were consistent with anger during the pre-meditation stage, while after meditation training and a second anger induction they elicited physiological evidence of relaxation. The current results examining meditation training show that the na?ve group's physiological measures mimicked those of the experienced group following a single session of meditation training.
|
['Adolescent', 'Adult', 'Anger', 'Blood Pressure', 'Female', 'Heart Rate', 'Humans', 'Male', 'Meditation', 'Relaxation', 'Respiratory Rate', 'Young Adult']
| 26,748,026
|
[['M01.060.057'], ['M01.060.116'], ['F01.470.093'], ['E01.370.600.875.249', 'G09.330.380.076'], ['E01.370.600.875.500', 'G09.330.380.500'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['E02.190.525.374', 'E02.190.901.455', 'F04.754.137.750.500'], ['I03.450.769'], ['E01.370.600.875.875', 'G09.772.705.730'], ['M01.060.116.815']]
|
['Named Groups [M]', 'Psychiatry and Psychology [F]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Phenomena and Processes [G]', 'Organisms [B]', 'Anthropology, Education, Sociology, and Social Phenomena [I]']
| 0
| 1
| 0
| 0
| 1
| 1
| 1
| 0
| 1
| 0
| 0
| 1
| 0
| 0
|
Alveolar band in patients with cleft lip and cleft alveolar deformities.
|
A complete cleft of the lip is often interrupted by a Simonarzt band. Very rarely, a similar fibrous soft tissue band can be seen interrupting the complete cleft of the alveolus. This alveolar band has not been previously described in the literature.
|
['Alveolar Process', 'Cleft Lip', 'Cleft Palate', 'Female', 'Humans', 'Male']
| 23,524,819
|
[['A02.835.232.781.324.502.125', 'A14.521.125', 'A14.549.167.646.094'], ['C07.465.409.225', 'C07.465.525.164', 'C07.650.525.164', 'C16.131.850.525.164'], ['C05.500.460.185', 'C05.660.207.540.460.185', 'C07.320.440.185', 'C07.465.525.185', 'C07.650.500.460.185', 'C07.650.525.185', 'C16.131.621.207.540.460.185', 'C16.131.850.500.460.185', 'C16.131.850.525.185'], ['B01.050.150.900.649.313.988.400.112.400.400']]
|
['Anatomy [A]', 'Diseases [C]', 'Organisms [B]']
| 1
| 1
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 0
| 0
| 0
| 0
| 0
|
Constitutive activation of nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer.
|
To date, no effective treatment for patients with advanced androgen-independent prostate cancer is available, whereas androgen ablation therapy, surgery, and radiation therapy are effective in treating local, androgen-dependent tumors. The mechanisms underlying the differences between androgen-dependent and -independent prostate cancer remain elusive. Interleukin (IL)-6 is a pleiotropic cytokine whose expression under normal physiological conditions is tightly controlled. However, aberrant constitutive IL-6 gene expression has been implicated in prostate cancer progression and resistance to chemotherapy and has been directly linked to prostate cancer morbidity and mortality. Particularly striking is the large increase in the expression of IL-6 in hormone-refractory prostate cancer. IL-6, in addition to its role as an immunomodulatory cytokine, functions as a growth and differentiation factor for prostate cancer cells. To determine the molecular mechanisms that lead to deregulated IL-6 expression in advanced prostate cancer, we examined the regulatory elements involved in IL-6 gene expression in androgen-independent prostate cancer cells. We demonstrate that, in contrast to the androgen-sensitive LNCaP cells, androgen-insensitive PC-3 and DU145 cells express high levels of IL-6 protein and mRNA due to enhanced promoter activity. Deregulated activation of the IL-6 promoter is for the most part mediated by a combined constitutive activation of the nuclear factor (NF)-kappaB p50 and p65 and the activator protein 1 (AP-1) JunD and Fra-1 family members as demonstrated by electrophoretic mobility shift assays, site-directed mutagenesis, and transfection experiments. Mutation of the NF-kappaB and AP-1 sites drastically reduces IL-6 promoter activity in both androgen-independent prostate cancer cell lines. Additionally, inhibition of these transcription factors using adenovirus vectors encoding either the IkappaBalpha repressor gene or a dominant negative JunD mutant leads to a strong down-regulation of IL-6 gene expression at the mRNA and protein level as measured by real-time PCR and ELISA, respectively. Furthermore, the blockade of IL-6 gene expression results in drastic inhibition of the constitutively activated signal transducers and activators of transcription 3 signaling pathway in DU145 cells. Our data demonstrate for the first time that a combined aberrant activation of NF-kappaB p50 and p65 and AP-1 JunD and Fra-1 in androgen-independent prostate cancer cells results in deregulated IL-6 expression, suggesting a novel potential entry point for therapeutic intervention in prostate cancer.
|
['DNA-Binding Proteins', 'Down-Regulation', 'Gene Expression Regulation, Neoplastic', 'Humans', 'I-kappa B Proteins', 'Interleukin-6', 'Male', 'NF-kappa B', 'NF-kappa B p50 Subunit', 'Neoplasms, Hormone-Dependent', 'Phosphorylation', 'Promoter Regions, Genetic', 'Prostatic Neoplasms', 'Proto-Oncogene Proteins c-fos', 'Proto-Oncogene Proteins c-jun', 'RNA, Messenger', 'STAT3 Transcription Factor', 'Trans-Activators', 'Transcription Factor RelA', 'Transcriptional Activation', 'Transfection', 'Tumor Cells, Cultured']
| 12,727,841
|
[['D12.776.260'], ['G02.111.240', 'G05.308.200', 'G07.690.773.937'], ['G05.308.370'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['D12.644.360.365', 'D12.776.260.420', 'D12.776.476.381', 'D12.776.930.326'], ['D12.644.276.374.465.224', 'D12.776.467.374.465.202', 'D23.529.374.465.224'], ['D05.500.672', 'D12.776.260.600', 'D12.776.660.600', 'D12.776.930.600'], ['D12.776.260.600.124', 'D12.776.660.600.124', 'D12.776.930.600.124'], ['C04.626'], ['G02.111.665', 'G02.607.780', 'G03.796'], ['G02.111.570.080.689.675', 'G05.360.080.689.675', 'G05.360.340.024.340.137.750.680'], ['C04.588.945.440.770', 'C12.294.260.750', 'C12.294.565.625', 'C12.758.409.750'], ['D12.776.260.108.765', 'D12.776.624.664.700.179', 'D12.776.660.760', 'D12.776.930.127.765'], ['D12.776.260.108.820', 'D12.776.624.664.700.182', 'D12.776.660.763', 'D12.776.930.127.820'], ['D13.444.735.544'], ['D12.644.360.024.342.300', 'D12.776.157.057.186.300', 'D12.776.476.024.430.300', 'D12.776.930.840.300'], ['D12.776.260.755', 'D12.776.930.900', 'D12.776.964.925.984'], ['D12.776.260.600.249', 'D12.776.660.600.249', 'D12.776.930.600.249'], ['G05.308.800'], ['E05.393.350.810', 'G05.728.860'], ['A11.251.860']]
|
['Chemicals and Drugs [D]', 'Phenomena and Processes [G]', 'Organisms [B]', 'Diseases [C]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Anatomy [A]']
| 1
| 1
| 1
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 0
|
PcDWF1, a pear brassinosteroid biosynthetic gene homologous to AtDWARF1, affected the vegetative and reproductive growth of plants.
|
BACKGROUND: The steroidal hormones brassinosteroids (BRs) play important roles in plant growth and development. The pathway and genes involved in BR biosynthesis have been identified primarily in model plants like Arabidopsis, but little is known about BR biosynthesis in woody fruits such as pear.RESULTS: In this study, we found that applying exogenous brassinolide (BL) could significantly increase the stem growth and rooting ability of Pyrus ussuriensis. PcDWF1, which had a significantly lower level of expression in the dwarf-type pear than in the standard-type pear, was cloned for further analysis. A phylogenetic analysis showed that PcDWF1 was a pear brassinosteroid biosynthetic gene that was homologous to AtDWARF1. The subcellular localization analysis indicated that PcDWF1 was located in the plasma membrane. Overexpression of PcDWF1 in tobacco (Nicotiana tabacum) or pear (Pyrus ussuriensis) plants promoted the growth of the stems, which was caused by a larger cell size and more developed xylem than those in the control plants, and the rooting ability was significantly enhanced. In addition to the change in vegetative growth, the tobacco plants overexpressing PcDWF1 also had a delayed flowering time and larger seed size than did the control tobacco plants. These phenotypes were considered to result from the higher BL contents in the transgenic lines than in the control tobacco and pear plants.CONCLUSIONS: Taken together, these results reveal that the pear BR biosynthetic gene PcDWF1 affected the vegetative and reproductive growth of Pyrus ussuriensis and Nicotiana tabacum and could be characterized as an important BR biosynthetic gene in perennial woody fruit plants.
|
['Brassinosteroids', 'Flowers', 'Fruit', 'Gene Expression Regulation, Plant', 'Plant Proteins', 'Plants, Genetically Modified', 'Pyrus', 'Tobacco']
| 32,143,576
|
[['D04.210.500.247.808.756.071', 'D10.570.938.795.071', 'D23.704.500.071'], ['A18.024.249.500'], ['A18.024.500', 'G07.203.300.562', 'J02.500.562'], ['G05.308.375'], ['D12.776.765'], ['B01.650.520', 'B05.620.600'], ['B01.650.940.800.575.912.250.859.937.500.699'], ['B01.650.940.800.575.912.250.908.500.900']]
|
['Chemicals and Drugs [D]', 'Anatomy [A]', 'Phenomena and Processes [G]', 'Technology, Industry, and Agriculture [J]', 'Organisms [B]']
| 1
| 1
| 0
| 1
| 0
| 0
| 1
| 0
| 0
| 1
| 0
| 0
| 0
| 0
|
O2- and O4-ethylthymine and the ethylphosphotriester dTp(Et)dT are highly persistent DNA modifications in slowly dividing tissues of the ethylnitrosourea-treated rat.
|
Male Wistar rats received a single i.p. injection of [3H]ethylnitrosourea (140 mg/kg) and were killed after 2 h, 1, 3, 6, 28 or 56 days. DNA of the following organs was isolated and analysed for the presence of 12 different ethylated bases and ethylphosphotriesters: brain, lung, liver, spleen, kidney, intestine, testis and bone marrow. At 2 h after injection the extent of DNA ethylation was found to be heterogeneous: highest in liver and lowest (3-4 times lower) in testis and brain. The rates at which O2- and O4-ethylthymine and the ethylphosphotriester dTp(Et)dT were lost, were very low in all organs except intestine and spleen. Most likely, loss in the latter organs is exclusively due to cell turnover. The rate of O6-ethylguanine repair strongly varied from organ to organ: high in liver, very low in testis and brain and intermediate in the other organs. In none of the DNAs were significant amounts of imidazole ring-opened 7-ethylguanine found. Our results strengthen the notion that a substantial part of carcinogen-induced DNA damage is of a highly persistent nature and might contribute to the carcinogenic process long after the original exposure has occurred.
|
['Animals', 'Cell Division', 'DNA', 'DNA Damage', 'Dinucleoside Phosphates', 'Ethylnitrosourea', 'Kinetics', 'Male', 'Rats', 'Rats, Inbred Strains', 'Thymine', 'Thymine Nucleotides', 'Tissue Distribution']
| 3,608,071
|
[['B01.050'], ['G04.144.220', 'G04.161.750.500', 'G05.113', 'G07.345.249.410.750.500'], ['D13.444.308'], ['G05.200'], ['D13.695.250'], ['D02.065.950.594.310', 'D02.654.692.300'], ['G01.374.661', 'G02.111.490'], ['B01.050.150.900.649.313.992.635.505.700'], ['B01.050.050.199.520.760', 'B01.050.150.900.649.313.992.635.505.700.400'], ['D03.383.742.698.875.899'], ['D03.383.742.686.706', 'D13.695.201.789', 'D13.695.740.706'], ['G03.787.917', 'G07.690.725.949']]
|
['Organisms [B]', 'Phenomena and Processes [G]', 'Chemicals and Drugs [D]']
| 0
| 1
| 0
| 1
| 0
| 0
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 0
|
Rapid and efficient chiral separation of nateglinide and its L-enantiomer on monolithic molecularly imprinted polymers.
|
A monolithic molecularly imprinted polymer (monolithic MIP) was designed and prepared for chiral separation of nateglinide and its L-enantiomer. The enantiomers were rapidly separated on this novel monolithic MIP based chiral stationary phase (MIP-CSP), whereas the enantioseparation was not obtained on the non-imprinted polymer (NIP). Chiral recognition was found to be dependent on the stereo structures and the arrangement of functional groups of the imprinted molecule and the cavities on MIP. Thermodynamic data (deltadeltaH and deltadeltaS) obtained by Van't Hoff plots revealed an enthalpy-controlled enantioseparation. The binding capacity was evaluated by frontal analysis. Monolithic nateglinide-MIP had an effective number of binding sites Bt = 41.15 micromol g(-1) with a dissociation constant of Kd = 7.40 mM. The morphological characteristics of the monolithic MIP were investigated by pore analysis and scanning electron microscope (SEM). Results showed that both mesopores and macropores were formed in the monolith. Over all, this study presents a new and practical possibility for providing high rates of mass transfer, fast separations and high efficiencies without the pressure constraints of the traditional bulk molecularly imprinted polymers, through the monolithic MIPs.
|
['Acrylic Resins', 'Chromatography, High Pressure Liquid', 'Cyclohexanes', 'Microscopy, Electron, Scanning', 'Nateglinide', 'Phenylalanine', 'Stereoisomerism', 'Thermodynamics']
| 16,196,134
|
[['D05.750.716.822.111', 'D25.720.716.822.111', 'J01.637.051.720.716.822.111'], ['E05.196.181.400.300'], ['D02.455.426.392.368.367'], ['E01.370.350.515.402.541', 'E05.595.402.541'], ['D02.455.426.392.368.367.745', 'D12.125.072.050.685.448'], ['D12.125.072.050.685', 'D12.125.142.666'], ['G02.607.445.682'], ['G01.906']]
|
['Chemicals and Drugs [D]', 'Technology, Industry, and Agriculture [J]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Phenomena and Processes [G]']
| 0
| 0
| 0
| 1
| 1
| 0
| 1
| 0
| 0
| 1
| 0
| 0
| 0
| 0
|
Tuning the ion selectivity of glutamate transporter-associated uncoupled conductances.
|
The concentration of glutamate within a glutamatergic synapse is tightly regulated by excitatory amino acid transporters (EAATs). In addition to their primary role in clearing extracellular glutamate, the EAATs also possess a thermodynamically uncoupled Cl(-) conductance. This conductance is activated by the binding of substrate and Na(+), but the direction of Cl(-) flux is independent of the rate or direction of substrate transport; thus, the two processes are thermodynamically uncoupled. A recent molecular dynamics study of the archaeal EAAT homologue GltPh (an aspartate transporter from Pyrococcus horikoshii) identified an aqueous pore at the interface of the transport and trimerization domains, through which anions could permeate, and it was suggested that an arginine residue at the most restricted part of this pathway might play a role in determining anion selectivity. In this study, we mutate this arginine to a histidine in the human glutamate transporter EAAT1 and investigate the role of the protonation state of this residue on anion selectivity and transporter function. Our results demonstrate that a positive charge at this position is crucial for determining anion versus cation selectivity of the uncoupled conductance of EAAT1. In addition, because the nature of this residue influences the turnover rate of EAAT1, we reveal an intrinsic link between the elevator movement of the transport domain and the Cl(-) channel.
|
['Animals', 'Excitatory Amino Acid Transporter 1', 'Glutamic Acid', 'Humans', 'Ion Transport', 'Molecular Dynamics Simulation', 'Xenopus laevis']
| 27,296,367
|
[['B01.050'], ['D12.776.157.530.200.249.500.500.500', 'D12.776.157.530.450.625.147.500', 'D12.776.157.530.562.374.781.500', 'D12.776.157.530.937.250.500.500', 'D12.776.543.585.200.249.500.500.500', 'D12.776.543.585.450.625.147.500', 'D12.776.543.585.562.374.781.500', 'D12.776.543.585.937.250.500.500'], ['D12.125.067.625.349', 'D12.125.119.409.349', 'D12.125.427.300'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['G03.143.500'], ['E05.599.595.500', 'G02.111.570.895', 'L01.224.160.500'], ['B01.050.150.900.090.180.610.500.562']]
|
['Organisms [B]', 'Chemicals and Drugs [D]', 'Phenomena and Processes [G]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Information Science [L]']
| 0
| 1
| 0
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 1
| 0
| 0
| 0
|
Serial optical coherence tomography assessment of malapposed struts after everolimus-eluting stent implantation. A subanalysis from the HEAL-EES study.
|
BACKGROUND: Incomplete stent apposition (ISA) is related to stent thrombosis, which is a serious adverse event. We aim to assess the time-course of ISA after 2nd generation everolimus-eluting stent (EES) implantation.METHODS: In HEAL-EES study, we enrolled 36 patients who underwent percutaneous coronary intervention (PCI) with EES. OCT imaging was performed at baseline and follow-up. Patients were randomized 1:1:1 into 3 groups according to the time in which follow-up was performed: group A (6-month), group B (9-month), and group C (12-month). In this subanalysis, patients who had ISA segments at baseline and/or follow-up OCT were analyzed.RESULT: At baseline, among 41 lesions in 36 patients, 20 lesions in 18 patients had ISA segments and were analyzed. At baseline, there were 3.0% ISA struts in group A (n=8), 2.8% in group B (n=4), and 4.5% in group C (n=8). At follow-up, ISA struts were present in 0.09%, 0.16% and 0.64%; respectively in groups A, B, and C. At follow-up, there was a significant decrease in the frequency of ISA: group A 3.0% vs. 0.09% (p<0.001), group B 2.8% vs. 0.16% (p<0.001), and group C 4.5% vs. 0.64% (p<0.001). In group A, there was one late acquired ISA at follow-up.CONCLUSIONS: In patients undergoing 2nd generation EES implantation, area of acute ISA assessed by OCT, was almost resolved at 6-month follow-up.
|
['Aged', 'Cardiovascular Agents', 'Coronary Artery Disease', 'Coronary Thrombosis', 'Coronary Vessels', 'Drug-Eluting Stents', 'Everolimus', 'Female', 'Humans', 'Male', 'Middle Aged', 'Neointima', 'Percutaneous Coronary Intervention', 'Predictive Value of Tests', 'Prosthesis Design', 'Randomized Controlled Trials as Topic', 'Retrospective Studies', 'Time Factors', 'Tomography, Optical Coherence', 'Treatment Outcome']
| 27,634,493
|
[['M01.060.116.100'], ['D27.505.954.411'], ['C14.280.647.250.260', 'C14.907.137.126.339', 'C14.907.585.250.260'], ['C14.280.647.250.290', 'C14.907.355.830.220', 'C14.907.585.250.290'], ['A07.015.114.269', 'A07.015.908.194'], ['E07.695.750.500'], ['D02.540.505.760.500'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['M01.060.116.630'], ['C23.550.722'], ['E04.100.814.529.968', 'E04.502.382.968'], ['E05.318.370.800.650', 'N05.715.360.325.700.640', 'N06.850.520.445.800.650'], ['E05.320.550', 'E07.695.680'], ['E05.318.372.250.250.365.500', 'N05.715.360.330.250.250.365.500', 'N06.850.520.450.250.250.365.500'], ['E05.318.372.500.500.500', 'E05.318.372.500.750.750', 'N05.715.360.330.500.500.500', 'N05.715.360.330.500.750.825', 'N06.850.520.450.500.500.500', 'N06.850.520.450.500.750.825'], ['G01.910.857'], ['E01.370.350.589.249.500', 'E01.370.350.825.805.500', 'E05.642.249.500'], ['E01.789.800', 'N04.761.559.590.800', 'N05.715.360.575.575.800']]
|
['Named Groups [M]', 'Chemicals and Drugs [D]', 'Diseases [C]', 'Anatomy [A]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Organisms [B]', 'Health Care [N]', 'Phenomena and Processes [G]']
| 1
| 1
| 1
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 1
| 1
| 0
|
Ligand-based targeted delivery of a peptide modified nanocarrier to endothelial cells in adipose tissue.
|
Ligand-based targeted delivery is an emerging platform in nanomedicine. We report herein on a peptide modified nanocarrier for a ligand-based targeted delivery system. The liposomal surface of the carrier was first modified with a linear peptide, followed by an adipose tissue-specific circular peptide (KGGRAKD) via a polyethylene glycol (PEG) spacer. To evaluate the specificity of the carrier, we purified primary cells from the endothelium of adipose tissue. The liposomes bound only to isolated primary cultured endothelial cells derived from inguinal adipose tissue (pcEC-IWAT) and not to other endothelial cell lines, such as MBEC-4 and MFLM-4. Cellular uptake was confirmed both qualitatively and quantitatively by confocal laser scanning microscopy (CLSM) and flow cytometry. The mechanism for the intracellular uptake of tPep-PEG-LPs into pcEC-IWAT, as evidenced by three independent experiments, involves saturation of receptor binding sites by excess free peptide, the blocking of receptors by an anti-prohibitin antibody and low temperature (4°C) experiments, resulting in the inhibition of uptake of tPep-PEG-LPs into pcEC-IWAT, suggesting that receptor mediated endocytosis largely contributed to the observed cellular uptake. A co-localization study using double labeled modified liposomes (lipid membrane: NBD-DOPE and aqueous phase: rhodamine) indicated that a predominant part of tPep-PEG-LPs was found without co-localization with lysosomes and retained their intactness. The selective delivery of tPep-PEG-LPs to endothelial cells in adipose tissue represents a potential approach for the design of diverse nanocarrier-based targeted delivery systems for targeting the vasculature in adipose tissue.
|
['Adipose Tissue', 'Animals', 'Cell Line', 'Cytoplasm', 'Drug Carriers', 'Drug Compounding', 'Endothelial Cells', 'Flow Cytometry', 'Ligands', 'Liposomes', 'Mice', 'Microscopy, Confocal', 'NIH 3T3 Cells', 'Nanoparticles', 'Obesity', 'Oligopeptides', 'Organ Specificity', 'Protein Binding']
| 20,647,023
|
[['A10.165.114'], ['B01.050'], ['A11.251.210'], ['A11.284.430.214'], ['D26.255.260', 'E02.319.300.380'], ['E05.916.270'], ['A11.436.275'], ['E01.370.225.500.363.342', 'E01.370.225.500.386.350', 'E05.196.712.516.600.240.350', 'E05.200.500.363.342', 'E05.200.500.386.350', 'E05.242.363.342', 'E05.242.386.350'], ['D27.720.470.480'], ['D25.479.517', 'D26.255.260.517', 'J01.637.051.479.517', 'J01.637.087.500.517'], ['B01.050.150.900.649.313.992.635.505.500'], ['E01.370.350.515.395', 'E05.595.395'], ['A11.251.210.100.550', 'A11.329.228.100.550'], ['J01.637.512.600'], ['C18.654.726.500', 'C23.888.144.699.500', 'E01.370.600.115.100.160.120.699.500', 'G07.100.100.160.120.699.500'], ['D12.644.456'], ['G07.650'], ['G02.111.679', 'G03.808']]
|
['Anatomy [A]', 'Organisms [B]', 'Chemicals and Drugs [D]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Technology, Industry, and Agriculture [J]', 'Diseases [C]', 'Phenomena and Processes [G]']
| 1
| 1
| 1
| 1
| 1
| 0
| 1
| 0
| 0
| 1
| 0
| 0
| 0
| 0
|
Autoregulation of RNA helicase expression in response to temperature stress in Synechocystis sp. PCC 6803.
|
RNA helicases are ubiquitous enzymes whose modification of RNA secondary structure is known to regulate RNA function. The pathways controlling RNA helicase expression, however, have not been well characterized. Expression of the cyanobacterial RNA helicase, crhR, is regulated in response to environmental signals that alter the redox poise of the electron transport chain, including light and temperature. Here we analyze crhR expression in response to alteration of abiotic conditions in wild type and a crhR mutant, providing evidence that CrhR autoregulates its own expression through a combination of transcriptional and post-transcriptional mechanisms. Temperature regulates crhR expression through alteration of both transcript and protein half-life which are significantly extended at low temperature (20°C). CrhR-dependent mechanisms regulate both the transient accumulation of crhR transcript at 20°C and stability of the CrhR protein at all temperatures. CrhR-independent mechanisms regulate temperature sensing and induction of crhR transcript accumulation at 20°C and the temperature regulation of crhR transcript stability, suggesting CrhR is not directly associated with crhR mRNA turnover. Many of the processes are CrhR- and temperature-dependent and occur in the absence of a correlation between crhR transcript and protein abundance. The data provide important insights into not only how RNA helicase gene expression is regulated but also the role that rearrangement of RNA secondary structure performs in the molecular response to temperature stress. We propose that the crhR-regulatory pathway exhibits characteristics similar to the heat shock response rather than a cold stress-specific mechanism.
|
['Bacterial Proteins', 'Blotting, Northern', 'Blotting, Western', 'Cold Temperature', 'Gene Expression Regulation, Enzymologic', 'Half-Life', 'Heat-Shock Response', 'Homeostasis', 'Light', 'Mutation', 'RNA Helicases', 'RNA, Messenger', 'Stress, Physiological', 'Synechocystis', 'Temperature', 'Time Factors']
| 23,119,089
|
[['D12.776.097'], ['E05.196.401.095', 'E05.301.300.074', 'E05.601.100'], ['E05.196.401.143', 'E05.301.300.096', 'E05.478.566.320.200', 'E05.601.262', 'E05.601.470.320.200'], ['G01.906.595.272', 'G16.500.275.063.725.710.300', 'G16.500.750.775.710.300', 'N06.230.300.100.725.154', 'N06.230.300.100.725.710.300'], ['G05.308.320'], ['G01.910.405'], ['G07.775.500'], ['G07.410'], ['G01.358.500.505.650', 'G01.590.540', 'G01.750.250.650', 'G01.750.770.578'], ['G05.365.590'], ['D08.811.913.696.445.735.720'], ['D13.444.735.544'], ['G07.775'], ['B03.280.750', 'B03.440.475.100.750'], ['G01.906.595', 'G16.500.275.063.725.710', 'G16.500.750.775.710', 'N06.230.150.450', 'N06.230.300.100.725.710'], ['G01.910.857']]
|
['Chemicals and Drugs [D]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Phenomena and Processes [G]', 'Health Care [N]', 'Organisms [B]']
| 0
| 1
| 0
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 0
| 1
| 0
|
Nucleotide receptors activate cation, potassium, and chloride currents in a liver cell line.
|
By use of whole cell patch-clamp techniques, the effects of extracellular ATP on membrane ion currents of HTC cells from a rat liver tumor line were evaluated. ATP (500 microM) or the nonhydrolyzable analogue adenosine 5'-O-(3-thiotriphosphate) caused sequential activation of three currents: Icat (-1,325 +/- 255 pA at -80 mV) occurred early, was due to increased Na+ and K+ permeability, was present in 56% of 64 consecutive cells, and rapidly inactivated; IK (274 +/- 45 pA at 0 mV) was present in 59% of cells and also inactivated; and ICl (1,172 +/- 237 pA at +60 mV) was present in 94% of studies, was sustained, and exhibited outward rectification of the current-voltage relation. All three currents were present in 39% of cells. Increasing intracellular Ca2+ concentration ([Ca2+]i) by exposure to the 5'-nucleotide receptor agonist UTP (500 microM) or to thapsigargin activated Icat and IK but not ICl, whereas increasing ethylene glycol-bis(beta-aminoethyl ether)-N,N,N',N'-tetraacetic acid in the pipette (> or = 5 mM) inhibited ATP-dependent activation of Icat and IK but not ICl. A P2x-preferring agonist alpha, beta-methylene ATP (500 microM) did not activate currents; a P2y-preferring agonist 2-methylthioadenosine triphosphate activated Icat and IK at concentrations of 500 microM but not 50 microM. In perforated patch recordings, ATP produced triphasic changes in membrane potential with initial depolarization due to Icat, subsequent hyperpolarization due to IK, and a later sustained depolarization due to ICl. These findings indicate that ATP modulates HTC cell ion permeability through initial activation of Icat and IK mediated by 5'-nucleotide receptors which mobilize [Ca2+], and sustained activation of ICl through a separate Ca(2+)-independent mechanism.
|
['Adenosine Triphosphate', 'Animals', 'Calcium', 'Cations', 'Chlorides', 'Electric Conductivity', 'Intracellular Membranes', 'Liver', 'Membrane Potentials', 'Nucleotides', 'Potassium', 'Rats', 'Receptors, Cell Surface', 'Terpenes', 'Thapsigargin', 'Tumor Cells, Cultured', 'Uridine Triphosphate']
| 8,178,992
|
[['D03.633.100.759.646.138.236', 'D13.695.667.138.236', 'D13.695.827.068.236'], ['B01.050'], ['D01.268.552.100', 'D01.552.539.288', 'D23.119.100'], ['D01.248.497.300'], ['D01.210.450.150', 'D01.248.497.158.215'], ['G01.358.500.249.277'], ['A11.284.149.450', 'A11.284.835.514'], ['A03.620'], ['G01.154.535', 'G04.580', 'G07.265.675', 'G11.561.570'], ['D09.408.620', 'D13.695'], ['D01.268.549.550', 'D01.268.557.575', 'D01.552.528.652', 'D01.552.547.650'], ['B01.050.150.900.649.313.992.635.505.700'], ['D12.776.543.750'], ['D02.455.849'], ['D02.455.426.392.368.284.500.888', 'D02.455.849.765.674.500.750.888', 'D04.663.500.750.888'], ['A11.251.860'], ['D03.383.742.686.850.950', 'D13.695.740.850.950', 'D13.695.827.919.950']]
|
['Chemicals and Drugs [D]', 'Organisms [B]', 'Phenomena and Processes [G]', 'Anatomy [A]']
| 1
| 1
| 0
| 1
| 0
| 0
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 0
|
NKG2D modulates aggravation of liver inflammation by activating NK cells in HBV infection.
|
Hepatitis B virus (HBV) infection is thought to be an immune-mediated liver disease. The mechanisms underlying natural killer (NK) cell group 2D receptor (NKG2D) that activates NK cells and participates in anti-HBV immunity and immunopathology has not been thoroughly elucidated. Peripheral NKG2D+ and IFN-ã+ NK cells frequencies and intrahepatic NKG2D and IFN-ã mRNA and protein expressions were determined in HBV-infected patients. Levels of NKG2D and IFN-ã mRNA and protein in NK cells, co-cultured with HBV-replicating HepG2 cells with or without NKG2D blockade, were analyzed. Serum and supernatant IFN-ã, TNF-á, perforin and granzyme B were measured. In results, peripheral NKG2D+ and IFN-ã+ NK cells frequencies, intrahepatic NKG2D and IFN-ã mRNA and protein levels, and serum IFN-ã, TNF-á, perforin and granzyme B levels were all highest in HBV-related acute-on-chronic liver failure group, followed by chronic hepatitis B and chronic HBV carrier groups. In vitro, NKG2D and IFN-ã mRNA and protein levels were higher in NK cells with IFN-á stimulation than without stimulation. Supernatant IFN-ã, TNF-á, perforin and granzyme B levels were increased under co-culture or IFN-á stimulating conditions, but were partially blocked by NKG2DmAb. In conclusion, NKG2D regulates immune inflammation and anti-viral response partly through activation of NK cells during HBV infection.
|
['Adult', 'Coculture Techniques', 'Disease Progression', 'Female', 'Granzymes', 'Hep G2 Cells', 'Hepatitis B virus', 'Hepatitis B, Chronic', 'Humans', 'Interferon-gamma', 'Killer Cells, Natural', 'Liver', 'Male', 'Middle Aged', 'NK Cell Lectin-Like Receptor Subfamily K', 'Perforin', 'Prospective Studies', 'Tumor Necrosis Factor-alpha']
| 28,273,905
|
[['M01.060.116'], ['E05.481.500.374'], ['C23.550.291.656'], ['D08.811.277.656.300.760.397', 'D08.811.277.656.959.350.397'], ['A11.251.860.180.432', 'A11.436.348.500'], ['B04.280.375.650.425', 'B04.450.390.650.425'], ['C01.221.250.500.100', 'C01.925.256.430.400.100', 'C01.925.440.435.100', 'C06.552.380.350.100', 'C06.552.380.705.437.100'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['D12.644.276.374.440.893', 'D12.644.276.374.480.615.350', 'D12.776.467.374.440.893', 'D12.776.467.374.480.615.350', 'D23.529.374.440.893', 'D23.529.374.480.615.350'], ['A11.118.637.555.567.537', 'A15.145.229.637.555.567.537', 'A15.382.490.555.567.537'], ['A03.620'], ['M01.060.116.630'], ['D12.776.543.750.705.895.800.910'], ['D12.776.543.695.875'], ['E05.318.372.500.750.625', 'N05.715.360.330.500.750.650', 'N06.850.520.450.500.750.650'], ['D12.644.276.374.500.800', 'D12.644.276.374.750.626', 'D12.776.124.900', 'D12.776.395.930', 'D12.776.467.374.500.800', 'D12.776.467.374.750.626', 'D23.529.374.500.800', 'D23.529.374.750.626']]
|
['Named Groups [M]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Diseases [C]', 'Chemicals and Drugs [D]', 'Anatomy [A]', 'Organisms [B]', 'Health Care [N]']
| 1
| 1
| 1
| 1
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 1
| 1
| 0
|
Comparison of Laparoscopic Approaches for Dismembered Pyeloplasty in Children With Ureteropelvic Junction Obstruction: Critical Analysis of 11-Year Experiences in a Single Surgeon.
|
OBJECTIVE: The choice of different laparoscopic approaches of laparoscopic pyeloplasty (LP) in children remains controversial. We present a comparison of different approaches of LP in children and a critical analysis of 11-year experiences in a single surgeon.MATERIALS AND METHODS: There were 1750 patients (1889 sides) who underwent LP between 2003 and 2014 reviewed. The diagnosis and outcomes of ureteropelvic junction obstruction (UPJO) were reviewed based on clinical and imaging data. Retroperitoneal laparoscopic pyeloplasty (RPLP) were performed in 451 cases (RPLP group), conventional transperitoneal laparoscopic pyeloplasty (CTLP) were performed in 311 cases (CTLP group), transumbilical single-site laparoscopic pyeloplasty (TSLP) were performed in 322 cases (TSLP group), and transumbilical multiport laparoscopic pyeloplasty (TMLP) were performed in 805 cases (TMLP group). We assessed preoperative clinical data and outcomes, and analyzed the transition experience. Data are expressed as medians for continuous variables.RESULTS: The start of oral feeding, hospital stay, and the operative time of RPLP group were 1.10 ± 0.10 days, 5.22 ± 1.32 days, and 138.2 ± 20.1 minutes, respectively. Compared with the other 3 groups, the start of oral feeding was the soonest, hospital stay was the shortest, and the operative time was the longest in the RPLP group (P < .01 or .05). The cosmetic result of the TMLP group was 7.07 ± 1.20 scores, and there are significant differences in cosmetic results between the TMLP group and the other 3 groups (P < .05).CONCLUSION: Although the 4 laparoscopic approaches for LP in children with UPJO are safe and efficient procedures with equivalent success rates, we recommend RPLP or TMLP as a treatment option for children with UPJO.
|
['Adolescent', 'Child', 'Child, Preschool', 'Female', 'Follow-Up Studies', 'Forecasting', 'Humans', 'Infant', 'Kidney Pelvis', 'Laparoscopy', 'Male', 'Operative Time', 'Reconstructive Surgical Procedures', 'Retroperitoneal Space', 'Retrospective Studies', 'Surgeons', 'Treatment Outcome', 'Ureter', 'Ureteral Obstruction', 'Urologic Surgical Procedures']
| 27,765,585
|
[['M01.060.057'], ['M01.060.406'], ['M01.060.406.448'], ['E05.318.372.500.750.249', 'N05.715.360.330.500.750.350', 'N06.850.520.450.500.750.350'], ['I01.320'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['M01.060.703'], ['A05.810.453.537'], ['E01.370.388.250.520', 'E04.502.250.520'], ['E04.614.374.500', 'N02.421.585.753.374.500'], ['E04.680'], ['A01.923.047.025.750'], ['E05.318.372.500.500.500', 'E05.318.372.500.750.750', 'N05.715.360.330.500.500.500', 'N05.715.360.330.500.750.825', 'N06.850.520.450.500.500.500', 'N06.850.520.450.500.750.825'], ['M01.526.485.810.910', 'N02.360.810.910'], ['E01.789.800', 'N04.761.559.590.800', 'N05.715.360.575.575.800'], ['A05.810.776'], ['C12.777.725.776', 'C13.351.968.725.776'], ['E04.950.774']]
|
['Named Groups [M]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Health Care [N]', 'Anthropology, Education, Sociology, and Social Phenomena [I]', 'Organisms [B]', 'Anatomy [A]', 'Diseases [C]']
| 1
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 1
| 0
| 0
| 1
| 1
| 0
|
Consistent injury in the striatum of C57BL/6 mice after transient bilateral common carotid artery occlusion.
|
OBJECTIVE: The recent availability of transgenic mice enables us to study the functional role of single gene products in cerebral ischemia. To establish an experimental murine model of transient forebrain ischemia, this study examined the temporal profile of ischemic neuronal damage in the striatum after bilateral common carotid artery occlusion.METHODS: C57BL/6 mice, which are frequently used for genetic manipulations, were subjected to 15-minute bilateral common carotid artery occlusion. Ischemic injury was examined (4, 8, 24, 48, and 96 h after reperfusion) by Nissl staining, terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate-biotin nick-end-labeling, and nuclear staining with Hoechst 33258 dye.RESULTS: Regional cerebral blood flow was decreased to 11 +/- 6% of control values during the ischemic insult. Striatal injury was observed in 95% of animals examined after 15-minute bilateral common carotid artery occlusion. The number of small and medium-size neurons in the striatum was significantly (P < 0.05) decreased 8 hours after reperfusion and continued to decrease until 96 hours, whereas the number of large neurons remained constant. Terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate-biotin nick-end-labeling-positive cells appeared in the dorsomedial region of the striatum 48 hours after the ischemic insult and throughout the striatum 96 hours after the ischemic insult. Brain sections stained with Hoechst 33258 dye also demonstrated apoptotic nuclei 96 hours after the ischemic insult.CONCLUSION: Striatal injury after transient forebrain ischemia is reproducible in C57BL/6 mice and is a good model to study the molecular mechanisms of ischemic injury, including delayed neuronal death, using transgenic mice.
|
['Animals', 'Apoptosis', 'Brain Ischemia', 'Brain Mapping', 'Carotid Stenosis', 'Corpus Striatum', 'Dominance, Cerebral', 'In Situ Nick-End Labeling', 'Ischemic Attack, Transient', 'Mice', 'Mice, Inbred C57BL', 'Necrosis', 'Neurons', 'Reperfusion Injury']
| 9,766,318
|
[['B01.050'], ['G04.146.954.035'], ['C10.228.140.300.150', 'C14.907.253.092'], ['E01.370.350.578.875.500', 'E01.370.376.537.625.500', 'E05.629.875.500'], ['C10.228.140.300.200.360', 'C14.907.137.230', 'C14.907.253.123.360'], ['A08.186.211.200.885.287.249.487'], ['F02.830.297', 'G11.561.225'], ['E05.393.475'], ['C10.228.140.300.150.836', 'C14.907.253.092.836'], ['B01.050.150.900.649.313.992.635.505.500'], ['B01.050.050.199.520.520.420', 'B01.050.150.900.649.313.992.635.505.500.400.420'], ['C23.550.717'], ['A08.675', 'A11.671'], ['C14.907.725', 'C23.550.767.877']]
|
['Organisms [B]', 'Phenomena and Processes [G]', 'Diseases [C]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Anatomy [A]', 'Psychiatry and Psychology [F]']
| 1
| 1
| 1
| 0
| 1
| 1
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 0
|
Liver histology and immunohistochemical findings in asymptomatic Indians with incidental detection of hepatitis B virus infection.
|
BACKGROUND AND OBJECTIVES: The relationship between hepatocyte expression of hepatitis B virus (HBV) antigens, liver histology and viral replication in asymptomatic subjects with incidental detection of hepatitis B surface antigen (HBsAg) remains unclear. We evaluated the histological activity index (HAI) and hepatocyte expression of viral antigens with replicative status in asymptomatic chronic HBV infection.METHODS: Asymptomatic subjects with incidental detection of HBsAg and ALT levels less than twice the upper limit of normal were grouped as follows: Group A - negative for HBeAg and HBV DNA (no HBV replication); B - HBeAg negative, HBV DNA positive (low HBV replication or pre-core mutant); C - positive HBeAg and HBV DNA (high viral replication). Liver biopsies were assessed for HAI (Ishak's scoring system). These were also subjected to immunohistochemistry for expression of HBsAg and hepatitis B core antigen (HBcAg); distribution, staining pattern and quantitative measurement of antigen expression were assessed.RESULTS: Median HAI was similar in the three groups (1.0, 2.0 and 2.0 in groups A, B and C, respectively). All subjects in Group C showed discrete cytoplasmic expression of HBsAg, whereas the other two groups showed heterogeneity in distribution and pattern of HBsAg staining. Quantitative measurement of cytoplasmic HBsAg revealed similar results in the three groups. Core antigen (nuclear) was detected in 4 of 5 subjects in Group C and none of those in Groups A and B. Ground-glass hepatocytes were seen in 20 and orcein-positive cells in 26 cases. HBsAg was detected by immunohistochemistry in 37 biopsies.CONCLUSIONS: Among asymptomatic subjects with chronic HBV infection, those with high rate of viral replication had discrete cytoplasmic HBsAg expression and nuclear expression of core antigen; these findings were uncommon in subjects with low or no viral replication.
|
['Adult', 'Alanine Transaminase', 'Biomarkers', 'DNA, Viral', 'Female', 'Hepatitis B Core Antigens', 'Hepatitis B Surface Antigens', 'Hepatitis B virus', 'Hepatitis B, Chronic', 'Hepatocytes', 'Humans', 'Immunohistochemistry', 'Incidental Findings', 'Liver', 'Male', 'Sensitivity and Specificity', 'Virus Replication']
| 16,877,824
|
[['M01.060.116'], ['D08.811.913.477.700.100'], ['D23.101'], ['D13.444.308.568'], ['D23.050.327.495.500.450'], ['D23.050.327.495.500.475'], ['B04.280.375.650.425', 'B04.450.390.650.425'], ['C01.221.250.500.100', 'C01.925.256.430.400.100', 'C01.925.440.435.100', 'C06.552.380.350.100', 'C06.552.380.705.437.100'], ['A11.436.348'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['E01.370.225.500.607.512', 'E01.370.225.750.551.512', 'E05.200.500.607.512', 'E05.200.750.551.512', 'E05.478.583', 'H01.158.100.656.234.512', 'H01.158.201.344.512', 'H01.158.201.486.512', 'H01.181.122.573.512', 'H01.181.122.605.512'], ['E01.410'], ['A03.620'], ['E05.318.370.800', 'E05.318.740.872', 'G17.800', 'N05.715.360.325.700', 'N05.715.360.750.725', 'N06.850.520.445.800', 'N06.850.520.830.872'], ['G06.920.925']]
|
['Named Groups [M]', 'Chemicals and Drugs [D]', 'Organisms [B]', 'Diseases [C]', 'Anatomy [A]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Disciplines and Occupations [H]', 'Phenomena and Processes [G]', 'Health Care [N]']
| 1
| 1
| 1
| 1
| 1
| 0
| 1
| 1
| 0
| 0
| 0
| 1
| 1
| 0
|
[A new method of non-invasive determination of the cardiac minute volume in ventilated patients].
|
A method for the determination of stroke volume and cardiac output from pulse-synchronized variations of pressure in mechanically ventilated patients is described. A comparison with 20 readings obtained by thermodilution showed good correlation (r = 0.9866).
|
['Aged', 'Cardiac Output', 'Humans', 'Male', 'Middle Aged', 'Respiration, Artificial', 'Thermodilution']
| 1,741,905
|
[['M01.060.116.100'], ['E01.370.370.380.150', 'G09.330.380.124'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['M01.060.116.630'], ['E02.041.625', 'E02.365.647.729', 'E02.880.820'], ['E05.484.750']]
|
['Named Groups [M]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Phenomena and Processes [G]', 'Organisms [B]']
| 0
| 1
| 0
| 0
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 1
| 0
| 0
|
The effects of HSP27 against UVB-induced photoaging in rat skin.
|
Skin photoaging refers to the phenomenon of skin aging or accelerated aging as a result of long-term UV exposure. Ultraviolet radiation can lead to DNA damage, cell apoptosis, cell growth inhibition and carcinogenic effects. Evidence suggests that hsp27 can protect cells from apoptosis induced by various stimuli in vivo and in vitro. However, modulation in hsp27 expression toward skin protection against UVB treatment has not been investigated clearly. In this study, we aimed to investigate the effects of hsp27 against UVB-induced photoaging in rat skin and to explore the underlying mechanisms. In the present study, we identified that the level of hsp27 increased after UVB irradiation induced chronic photoaging rat model. In order to investigate the function of hsp27 in UVB-induced skin photoaging, we used adeno-associated virus (AAV) to specificity reduce the expression of hsp27 in rat skin. In contrast to UVB group, we found that collagen fibers were disorganized and elastic fibers were thickened and twisted in UVB-AAV group. In the UVB-AAV group, reduced hsp27 enhanced the oxidative stress. Aging markers (SA-â-Gal staining and the protein levels of p16, p53, p21) were significantly changed in the hsp27 decreased group. However, in hsp27 deletion group, the expression of antiapoptotic factor bcl-2 was decreased, while the apoptosis factor bax was increased after UVB irradiation. These findings suggested that hsp27 was involved in oxidative stress, aging and apoptosis of skin after UV exposure. Management the expression of hsp27 can be used as a potential intervention method to alleviate UVB-induced skin damage.
|
['Animals', 'Apoptosis', 'Female', 'HSP27 Heat-Shock Proteins', 'Male', 'Oxidative Stress', 'Rats', 'Rats, Sprague-Dawley', 'Skin', 'Skin Aging', 'Ultraviolet Rays']
| 30,902,393
|
[['B01.050'], ['G04.146.954.035'], ['D12.776.580.216.270.625'], ['G03.673', 'G07.775.750'], ['B01.050.150.900.649.313.992.635.505.700'], ['B01.050.150.900.649.313.992.635.505.700.750'], ['A17.815'], ['G13.750.804'], ['G01.358.500.505.650.891', 'G01.590.540.891', 'G01.750.250.650.891', 'G01.750.750.659', 'G01.750.770.578.891', 'G16.500.275.063.725.525.600', 'G16.500.750.775.525.600', 'N06.230.300.100.725.525.600']]
|
['Organisms [B]', 'Phenomena and Processes [G]', 'Chemicals and Drugs [D]', 'Anatomy [A]', 'Health Care [N]']
| 1
| 1
| 0
| 1
| 0
| 0
| 1
| 0
| 0
| 0
| 0
| 0
| 1
| 0
|
Isolation and regulation of Sinorhizobium meliloti 1021 loci induced by oxygen limitation.
|
Eleven Sinorhizobium meliloti 1021 loci whose expression was induced under low oxygen concentrations were identified in a collection of 5,000 strains carrying Tn5-1063 (luxAB) transcriptional reporter gene fusions. The 11 Tn5-1063-tagged loci were cloned and characterized. The dependence of the expression of the tagged loci on the FixL/FixJ oxygen-sensing two-component regulatory system was examined. Three of the loci were found to be dependent upon fixL and fixJ for their expression, while one locus showed a partial dependence. The remaining seven loci showed fixL- and fixJ-independent induction of expression in response to oxygen limitation. This suggests that in S. meliloti, additional regulatory system(s) exist that respond either directly or indirectly to oxygen limitation conditions.
|
['Amino Acid Sequence', 'Bacterial Proteins', 'DNA Transposable Elements', 'Gene Expression Regulation, Bacterial', 'Hemeproteins', 'Histidine Kinase', 'Luciferases', 'Luminescent Measurements', 'Molecular Sequence Data', 'Oxygen', 'Recombinant Fusion Proteins', 'Sinorhizobium meliloti', 'Symbiosis']
| 11,472,955
|
[['G02.111.570.060', 'L01.453.245.667.060'], ['D12.776.097'], ['D13.444.308.520', 'G02.111.570.080.708.330.200', 'G05.360.080.708.330.200', 'G05.360.340.024.425.200'], ['G05.308.300'], ['D12.776.422'], ['D08.811.913.696.620.682.424'], ['D08.811.682.517', 'D12.776.532.510'], ['E05.196.712.516'], ['L01.453.245.667'], ['D01.268.185.550', 'D01.362.670'], ['D12.776.828.300'], ['B03.440.400.425.700.887.500', 'B03.660.050.662.835.800'], ['G06.550.800', 'G16.840']]
|
['Phenomena and Processes [G]', 'Information Science [L]', 'Chemicals and Drugs [D]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Organisms [B]']
| 0
| 1
| 0
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 1
| 0
| 0
| 0
|
A study of fractional CO₂ laser resurfacing: the best fluences through a clinical, histological, and ultrastructural evaluation.
|
BACKGROUND: Fractional resurfacing is a laser treatment modality to create numerous microscopic thermal injury zones of controlled width, depth, and density that are surrounded by a reservoir of spared epidermal and dermal tissue, allowing rapid repair of laser-induced thermal injury.OBJECTIVE: To evaluate the safety and efficacy of a fractional CO(2) laser system in the treatment of photo-damaged skin with clinical, histological, and ultrastructural evaluation, with special attention to one of the parameters of this laser system: the fluences.MATERIALS AND METHODS: Twelve patients with Fitzpatrick skin types II to III with photo-damage skin underwent fractional laser treatment with one single-pass superficial on the face and forearm. Clinical outcome and histological and ultrastructural changes were assessed.RESULTS: Light microscopy of biopsies gave important information about skin changes at three different times after fractional treatment, especially revealing some differences between the fluences used in the three groups of patients.CONCLUSION: Fractional resurfacing offers significant surgical advantages allowing to achieve excellent esthetic results in balance with the biological structure. Besides, our study shows already that with 2.07 and 2.77 J/cm(2) , instead of 4.15 J/cm(2) , it is possible to reach a biological response without scar formation.
|
['Collagen', 'Dermis', 'Dose Fractionation, Radiation', 'Epidermis', 'Female', 'Humans', 'Laser Therapy', 'Lasers, Gas', 'Middle Aged', 'Rejuvenation', 'Skin Aging', 'Treatment Outcome']
| 21,896,133
|
[['D05.750.078.280', 'D12.776.860.300.250'], ['A17.815.180'], ['E02.815.639.200'], ['A10.272.497', 'A17.815.250'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['E02.594', 'E04.014.520'], ['E07.632.490.367', 'E07.710.520.367'], ['M01.060.116.630'], ['E02.849'], ['G13.750.804'], ['E01.789.800', 'N04.761.559.590.800', 'N05.715.360.575.575.800']]
|
['Chemicals and Drugs [D]', 'Anatomy [A]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Organisms [B]', 'Named Groups [M]', 'Phenomena and Processes [G]', 'Health Care [N]']
| 1
| 1
| 0
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 1
| 1
| 0
|
Apoptosis in v-myc transformation of myelomonocytic cells and its modulation by CSF-1.
|
c-myc is a proto-oncogene essential for cell growth. When activated, its expression can lead to uncontrolled cell proliferation, transformation and tumorigenesis. The cell line tEMmyc4 is a murine myelomonocytic cell line that was established following transformation by v-myc. It has a high level of v-myc expression and constitutively expresses endogenous CSF-1, the monocytic growth and viability factor. Under growth restricting conditions (high cell density serum deprivation, heat shock, or dexamethasone addition) cells of this line were found to undergo cell death through apoptosis. The induction of apoptosis by dexamethasone was associated with a decrease in constitutive CSF-1 expression without significant change in v-myc expression. Exogenous CSF-1 rescued these cells from dexamethasone induced-apoptosis. In vivo studies showed that tEMmyc4 cells were tumorigenic in syngeneic animals despite exhibiting some spontaneous apoptosis within the tumour mass. Co-administration of dexamethasone with the tumour cells significantly inhibited tumor development and the administration of dexamethasone to mice with established tumors resulted in tumor regression in all mice. This regression was associated with a high level of apoptosis and necrosis in the tumors. This study shows a correlation between the in vitro and in vivo induction of apoptosis and indicates that cancer cells bearing activated oncogenes may be more sensitive to apoptosis induction by chemotherapeutic agents.
|
['Animals', 'Apoptosis', 'Cell Division', 'Cell Survival', 'Cell Transformation, Neoplastic', 'Cells, Cultured', 'Dexamethasone', 'Genes, myc', 'Growth Substances', 'Macrophage Colony-Stimulating Factor', 'Mice', 'Monocytes']
| 8,649,820
|
[['B01.050'], ['G04.146.954.035'], ['G04.144.220', 'G04.161.750.500', 'G05.113', 'G07.345.249.410.750.500'], ['G04.346'], ['C04.697.098.500', 'C23.550.727.098.500'], ['A11.251'], ['D04.210.500.745.432.769.344', 'D04.210.500.908.238'], ['G05.360.340.024.340.375.500.791.420'], ['D27.505.696.377'], ['D12.644.276.374.410.240.500', 'D12.776.395.240.500', 'D12.776.467.374.410.240.500', 'D23.529.374.410.240.500'], ['B01.050.150.900.649.313.992.635.505.500'], ['A11.118.637.555.652', 'A11.148.580', 'A11.627.624', 'A11.733.547', 'A15.145.229.637.555.652', 'A15.378.316.580', 'A15.382.490.555.652', 'A15.382.670.547', 'A15.382.680.547']]
|
['Organisms [B]', 'Phenomena and Processes [G]', 'Diseases [C]', 'Anatomy [A]', 'Chemicals and Drugs [D]']
| 1
| 1
| 1
| 1
| 0
| 0
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 0
|
ICD defibrillation failure solved in an unusual fashion.
|
An implantable cardioverter defibrillator (ICD) is designed to sense life-threatening ventricular arrhythmias and terminate them, either by rapid pacing or by delivering an electrical shock. Nowadays it is a proven therapy for both primary and secondary prevention of sudden cardiac death. The typical configuration of an ICD consists of a right ventricular sensing/defibrillator lead with two coils (one distal, located in the right ventricle, and one proximal, located at the superior vena cava-right atrium junction) and an active can, the so-called "ventricular triad". Although effective in the vast majority of patients, it could be argued that this is not the most rational arrangement in electrical terms, since the main shock vector is anteriorly displaced in relation to the greater portion of the left ventricular mass. We describe a case of an ICD defibrillation failure that was solved by placing an additional defibrillator lead in a tributary of the coronary sinus.
|
['Adult', 'Defibrillators, Implantable', 'Humans', 'Male', 'Prosthesis Failure', 'Ventricular Fibrillation']
| 20,734,580
|
[['M01.060.116'], ['E07.305.250.159.175', 'E07.305.250.319.175', 'E07.695.202.175'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['C23.550.767.865', 'E05.325.771'], ['C14.280.067.922', 'C23.550.073.922']]
|
['Named Groups [M]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Organisms [B]', 'Diseases [C]']
| 0
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 1
| 0
| 0
|
Rate-of-return guarantees for defined contribution plans.
|
This article explores the conceptual basis for an employer-backed minimum rate-of-return guarantee as an option under defined contribution plans. Expanding an earlier analysis, the author presents a prototype model of how the guarantee would work and discusses how it might be used for a mandatory Social Security defined contribution plan.
|
['Employment', 'Financial Management', 'Humans', 'Investments', 'Liability, Legal', 'Pensions', 'Retirement', 'Salaries and Fringe Benefits', 'Social Security', 'United States']
| 11,258,155
|
[['N01.824.245'], ['N03.219.463'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['N03.219.702'], ['I01.880.604.583.490', 'N03.706.535.547'], ['N01.824.417.510'], ['I03.702'], ['N01.824.417.700', 'N04.452.677.800'], ['N03.219.521.346.506.849', 'N03.219.521.576.823'], ['Z01.107.567.875']]
|
['Health Care [N]', 'Organisms [B]', 'Anthropology, Education, Sociology, and Social Phenomena [I]', 'Geographicals [Z]']
| 0
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 1
| 0
| 0
| 0
| 1
| 1
|
Epidermodysplasia-verruciformis-like eruption associated with gamma-papillomavirus infection in a patient with adult T-cell leukemia.
|
Epidermodysplasia verruciformis (EV) is a genodermatosis characterized by widespread and persistent cutaneous lesions caused by beta-papillomaviruses. Rare cases of acquired EV-like eruption associated with beta-papillomavirus infection have been reported in immunosuppressed patients. We report a case of acquired EV-like eruption in an immunosuppressed patient with adult T-cell leukemia. The cutaneous lesions clinically resembled pityriasis versicolor and exhibited the typical histological features of EV, but in some areas of the same biopsy specimen characteristic homogeneous intracytoplasmic inclusion bodies were observed. Although beta-papillomavirus was not detected by highly sensitive polymerase chain reaction, a putative novel type of gamma-papillomavirus was identified. This is the first documentation of an association between EV-like eruption and gamma-papillomavirus infection.
|
['Biopsy', 'DNA, Viral', 'Diagnosis, Differential', 'Epidermodysplasia Verruciformis', 'Gammapapillomavirus', 'Humans', 'Leukemia-Lymphoma, Adult T-Cell', 'Male', 'Middle Aged', 'Papillomavirus Infections', 'Polymerase Chain Reaction', 'Skin']
| 19,696,474
|
[['E01.370.225.500.384.100', 'E01.370.225.998.054', 'E01.370.388.100', 'E04.074', 'E05.200.500.384.100', 'E05.200.998.054', 'E05.242.384.100'], ['D13.444.308.568'], ['E01.171'], ['C01.925.256.650.810.345', 'C01.925.825.810.260', 'C01.925.928.914.345', 'C17.800.838.790.810.260'], ['B04.280.210.655.400', 'B04.613.204.655.400'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['C04.557.337.428.580.100', 'C15.604.515.560.575.100', 'C20.683.515.528.582.100'], ['M01.060.116.630'], ['C01.925.256.650', 'C01.925.928.725'], ['E05.393.620.500'], ['A17.815']]
|
['Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Chemicals and Drugs [D]', 'Diseases [C]', 'Organisms [B]', 'Named Groups [M]', 'Anatomy [A]']
| 1
| 1
| 1
| 1
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 1
| 0
| 0
|
Body image differences among Malay, Samoan, and Australian women.
|
Comparisons of body attitudes and associated behaviours were undertaken using Malay, Samoan, and Australian female students. The general goal of the research was to determine the degree to which the observed pattern of attitudes and behaviours was attributable to culture. The specific analyses comprised an examination of group differences using standard measures that included the Body Attitudes Questionnaire, the Three-Factor Eating Questionnaire and detailed questions concerning the use of diet and exercise as weight control strategies. The main findings concerned a number of cultural differences, particularly in relation to diet and exercise, that were evident even with the effect of body mass index held constant. These results are interpreted in terms of the efficacy of entrenched cultural beliefs in protecting against introduced, more dominant, cultural values. The Australian sample exhibited the most negative body image, although there was some evidence that Malays and Samoans were influenced by Western ideals of weight and shape. It is proposed that to fully understand the differential meaning of negative body image across cultures and the potential impact of westernisation, both within-group and between-group differences in body size need to be acknowledged.
|
['Adult', 'Attitude to Health', 'Australia', 'Body Image', 'Body Mass Index', 'Body Weight', 'Cross-Cultural Comparison', 'Diet', 'Exercise', 'Female', 'Health Knowledge, Attitudes, Practice', 'Humans', 'Malaysia', 'Obesity', 'Samoa']
| 16,672,204
|
[['M01.060.116'], ['F01.100.150', 'N05.300.150'], ['Z01.639.100', 'Z01.678.100.373'], ['F01.752.747.792.110', 'F02.463.593.112'], ['E01.370.600.115.100.125', 'E05.041.124.125', 'G07.100.100.125', 'N06.850.505.200.100.175'], ['C23.888.144', 'E01.370.600.115.100.160.120', 'E05.041.124.160.750', 'G07.100.100.160.120', 'G07.345.249.314.120'], ['I01.076.201.450.281', 'I01.880.853.100.257'], ['G07.203.650.240'], ['G11.427.410.698.277', 'I03.350'], ['F01.100.150.500', 'N05.300.150.410'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['Z01.252.145.487'], ['C18.654.726.500', 'C23.888.144.699.500', 'E01.370.600.115.100.160.120.699.500', 'G07.100.100.160.120.699.500'], ['Z01.639.760.815.800']]
|
['Named Groups [M]', 'Psychiatry and Psychology [F]', 'Health Care [N]', 'Geographicals [Z]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Phenomena and Processes [G]', 'Diseases [C]', 'Anthropology, Education, Sociology, and Social Phenomena [I]', 'Organisms [B]']
| 0
| 1
| 1
| 0
| 1
| 1
| 1
| 0
| 1
| 0
| 0
| 1
| 1
| 1
|
The peptide HDEF as a new retention signal is necessary and sufficient to direct proteins to the endoplasmic reticulum.
|
The key feature of tomato RNase LX localised solely outside the vacuole is the C-terminal peptide HDEF which is very similar to known endoplasmic reticulum (ER) retention signals. For functional testing of the ER-targeting ability of HDEF, different constructs including the complete RNase LX, two truncated forms without HDEF and the truncated chitinase FB7-1deltaVTP C-terminally flanked by HDEF, were expressed in Saccharomyces cerevisiae. The majority of RNase and chitinase, both containing HDEF, accumulates within the ER. However, the truncated constructs without the peptide are released into the medium. We provide compelling evidence that peptide HDEF at the C-terminus of secretory plant proteins is a new ER retention signal in yeast and most likely in plants.
|
['Amino Acid Sequence', 'Base Sequence', 'DNA Primers', 'Endoplasmic Reticulum', 'Endoribonucleases', 'Genes, Reporter', 'Lycopersicon esculentum', 'Oligopeptides', 'Protein Sorting Signals', 'Recombinant Fusion Proteins', 'Saccharomyces cerevisiae']
| 9,742,958
|
[['G02.111.570.060', 'L01.453.245.667.060'], ['G02.111.570.080', 'G05.360.080', 'L01.453.245.667.080'], ['D13.695.578.424.450.275', 'D27.720.470.530.600.223.600'], ['A11.284.430.214.190.875.248'], ['D08.811.277.352.355.350', 'D08.811.277.352.700.350'], ['G05.360.340.024.340.435'], ['B01.650.940.800.575.912.250.908.500.322'], ['D12.644.456'], ['D12.644.770', 'G02.111.570.060.670'], ['D12.776.828.300'], ['B01.300.107.795.785.800', 'B01.300.930.705.655']]
|
['Phenomena and Processes [G]', 'Information Science [L]', 'Chemicals and Drugs [D]', 'Anatomy [A]', 'Organisms [B]']
| 1
| 1
| 0
| 1
| 0
| 0
| 1
| 0
| 0
| 0
| 1
| 0
| 0
| 0
|
Catecholamines decrease nitric oxide production by cytokine-stimulated hepatocytes.
|
BACKGROUND: Catecholamines are significantly elevated in inflammatory responses and play a regulatory role in sepsis. Nitric oxide (NO), also a key inflammatory mediator in sepsis, is produced in large amounts by the inducible nitric oxide synthase (iNOS) in the liver. The purpose of this study was to test the hypothesis that catecholamines play a role in the regulation of NO production by hepatocytes.METHODS: Primary hepatocytes were isolated from healthy male Sprague-Dawley rats and either cultured with normal medium or stimulated with cytomix (interleukin-1 beta, interferon-gamma, and tumor necrosis factor-alpha) in the presence or absence of epinephrine or norepinephrine at varying concentrations. Total RNA was isolated 6 hours after treatment and analyzed by Northern blotting for iNOS mRNA. Protein extracts were obtained at 12 hours and were analyzed by Western immunoblotting for iNOS. Cell culture supernatants were analyzed for NO, determined as the stable end-product NO(2)(-), at 24 hours.RESULTS: Epinephrine and norepinephrine significantly decreased NO(2)(-) levels in stimulated hepatocytes but had no effect on iNOS mRNA or protein levels. The decrease in NO(2)(-) was reproduced by the adenylate cyclase stimulator, forskolin. The catecholamine-induced decrease in NO(2)(-) was completely reversed by the protein kinase A inhibitor Rp-8-Br-cyclic adenosine monophosphate.CONCLUSIONS: Catecholamines decrease hepatocyte production of NO in response to cytokine stimulation. This effect seems to be due to post-translational events and appears to be mediated in part by cyclic adenosine monophosphate.
|
['8-Bromo Cyclic Adenosine Monophosphate', 'Adenoviridae', 'Animals', 'Antineoplastic Agents', 'Biopterin', 'Cell Survival', 'Cells, Cultured', 'Cyclic AMP-Dependent Protein Kinase Type II', 'Cyclic AMP-Dependent Protein Kinases', 'Cytokines', 'Enzyme Inhibitors', 'Epinephrine', 'Gene Expression Regulation, Enzymologic', 'Gene Transfer Techniques', 'Hepatocytes', 'Interferon-gamma', 'Interleukin-1', 'Male', 'Nitrates', 'Nitric Oxide', 'Nitric Oxide Synthase', 'Nitric Oxide Synthase Type II', 'Nitrites', 'Norepinephrine', 'RNA, Messenger', 'Rats', 'Rats, Sprague-Dawley', 'Stimulation, Chemical', 'Sympathomimetics', 'Thionucleotides', 'Tumor Necrosis Factor-alpha']
| 11,490,358
|
[['D03.633.100.759.646.138.395.225', 'D13.695.462.200.225', 'D13.695.667.138.395.225', 'D13.695.827.068.395.225'], ['B04.280.030'], ['B01.050'], ['D27.505.954.248'], ['D03.633.100.733.631.202', 'D08.211.090'], ['G04.346'], ['A11.251'], ['D08.811.913.696.620.682.700.150.125.875', 'D12.644.360.200.125.875', 'D12.776.476.200.125.875'], ['D08.811.913.696.620.682.700.150.125', 'D12.644.360.200.125', 'D12.776.476.200.125'], ['D12.644.276.374', 'D12.776.467.374', 'D23.529.374'], ['D27.505.519.389'], ['D02.033.100.291.310', 'D02.092.063.291.310', 'D02.092.211.215.454', 'D02.092.311.461', 'D02.455.426.559.389.657.166.175.461'], ['G05.308.320'], ['E05.393.350'], ['A11.436.348'], ['D12.644.276.374.440.893', 'D12.644.276.374.480.615.350', 'D12.776.467.374.440.893', 'D12.776.467.374.480.615.350', 'D23.529.374.440.893', 'D23.529.374.480.615.350'], ['D12.644.276.374.465.010', 'D12.644.276.374.500.400', 'D12.776.467.374.465.010', 'D12.776.467.374.500.400', 'D23.529.374.465.131', 'D23.529.374.500.400'], ['D01.248.497.158.606', 'D01.625.525.550', 'D02.583'], ['D01.339.387', 'D01.625.550.500', 'D01.625.700.500', 'D01.650.550.587.600'], ['D08.811.682.664.500.772'], ['D08.811.682.664.500.772.500', 'D12.776.157.687.575', 'D12.776.660.720.575'], ['D01.248.497.158.635', 'D01.625.600.600', 'D02.633'], ['D02.033.100.291.502', 'D02.092.063.480', 'D02.092.211.215.746', 'D02.092.311.830', 'D02.455.426.559.389.657.166.175.830'], ['D13.444.735.544'], ['B01.050.150.900.649.313.992.635.505.700'], ['B01.050.150.900.649.313.992.635.505.700.750'], ['G07.690.773.996'], ['D27.505.696.663.050.870'], ['D02.886.765', 'D13.695.900'], ['D12.644.276.374.500.800', 'D12.644.276.374.750.626', 'D12.776.124.900', 'D12.776.395.930', 'D12.776.467.374.500.800', 'D12.776.467.374.750.626', 'D23.529.374.500.800', 'D23.529.374.750.626']]
|
['Chemicals and Drugs [D]', 'Organisms [B]', 'Phenomena and Processes [G]', 'Anatomy [A]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]']
| 1
| 1
| 0
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 0
|
[Effect of ACTH administration on liberation of testosterone by the Leydig cell (author's transl)].
|
The possible r?le of the Leydig cells ithe changes of testosterone levels induced by ACTH administration is studied. 14 male Wistar rats weighing about 300 g were separated in two groups. One was treated with I mU.I./100 g/day of ACTH i.m. for 6 days and the other with saline solution as control Rats, testes and adrenal glands were weighed and plasma testosterone levels were measured. The Leydig cells dispersed collagenase was inbubated for 120 min at 37 degrees C in the presence and in the absence of 10 mU.I. of HCG. The weight of adrenal glands in the treated rats was greater than in the control group. Treated rats had lower plasma values than the controls. Testosterone secretion by the Leydig cells, in basal situation and after stimulation with HCG, was lower in the treated group. Leydig cells of untreated rats were incubated with 12.5, 6.2, 3.1, 1.5 mU.I. of ACTH and supplemented with 2.5 pU.I. of HCG. No difference in testosterone secretion in either groups was observed.
|
['Adrenal Glands', 'Adrenocorticotropic Hormone', 'Animals', 'Body Weight', 'Leydig Cells', 'Male', 'Organ Size', 'Rats', 'Stimulation, Chemical', 'Testosterone']
| 208,125
|
[['A06.300.071'], ['D06.472.699.327.935.531.500', 'D06.472.699.631.525.600.531.500', 'D12.644.400.400.935.531.500', 'D12.644.548.365.935.531.500', 'D12.644.548.691.525.690.531.500', 'D12.776.631.650.405.935.531.500'], ['B01.050'], ['C23.888.144', 'E01.370.600.115.100.160.120', 'E05.041.124.160.750', 'G07.100.100.160.120', 'G07.345.249.314.120'], ['A05.360.444.849.513', 'A06.300.312.782.513', 'A11.382.906', 'A11.436.513'], ['E01.370.600.115.100.660', 'E05.041.124.715', 'G07.100.100.660', 'G07.345.249.690'], ['B01.050.150.900.649.313.992.635.505.700'], ['G07.690.773.996'], ['D04.210.500.054.079.429.824', 'D06.472.334.851.968.984']]
|
['Anatomy [A]', 'Chemicals and Drugs [D]', 'Organisms [B]', 'Diseases [C]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Phenomena and Processes [G]']
| 1
| 1
| 1
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 0
|
Lipid-Based Liquid Crystalline Nanoparticles Facilitate Cytosolic Delivery of siRNA via Structural Transformation.
|
RNA interference (RNAi) technology has shown great promise for the treatment of cancer and other genetic disorders. Despite the efforts to increase the target tissue distribution, the safe and effective delivery of siRNA to the diseased cells with sufficient cytosolic transport is another critical factor for successful RNAi clinical application. Here, the constructed lipid-based liquid crystalline nanoparticles, called nano-Transformers, can transform thestructure in the intracellular acidic environment and perform high-efficient siRNA delivery for cancer treatment. The developed nano-Transformers have satisfactory siRNA loading efficiency and low cytotoxicity. Different from the traditional cationic nanocarriers, the endosomal membrane fusion induced by the conformational transition of lipids contributes to the easy dissociation of siRNA from nanocarriers and direct release of free siRNA into cytoplasm. We show that transfection with cyclin-dependent kinase 1 (CDK1)-siRNA-loaded nano-Transformers causes up to 95% reduction of relevant mRNA in vitro and greatly inhibits the tumor growth without causing any immunogenic response in vivo. This work highlights that the lipid-based nano-Transformers may become the next generation of siRNA delivery system with higher efficacy and improved safety profiles.
|
['Animals', 'CDC2 Protein Kinase', 'Hep G2 Cells', 'Humans', 'Lipids', 'Liquid Crystals', 'Mice, Inbred BALB C', 'Mice, Nude', 'Nanoparticles', 'Neoplasms', 'RNA Interference', 'RNA, Messenger', 'RNA, Small Interfering', 'RNAi Therapeutics']
| 29,561,622
|
[['B01.050'], ['D08.811.913.696.620.682.700.646.500.500.250', 'D08.811.913.696.620.682.700.646.500.984.500', 'D12.644.360.250.067.249', 'D12.644.360.250.580.500', 'D12.776.167.200.067.249', 'D12.776.167.200.580.500', 'D12.776.476.250.067.249', 'D12.776.476.250.580.500', 'D12.776.744.360'], ['A11.251.860.180.432', 'A11.436.348.500'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['D10'], ['J01.637.506'], ['B01.050.050.199.520.520.338', 'B01.050.150.900.649.313.992.635.505.500.400.338'], ['B01.050.150.900.649.313.992.635.505.500.550.500'], ['J01.637.512.600'], ['C04'], ['G05.308.203.374.790'], ['D13.444.735.544'], ['D13.150.650.700', 'D13.444.735.150.700', 'D13.444.735.790.552.875'], ['E02.095.301.250']]
|
['Organisms [B]', 'Chemicals and Drugs [D]', 'Anatomy [A]', 'Technology, Industry, and Agriculture [J]', 'Diseases [C]', 'Phenomena and Processes [G]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]']
| 1
| 1
| 1
| 1
| 1
| 0
| 1
| 0
| 0
| 1
| 0
| 0
| 0
| 0
|
Tenfold population increase in Western Europe at the Neandertal-to-modern human transition.
|
European Neandertals were replaced by modern human populations from Africa ~40,000 years ago. Archaeological evidence from the best-documented region of Europe shows that during this replacement human populations increased by one order of magnitude, suggesting that numerical supremacy alone may have been a critical factor in facilitating this replacement.
|
['Animals', 'Archaeology', 'Fossils', 'France', 'Hominidae', 'Humans', 'Population Density', 'Population Dynamics', 'Population Growth', 'Time', 'Tool Use Behavior']
| 21,798,948
|
[['B01.050'], ['I01.076.201.208'], ['I01.076.368.584.311'], ['Z01.542.286'], ['B01.050.150.900.649.313.988.400.112.400'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['N01.224.600', 'N06.850.505.400.600'], ['I01.240.600', 'N01.224.625', 'N06.850.505.400.700'], ['I01.240.600.660', 'N01.224.625.660', 'N06.850.505.400.700.660'], ['G01.910'], ['F01.145.113.840']]
|
['Organisms [B]', 'Anthropology, Education, Sociology, and Social Phenomena [I]', 'Geographicals [Z]', 'Health Care [N]', 'Phenomena and Processes [G]', 'Psychiatry and Psychology [F]']
| 0
| 1
| 0
| 0
| 0
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 1
| 1
|
Oral Polypodium Leucotomos Extract and Its Impact on Visible Light-Induced Pigmentation in Human Subjects
|
BACKGROUND: Visible light (VL) has multiple effects on the skin that currently available sunscreens do not protect against. Polypodium leucotomos extract (PLE) has properties that may offer protection against VL.
OBJECTIVES: To determine the effectiveness of PLE in preventing VL-induced effects.
METHODS: Twenty-two subjects with Fitzpatrick skin phototype IV-VI were enrolled. On day 0, subjects were irradiated with VL. Clinical Investigator’s Global Assessment (IGA) scoring and spectroscopic evaluations were performed immediately, 24 hours, and 7 days after irradiation. Subjects then received a 28-day supply of PLE (480 mg daily). Irradiation and evaluation were repeated. Three 4-mm punch biopsies were obtained for immunohistochemistry analysis: one from normal unirradiated skin and the other two twenty-four hours after irradiation, pre- and post-PLE, from sites irradiated with highest dose of VL.
RESULTS: All subjects had immediate pigment darkening, persistent pigment darkening, and delayed tanning both pre- and post-PLE. For the highest VL dose (480 J/cm²) spectroscopic assessments demonstrated a statistically significant decrease in persistent pigment darkening and delayed tanning post-PLE. In addition, there was a significant decrease in cyclooxygenase-2, and a trend towards decreases in the markers for cellular damage post-PLE. While there was a trend towards lower IGA scores post-PLE, statistical significance was not reached possibly due to lack of sensitivity of the visual IGA scoring system in detecting small changes.
CONCLUSIONS: Spectroscopic data and immunohistochemistry indicate an effect of PLE on visible light induced effects. As such, PLE may be used as an adjuvant to traditional means of photoprotection to protect against the effects of VL.
Clinical trial registration number: NCT02904798.
J Drugs Dermatol. 2019;18(12):1198-1203.
|
['Administration, Oral', 'Cyclooxygenase 2', 'Female', 'Humans', 'Hyperpigmentation', 'Light', 'Male', 'Plant Extracts', 'Polypodium', 'Skin Pigmentation']
| 31,859,468
|
[['E02.319.267.100'], ['D08.811.600.720.750'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['C17.800.621.430'], ['G01.358.500.505.650', 'G01.590.540', 'G01.750.250.650', 'G01.750.770.578'], ['D20.215.784.500', 'D26.667'], ['B01.650.940.800.575.912.063.700.666'], ['E01.370.600.115.450.500', 'E01.370.600.620.750', 'G07.100.175.500', 'G13.750.837', 'G16.690.890']]
|
['Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Chemicals and Drugs [D]', 'Organisms [B]', 'Diseases [C]', 'Phenomena and Processes [G]']
| 0
| 1
| 1
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 0
|
The Manchester procedure: anatomical, subjective and sexual outcomes.
|
INTRODUCTION AND HYPOTHESIS: Classical native-tissue techniques for pelvic organ prolapse (POP) repairs, such as the Manchester procedure (MP), have been revitalized because of vaginal mesh complications. However, there are conflicting opinions regarding sufficient apical (mid-compartment) support by the MP and concerns about the risk of dyspareunia. The aims of this study were therefore to investigate anatomical and patient-reported outcomes 1 year after MP.METHODS: Prospective cohort study of 153 females undergoing an MP for anterior compartment POP between October 2014 and June 2016. Pre- and 1-year postoperative evaluations included POP-Q measurements and the questionnaires Pelvic Floor Distress Inventory Short Form 20 (PFDI-20) and POP/Urinary Incontinence Sexual Questionnaire (PISQ-12).RESULTS: At 1 year, 97% (148/153) attended the follow-up. Significant anatomical improvements (p < 0.01) were obtained in all compartments. Mean Ba was -1.1 (± 1.4), mean C -5.9 (± 1.7) and mean D -7.0 (± 1.2) at follow-up. Point C ? -5 was present in 81.1%. POP-Q stage 0-1 was obtained in 99.3% in the mid-compartment (C < -1), but only in 48.6% in the anterior compartment (Ba < -1). A significant reduction in symptom scores was obtained for PFDI-20 (p < 0.01) and PISQ-12 (p = 0.01). No significant changes were seen in dyspareunia rates (q.5, PISQ-12), but 5.6% reported de novo dyspareunia. Concerning POP symptoms, 96.0% reported being cured or significantly improved.CONCLUSIONS: The Manchester procedure provides adequate apical support, albeit inferior anatomical anterior compartment results, and 96.0% reported being subjectively cured or substantially better at 1-year follow-up, with no significant change in dyspareunia.
|
['Dyspareunia', 'Female', 'Follow-Up Studies', 'Gynecologic Surgical Procedures', 'Humans', 'Norway', 'Organ Sparing Treatments', 'Pelvic Floor', 'Pelvic Organ Prolapse', 'Postoperative Complications', 'Prospective Studies', 'Quality of Life', 'Severity of Illness Index', 'Sexual Behavior', 'Surveys and Questionnaires', 'Sweden', 'Treatment Outcome']
| 29,532,126
|
[['C12.294.644.242', 'C13.351.500.665.313', 'F03.835.199'], ['E05.318.372.500.750.249', 'N05.715.360.330.500.750.350', 'N06.850.520.450.500.750.350'], ['E04.950.300'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['Z01.542.816.374'], ['E02.674'], ['A01.923.600.600', 'A02.633.567.050.750'], ['C23.300.842.624'], ['C23.550.767'], ['E05.318.372.500.750.625', 'N05.715.360.330.500.750.650', 'N06.850.520.450.500.750.650'], ['I01.800', 'K01.752.400.750', 'N06.850.505.400.425.837'], ['E05.318.308.980.438.475.456.500', 'N05.715.360.300.800.438.375.364.500', 'N06.850.520.308.980.438.475.364.500'], ['F01.145.802'], ['E05.318.308.980', 'N05.715.360.300.800', 'N06.850.520.308.980'], ['Z01.542.816.500'], ['E01.789.800', 'N04.761.559.590.800', 'N05.715.360.575.575.800']]
|
['Diseases [C]', 'Psychiatry and Psychology [F]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Health Care [N]', 'Organisms [B]', 'Geographicals [Z]', 'Anatomy [A]', 'Anthropology, Education, Sociology, and Social Phenomena [I]', 'Humanities [K]']
| 1
| 1
| 1
| 0
| 1
| 1
| 0
| 0
| 1
| 0
| 0
| 0
| 1
| 1
|
A case of Cushing syndrome secondary to ectopic adrenocorticotropic hormone producing carcinoid of the duodenum.
|
Cushing syndrome caused by adrenocorticotropic hormone (ACTH) production from solid tumors can result in life-threatening hypercortisolemia. Ectopic ACTH production is most commonly associated with bronchial carcinoids and squamous cell carcinoma of the lung. We report a case of Cushing syndrome caused by ectopic ACTH production from a carcinoid of the duodenum. The patient presented to an outside hospital in hypertensive crisis and diabetic ketoacidosis. After stabilization, diagnostic studies including a serum cortisol level, and computed tomography (CT) scans of the head, chest, abdomen, and pelvis revealed hypercortisolemia and a large mass in the head of the pancreas. Pancreaticoduodenectomy was performed. Pathologic investigation revealed a 1-cm carcinoid of the duodenum with two large metastatic lymph nodes near the head of the pancreas. This is the first reported case in the English literature of Cushing syndrome caused by ectopic ACTH production from a carcinoid of the duodenum.
|
['ACTH Syndrome, Ectopic', 'Adult', 'Carcinoid Tumor', 'Cushing Syndrome', 'Duodenal Neoplasms', 'Female', 'Humans', 'Pancreaticoduodenectomy']
| 15,986,979
|
[['C04.730.713.317'], ['M01.060.116'], ['C04.557.465.625.650.200', 'C04.557.470.200.025.200', 'C04.557.580.625.650.200'], ['C19.053.800.367'], ['C04.588.274.476.411.445', 'C06.301.371.411.445', 'C06.405.249.411.445', 'C06.405.469.275.270', 'C06.405.469.491.445'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['E04.210.760']]
|
['Diseases [C]', 'Named Groups [M]', 'Organisms [B]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]']
| 0
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 1
| 0
| 0
|
Eight weeks of non-nightly use of zolpidem for primary insomnia.
|
CONTEXT: Intermittent use (i.e., a few nights per week) of hypnotic medication is often recommended for the treatment of chronic insomnia despite an absence of efficacy and safety data using this regimen.STUDY OBJECTIVES: To evaluate the clinical efficacy and safety of intermittent pharmacotherapy for chronic insomnia.DESIGN AND SETTING: Randomized, double-blind, placebo-controlled, parallel groups, clinical trial at six sleep research sites.PATIENTS: One hundred-sixty-three (115 women, 48 men; mean age 44.1+ SE. 0.9 years), DSM-IV-defined primary insomnia patients were randomized, 134 patients completed the study.INTERVENTIONS: Eight weeks of treatment with either zolpidem 10 mg or placebo. Patients were instructed to take medication when they felt they needed it, but at least three and no more than five times per week.MAIN OUTCOME MEASURES: Investigator and Patient Global Ratings were the primary outcome variables. Secondary measures from daily questionnaires to assess efficacy, rebound insomnia and drug taking behavior.RESULTS: The Investigator's Global Rating indicated that intermittent use of zolpidem produced a significantly better therapeutic effect and significantly reduced insomnia severity throughout the 8-week study relative to placebo. Zolpidem was found to be effective in initiating and maintaining sleep on nights taken, as compared to placebo, based upon the Patient's Global Ratings and all subjective sleep variables. No evidence of rebound insomnia was found on nights that zolpidem was not taken. The number of nights a pill was taken did not differ between groups, nor did frequency of pill taking change in either group across the duration of the study. There were no significant effects of treatment upon quality of life or neurocognitive measures.CONCLUSIONS: Zolpidem 10 mg is effective in treating insomnia when used intermittently, without evidence of discontinuation effects or increased frequency of pill taking.
|
['Analysis of Variance', 'Double-Blind Method', 'Drug Administration Schedule', 'Humans', 'Hypnotics and Sedatives', 'Pyridines', 'Sleep Initiation and Maintenance Disorders', 'Surveys and Questionnaires', 'Time Factors', 'Zolpidem']
| 11,145,323
|
[['E05.318.740.150', 'N05.715.360.750.125', 'N06.850.520.830.150'], ['E05.318.370.300', 'E05.581.500.300', 'N05.715.360.325.320', 'N06.850.520.445.300'], ['E02.319.283'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['D27.505.696.277.350', 'D27.505.954.427.210.350'], ['D03.383.725'], ['C10.886.425.800.800', 'F03.870.400.800.800'], ['E05.318.308.980', 'N05.715.360.300.800', 'N06.850.520.308.980'], ['G01.910.857'], ['D03.383.725.971']]
|
['Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Health Care [N]', 'Organisms [B]', 'Chemicals and Drugs [D]', 'Diseases [C]', 'Psychiatry and Psychology [F]', 'Phenomena and Processes [G]']
| 0
| 1
| 1
| 1
| 1
| 1
| 1
| 0
| 0
| 0
| 0
| 0
| 1
| 0
|
Mechanistic study of photo-oxidation of Bisphenol-A (BPA) with hydrogen peroxide (H2O2) and sodium persulfate (SPS).
|
The removal of Bisphenol-A (BPA) from contaminated water using advanced oxidation methods such as UV-C assisted oxidation by hydrogen peroxide (H2O2) and sodium persulfate (SPS) has been reported by the authors earlier (Sharma et al., 2015a). In the present study, the authors report the removal of BPA from aqueous solution by the above two methods and its degradation mechanism. UV-C light (254 nm wavelength, 40 W power) was applied to BPA contaminated water at natural pH (pHN) under room temperature conditions. Experiments were carried out with the initial BPA concentration in the range of 0.04 mM-0.31 mM and the oxidant/BPA molar ratio in the range of 294:1-38:1 for UV-C/H2O2 and 31.5-4.06:1 for UV-C/SPS systems. The removal of BPA enhanced with decreasing BPA concentration. The total organic carbon also decreased with the UV-C irradiation time under optimum conditions ([H2O2]0 = 11.76 mM; [SPS]0 = 1.26 mM; temperature (29 ± 3 °C). Competition of BPA for reaction with HO or [Formula: see text] radicals at its higher concentrations results in a decrease in the removal of BPA. The intermediates with smaller and higher molecular weights than that of BPA were found in the treated water. Based on GC-MS and FTIR spectra of the reaction mixture, the formation of hydroxylated by-products testified the HO mediated oxidation pathway in the BPA degradation, while the formation of quinones and phenoxy phenols pointed to the [Formula: see text] dominating pathway through the formation of hydroxycyclohexadienyl (HCHD) and BPA phenoxyl radicals. The main route of BPA degradation is the hydroxylation followed by dehydration, coupling and ring opening reactions.
|
['Benzhydryl Compounds', 'Free Radicals', 'Gas Chromatography-Mass Spectrometry', 'Hydrogen Peroxide', 'Oxidants', 'Oxidation-Reduction', 'Phenols', 'Sodium Compounds', 'Sulfates', 'Ultraviolet Rays', 'Water Pollutants, Chemical', 'Water Purification']
| 26,468,603
|
[['D02.455.426.559.389.115'], ['D01.339', 'D02.389'], ['E05.196.181.349.500', 'E05.196.566.500'], ['D01.248.497.158.685.750.424', 'D01.339.431.374.424', 'D01.650.550.750.400', 'D02.389.338.253'], ['D27.720.642', 'D27.888.569.540'], ['G02.700', 'G03.295.531'], ['D02.455.426.559.389.657'], ['D01.857'], ['D01.248.497.158.845', 'D01.875.800.800.850'], ['G01.358.500.505.650.891', 'G01.590.540.891', 'G01.750.250.650.891', 'G01.750.750.659', 'G01.750.770.578.891', 'G16.500.275.063.725.525.600', 'G16.500.750.775.525.600', 'N06.230.300.100.725.525.600'], ['D27.888.284.903.655'], ['N06.850.780.200.800.800.900.900', 'N06.850.860.510.900.900']]
|
['Chemicals and Drugs [D]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Phenomena and Processes [G]', 'Health Care [N]']
| 0
| 0
| 0
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 0
| 1
| 0
|
Parkinsonian features in hereditary diffuse leukoencephalopathy with spheroids (HDLS) and CSF1R mutations.
|
Atypical Parkinsonism associated with white matter pathology has been described in cerebrovascular diseases, mitochondrial cytopathies, osmotic demyelinating disorders, leukoencephalopathies leukodystrophies, and others. Hereditary diffuse leukoencephalopathy with spheroids (HDLS) is an autosomal dominant disorder with symptomatic onset in midlife and death within a few years after symptom onset. Neuroimaging reveals cerebral white matter lesions that are pathologically characterized by non-inflammatory myelin loss, reactive astrocytosis, and axonal spheroids. Most cases are caused by mutations in the colony-stimulating factor 1 receptor (CSF1R) gene. We studied neuropathologically verified HDLS patients with CSF1R mutations to assess parkinsonian features. Ten families were evaluated with 16 affected individuals. During the course of the illness, all patients had at least some degree of bradykinesia. Fifteen patients had postural instability, and seven had rigidity. Two patients initially presented with parkinsonian gait and asymmetrical bradykinesia. These two patients and two others exhibited bradykinesia, rigidity, postural instability, and tremor (two with resting) early in the course of the illness. Levodopa/carbidopa therapy in these four patients provided no benefit, and the remaining 12 patients were not treated. The mean age of onset for all patients was about 45 years (range, 18-71) and the mean disease duration was approximately six years (range, 3-11). We also reviewed HDLS patients published prior to the CSF1R discovery for the presence of parkinsonian features. Out of 50 patients, 37 had gait impairments, 8 rigidity, 7 bradykinesia, and 5 resting tremor. Our report emphasizes the presence of atypical Parkinsonism in HDLS due to CSF1R mutations.
|
['Adolescent', 'Adult', 'Age of Onset', 'Aged', 'Antiparkinson Agents', 'Biological Specimen Banks', 'Brain', 'Family', 'Female', 'Gait Disorders, Neurologic', 'Gliosis', 'Humans', 'Hypokinesia', 'Image Processing, Computer-Assisted', 'Leukoencephalopathies', 'Magnetic Resonance Imaging', 'Male', 'Middle Aged', 'Muscle Rigidity', 'Mutation', 'Neuroimaging', 'Parkinson Disease', 'Receptor, Macrophage Colony-Stimulating Factor', 'Tremor', 'United Kingdom', 'Young Adult']
| 23,787,135
|
[['M01.060.057'], ['M01.060.116'], ['N05.715.350.075.100', 'N06.850.490.250.100'], ['M01.060.116.100'], ['D27.505.954.427.090.050'], ['N02.278.065'], ['A08.186.211'], ['F01.829.263', 'I01.880.853.150'], ['C10.597.404', 'C23.888.592.413'], ['C23.550.369'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['C10.597.350.400', 'C23.888.592.350.400'], ['L01.224.308'], ['C10.228.140.695'], ['E01.370.350.825.500'], ['M01.060.116.630'], ['C05.651.504', 'C10.597.613.550.500', 'C23.888.592.608.550.500'], ['G05.365.590'], ['E01.370.350.578', 'E01.370.376.537', 'E05.629'], ['C10.228.140.079.862.500', 'C10.228.662.600.400', 'C10.574.928.750'], ['D08.811.913.696.620.682.725.400.500', 'D12.776.543.750.630.492', 'D12.776.543.750.705.852.150.150', 'D12.776.543.750.750.400.200.200', 'D12.776.624.664.700.800'], ['C10.597.350.850', 'C23.888.592.350.850'], ['Z01.542.363'], ['M01.060.116.815']]
|
['Named Groups [M]', 'Health Care [N]', 'Chemicals and Drugs [D]', 'Anatomy [A]', 'Psychiatry and Psychology [F]', 'Anthropology, Education, Sociology, and Social Phenomena [I]', 'Diseases [C]', 'Organisms [B]', 'Information Science [L]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Phenomena and Processes [G]', 'Geographicals [Z]']
| 1
| 1
| 1
| 1
| 1
| 1
| 1
| 0
| 1
| 0
| 1
| 1
| 1
| 1
|
The effect of erythropoietin on autologous stem cell-mediated bone regeneration.
|
Mesenchymal stem cells (MSCs) although used for bone tissue engineering are limited by the requirement of isolation and culture prior to transplantation. Our recent studies have shown that biomaterial implants can be engineered to facilitate the recruitment of MSCs. In this study, we explore the ability of these implants to direct the recruitment and the differentiation of MSCs in the setting of a bone defect. We initially determined that both stromal derived factor-1alpha (SDF-1á) and erythropoietin (Epo) prompted different degrees of MSC recruitment. Additionally, we found that Epo and bone morphogenetic protein-2 (BMP-2), but not SDF-1á, triggered the osteogenic differentiation of MSCs in vitro. We then investigated the possibility of directing autologous MSC-mediated bone regeneration using a murine calvaria model. Consistent with our in vitro observations, Epo-releasing scaffolds were found to be more potent in bridging the defect than BMP-2 loaded scaffolds, as determined by computed tomography (CT) scanning, fluorescent imaging and histological analyses. These results demonstrate the tremendous potential, directing the recruitment and differentiation of autologous MSCs has in the field of tissue regeneration.
|
['Animals', 'Bone Regeneration', 'Cell Differentiation', 'Cell Proliferation', 'Chemokines', 'Chemotaxis', 'Erythropoietin', 'Immunohistochemistry', 'Implants, Experimental', 'Mesenchymal Stem Cell Transplantation', 'Mesenchymal Stem Cells', 'Mice', 'Mice, Inbred BALB C', 'Osteogenesis', 'Skull', 'Tissue Scaffolds', 'Transplantation, Autologous', 'X-Ray Microtomography']
| 23,831,188
|
[['B01.050'], ['G11.427.213.140', 'G16.762.150.150'], ['G04.152'], ['G04.161.750', 'G07.345.249.410.750'], ['D12.644.276.374.200', 'D12.776.467.374.200', 'D23.125.300', 'D23.469.200', 'D23.529.374.200'], ['F01.145.113.780.500', 'F01.145.875.439.500.500', 'G04.198.424', 'G07.568.500.590.500', 'G11.427.410.568.850.500'], ['D12.644.276.374.410.240.150', 'D12.776.395.240.150', 'D12.776.467.374.410.240.150', 'D23.529.374.410.240.150'], ['E01.370.225.500.607.512', 'E01.370.225.750.551.512', 'E05.200.500.607.512', 'E05.200.750.551.512', 'E05.478.583', 'H01.158.100.656.234.512', 'H01.158.201.344.512', 'H01.158.201.486.512', 'H01.181.122.573.512', 'H01.181.122.605.512'], ['E07.695.340'], ['E02.095.147.500.500.625', 'E04.936.225.687.625'], ['A11.329.830.500', 'A11.872.590.500'], ['B01.050.150.900.649.313.992.635.505.500'], ['B01.050.050.199.520.520.338', 'B01.050.150.900.649.313.992.635.505.500.400.338'], ['G07.345.500.325.377.625.050.500.729', 'G11.427.578.050.500.729'], ['A02.835.232.781'], ['E07.206.627', 'E07.695.825'], ['E04.936.664'], ['E01.370.350.700.810.810.900', 'E01.370.350.825.810.810.900']]
|
['Organisms [B]', 'Phenomena and Processes [G]', 'Chemicals and Drugs [D]', 'Psychiatry and Psychology [F]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Disciplines and Occupations [H]', 'Anatomy [A]']
| 1
| 1
| 0
| 1
| 1
| 1
| 1
| 1
| 0
| 0
| 0
| 0
| 0
| 0
|
Bayesian network meta-analysis comparing five contemporary treatment strategies for newly diagnosed acute promyelocytic leukaemia.
|
Acute promyelocytic leukemia (APL) is a curable subtype of acute myeloid leukemia. The optimum regimen for newly diagnosed APL remains inconclusive. In this Bayesian network meta-analysis, we compared the effectiveness of five regimens-arsenic trioxide (ATO) + all-trans retinoic acid (ATRA), realgar-indigo naturalis formula (RIF) which contains arsenic tetrasulfide + ATRA, ATRA + anthracycline-based chemotherapy (CT), ATO alone and ATRA alone, based on fourteen randomized controlled trials (RCTs), which included 1407 newly diagnosed APL patients. According to the results, the ranking efficacy of the treatment, including early death and complete remission in the induction stage, was the following: 1. ATO/RIF + ATRA; 2. ATRA + CT; 3. ATO, and 4. ATRA. For long-term benefit, ATO/RIF + ATRA significantly improved overall survival (OS) (hazard ratio = 0.35, 95%CI 0.15-0.82, p = 0.02) and event-free survival (EFS) (hazard ratio = 0.32, 95%CI 0.16-0.61, p = 0.001) over ATRA + CT regimen for the low-to-intermediate-risk patients. Thus, ATO + ATRA and RIF + ATRA might be considered the optimum treatments for the newly diagnosed APL and should be recommended as the standard care for frontline therapy.
|
['Bayes Theorem', 'Humans', 'Leukemia, Promyelocytic, Acute', 'Survival Analysis', 'Treatment Outcome']
| 27,322,078
|
[['E05.318.740.600.200', 'N05.715.360.750.625.150', 'N06.850.520.830.600.200'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['C04.557.337.539.275.700'], ['E05.318.740.998', 'N05.715.360.750.795', 'N06.850.520.830.998'], ['E01.789.800', 'N04.761.559.590.800', 'N05.715.360.575.575.800']]
|
['Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Health Care [N]', 'Organisms [B]', 'Diseases [C]']
| 0
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 0
| 1
| 0
|
Relevance of posttransplant flow cytometric T- and B-cell crossmatches in tacrolimus-treated renal transplant patients.
|
BACKGROUND: De novo development of anti-human leukocyte antigen (HLA) antibodies after transplantation is associated with increased rejection and decreased graft survival. In this study, the effect of posttransplant HLA antibodies on clinical outcome was evaluated in patients treated with tacrolimus by means of flow cytometric crossmatches (FCXm).METHODS: T- and B-cell FCXm were performed retrospectively on posttransplant sera of patients who received a graft between 1997 and 1999. Ninety-four kidney-only recipients were tested and all FCXm positive sera were investigated for the presence of HLA class I and II antibodies by Flow panel reactive antibodies.RESULTS: From 94 patients with a negative pretransplant complement-dependent cytotoxicity crossmatch, seven (7%) showed a positive pretransplant FCXm. After transplantation the FCXm became positive in five patients (6%). The predictive value of a positive FCXm after transplantation, and the log-transformed relative change in fluorescence ratio between pretransplant and posttransplant serum, were not significant to rejection within six months, nor to graft survival censored for death.CONCLUSIONS: The presence of HLA antibodies before rejection or graft failure could only be shown in a minority of patients; most antibodies were detected after graft failure, especially after transplantectomy. Monitoring through antibody testing after transplantation on the basis of our results has no added value with tacrolimus-based immunosuppression.
|
['Adolescent', 'Adult', 'Aged', 'Antibodies', 'B-Lymphocytes', 'Female', 'Flow Cytometry', 'Graft Rejection', 'Graft Survival', 'HLA Antigens', 'Histocompatibility Testing', 'Humans', 'Immunosuppressive Agents', 'Kidney Transplantation', 'Male', 'Middle Aged', 'Prognosis', 'Retrospective Studies', 'T-Lymphocytes', 'Tacrolimus']
| 17,102,764
|
[['M01.060.057'], ['M01.060.116'], ['M01.060.116.100'], ['D12.776.124.486.485.114', 'D12.776.124.790.651.114', 'D12.776.377.715.548.114'], ['A11.063.438', 'A11.118.637.555.567.562', 'A15.145.229.637.555.567.562', 'A15.382.032.438', 'A15.382.490.555.567.562'], ['E01.370.225.500.363.342', 'E01.370.225.500.386.350', 'E05.196.712.516.600.240.350', 'E05.200.500.363.342', 'E05.200.500.386.350', 'E05.242.363.342', 'E05.242.386.350'], ['G12.875.545.328'], ['G12.875.545.340'], ['D23.050.301.500.450', 'D23.050.705.552.450'], ['E01.370.225.812.385', 'E05.200.812.385', 'E05.478.594.385'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['D27.505.696.477.656'], ['E02.870.500', 'E04.936.450.485', 'E04.950.774.400'], ['M01.060.116.630'], ['E01.789'], ['E05.318.372.500.500.500', 'E05.318.372.500.750.750', 'N05.715.360.330.500.500.500', 'N05.715.360.330.500.750.825', 'N06.850.520.450.500.500.500', 'N06.850.520.450.500.750.825'], ['A11.118.637.555.567.569', 'A15.145.229.637.555.567.569', 'A15.382.490.555.567.569'], ['D02.540.505.810']]
|
['Named Groups [M]', 'Chemicals and Drugs [D]', 'Anatomy [A]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Phenomena and Processes [G]', 'Organisms [B]', 'Health Care [N]']
| 1
| 1
| 0
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 1
| 1
| 0
|
Biarylimidazoles as inhibitors of microsomal prostaglandin E2 synthase-1.
|
Microsomal prostaglandin E(2) synthase (mPGES-1) represents a potential target for novel analgesic and anti-inflammatory agents. High-throughput screening identified several leads of mPGES-1 inhibitors which were further optimized for potency and selectivity. A series of inhibitors bearing a biaryl imidazole scaffold exhibits excellent inhibition of PGE(2) production in enzymatic and cell-based assays. The synthesis of these molecules and their activities will be discussed.
|
['Animals', 'Anti-Inflammatory Agents', 'Cell Line', 'Dinoprostone', 'High-Throughput Screening Assays', 'Imidazoles', 'Intramolecular Oxidoreductases', 'Mice', 'Microsomes', 'Prostaglandin-E Synthases']
| 20,965,723
|
[['B01.050'], ['D27.505.954.158'], ['A11.251.210'], ['D10.251.355.255.550.250.200', 'D23.469.050.175.725.250.200'], ['E05.916.680'], ['D03.383.129.308'], ['D08.811.399.475'], ['B01.050.150.900.649.313.992.635.505.500'], ['A11.284.835.540'], ['D08.811.399.475.600']]
|
['Organisms [B]', 'Chemicals and Drugs [D]', 'Anatomy [A]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]']
| 1
| 1
| 0
| 1
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 0
| 0
| 0
|
Arylazoamidoximes and related compounds as NO-modulators.
|
Three amidinoarylhydrazines 1, three arylazoamidines 2, and nine arylazoamidoximes 3 have been synthesized and investigated for their potential to function as nitric oxide (NO) modulators. In-vitro studies demonstrated that 2 and 3 inhibited platelet aggregation (2c, IC(50 )= 3 microM) which could also be shown in vivo by inhibition of thrombus formation in arterioles (3a, 22%). Moreover, for all compounds antihypertensive effects were examined in vivo with SHR rats, with 2a being the most potent candidate by lowering blood pressure by 19%. However, no common underlying mechanism of action could be shown. Some of these compounds released HNO non-enzymatically. Incubations with NO synthase isoforms (NOSs) revealed, that compounds 1 to 3 were weak substrates for NOSs but arylazoamidoximes 3 remarkably elevated the NOSs activity in the presence of L-arginine (3h, up to fivefold). In addition, we examined effects on arginase and dimethylarginine dimethylaminohydrolase (DDAH), two further enzymes involved in the complex regulation of NO biosynthesis, to elucidate whether the observed in-vivo effects can be traced back to their modulation. Furthermore, the metabolic fate of arylazoamidoximes 3 was addressed by investigation of a possible N-reductive biotransformation. In summary, novel NO-modulating compound classes are presented, among which arylazoamidoximes 3 are potent activators of NOS isoforms, and arylazoamidines 2 exert in-vivo effects by unknown mechanisms.
|
['Animals', 'Blood Pressure', 'Fibrinolytic Agents', 'Nitric Oxide', 'Oximes', 'Platelet Aggregation Inhibitors', 'Rats', 'Rats, Inbred SHR', 'Structure-Activity Relationship', 'Vasodilator Agents']
| 19,921,683
|
[['B01.050'], ['E01.370.600.875.249', 'G09.330.380.076'], ['D27.505.519.421.750', 'D27.505.954.411.320', 'D27.505.954.502.427'], ['D01.339.387', 'D01.625.550.500', 'D01.625.700.500', 'D01.650.550.587.600'], ['D02.092.570.665'], ['D27.505.954.502.780'], ['B01.050.150.900.649.313.992.635.505.700'], ['B01.050.050.199.520.760.300', 'B01.050.150.900.649.313.992.635.505.700.400.300'], ['G02.111.830', 'G07.690.773.997'], ['D27.505.954.411.918']]
|
['Organisms [B]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Phenomena and Processes [G]', 'Chemicals and Drugs [D]']
| 0
| 1
| 0
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 0
|
Remote reperfusion lung injury is associated with AMP deaminase 3 activation and attenuated by inosine monophosphate.
|
BACKGROUND: Remote reperfusion lung injury occurs in patients with vascular occlusion and surgical procedures. Inosine monophosphate (IMP) produced by adenosine monophosphate deaminase (AMPD) 3 is involved in the remote reperfusion injury. The purpose of the present study was to identify whether IMP administration attenuated the remote reperfusion lung injury in a skeletal muscle ischemia-reperfusion model.METHODS AND RESULTS: A remote reperfusion lung injury was created using reperfusion after the bilateral ligation of the hind-limb. AMPD activity, myeloperoxidase (MPO) activity, IMP, AMPD3 mRNA and tumor necrosis factor (TNF)-alpha in the lungs before and after reperfusion were analyzed. Furthermore, the effects of IMP on these parameters were examined. AMPD3 mRNA, AMPD activity and IMP production in the lungs significantly increased after ischemia-reperfusion with increases in MPO activity, TNF-alpha level and decreased oxygen saturation (SpO(2)). Histological examination of the lungs demonstrated significant neutrophil infiltration and accumulation. IMP administration significantly reduced MPO activity, TNF-alpha and neutrophil infiltration, with ameliorated SpO(2).CONCLUSIONS: Along with the activation of AMPD3, ischemia-reperfusion-induced lung inflammation is associated with increased MPO activity and TNF-alpha level. IMP significantly decreased the lung injury, MPO activity, TNF-alpha and increased SpO(2). These findings may lead to the development of a new therapeutic strategy for remote reperfusion lung injury.
|
['AMP Deaminase', 'Animals', 'Disease Models, Animal', 'Enzyme Activation', 'Gene Expression Regulation, Enzymologic', 'Inosine Monophosphate', 'Lung', 'Lung Injury', 'Male', 'Mice', 'Mice, Inbred BALB C', 'Muscle, Skeletal', 'Peroxidase', 'RNA, Messenger', 'Reperfusion Injury', 'Tumor Necrosis Factor-alpha']
| 17,384,464
|
[['D08.811.277.151.653.060'], ['B01.050'], ['C22.232', 'E05.598.500', 'E05.599.395.080'], ['G02.111.263', 'G03.328'], ['G05.308.320'], ['D03.633.100.759.646.616.500', 'D13.695.667.616.500', 'D13.695.827.519.500'], ['A04.411'], ['C08.381.520', 'C26.891.554'], ['B01.050.150.900.649.313.992.635.505.500'], ['B01.050.050.199.520.520.338', 'B01.050.150.900.649.313.992.635.505.500.400.338'], ['A02.633.567', 'A10.690.552.500'], ['D08.811.682.732.700'], ['D13.444.735.544'], ['C14.907.725', 'C23.550.767.877'], ['D12.644.276.374.500.800', 'D12.644.276.374.750.626', 'D12.776.124.900', 'D12.776.395.930', 'D12.776.467.374.500.800', 'D12.776.467.374.750.626', 'D23.529.374.500.800', 'D23.529.374.750.626']]
|
['Chemicals and Drugs [D]', 'Organisms [B]', 'Diseases [C]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Phenomena and Processes [G]', 'Anatomy [A]']
| 1
| 1
| 1
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 0
|
A new tremor mutant in the Pietrain pig: an animal model of orthostatic tremor? Clinical and neurophysiological observations.
|
A new tremor mutant, the "Campus syndrome" was studied in a breed of Pietrain pigs. Affected pigs showed a coarse tremor of the extremities when standing and walking, so they tended to remain recumbent, during which the tremor was suppressed. Needle electromyographic recordings of the semitendinosus muscle plus accelerometry revealed a high-amplitude 14- to 15-Hz tremor pattern activated specifically upon standing but maintained during walking. The observed syndrome thus bears similarities to the human condition of orthostatic tremor and might serve as an animal model for this as yet poorly understood disorder.
|
['Animals', 'Animals, Inbred Strains', 'Case-Control Studies', 'Disease Models, Animal', 'Electromyography', 'Extremities', 'Gait', 'Humans', 'Muscle, Skeletal', 'Neural Conduction', 'Observation', 'Oscillometry', 'Posture', 'Swine', 'Tremor', 'Ulnar Nerve', 'Videotape Recording']
| 9,380,058
|
[['B01.050'], ['B01.050.050.199.520'], ['E05.318.372.500.500', 'N05.715.360.330.500.500', 'N06.850.520.450.500.500'], ['C22.232', 'E05.598.500', 'E05.599.395.080'], ['E01.370.405.255', 'E01.370.530.255'], ['A01.378'], ['E01.370.600.250', 'G11.427.410.568.900.750'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['A02.633.567', 'A10.690.552.500'], ['G07.265.753', 'G11.561.601'], ['E05.581.249'], ['E05.654'], ['G11.427.695'], ['B01.050.150.900.649.313.500.880'], ['C10.597.350.850', 'C23.888.592.350.850'], ['A08.800.800.720.050.850'], ['J01.897.280.500.846.734', 'J01.897.280.500.898.840', 'L01.178.590.875.840', 'L01.178.820.090.846.734', 'L01.178.820.090.898.840', 'L01.280.940.840', 'L01.280.960.880']]
|
['Organisms [B]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Health Care [N]', 'Diseases [C]', 'Anatomy [A]', 'Phenomena and Processes [G]', 'Technology, Industry, and Agriculture [J]', 'Information Science [L]']
| 1
| 1
| 1
| 0
| 1
| 0
| 1
| 0
| 0
| 1
| 1
| 0
| 1
| 0
|
Evaluating different criteria for defining a complete ambulatory blood pressure monitoring recording: data from the Jackson Heart Study.
|
OBJECTIVE: We determined differences in the prevalence of blood pressure (BP) phenotypes and the association of these phenotypes with left ventricular hypertrophy (LVH) for individuals who fulfilled and did not fulfill various criteria used for defining a complete ambulatory blood pressure monitoring (ABPM) recording.METHODS: We analyzed data for 1141 participants from the Jackson Heart Study. Criteria evaluated included having greater than or equal to 80% of planned readings with more than or equal to one reading per hour (Spanish ABPM Registry criteria), more than or equal to 70% of planned readings with a minimum of 20 daytime and seven nighttime readings (2013 European Society of Hypertension criteria), greater than or equal to 14 daytime and greater than or equal to seven nighttime readings (2003 European Society of Hypertension criteria), more than or equal to 10 daytime and more than or equal to 5 nighttime readings (International Database of Ambulatory Blood Pressure in Relation to Cardiovascular Outcome criteria), and greater than or equal to 14 daytime readings (UK National Institute of Health and Clinical Excellence criteria).RESULTS: Between 45.0% (Spanish ABPM Registry) and 91.8% (UK National Institute of Health and Clinical Excellence) of the participants fulfilled the different criteria for a complete ABPM recording. Across the various criteria evaluated, 55.5-57.8% of participants had nocturnal hypertension and 62.8-66.8% had nondipping systolic BP. Among participants with clinic-measured systolic/diastolic BP of more than or equal to 140/90 mmHg, 22.9-26.5% had white-coat hypertension. The prevalence of daytime, 24-h, sustained, and masked hypertension differed by up to 2% for participants fulfilling each criterion. The association of BP phenotypes with LVH was similar for participants who fulfilled versus those who did not fulfill different criteria (each P>0.05).CONCLUSION: Irrespective of the criteria used for defining a complete ABPM recording, the prevalence of BP phenotypes and their association with LVH were similar.
|
['Aged', 'Blood Pressure', 'Blood Pressure Monitoring, Ambulatory', 'Female', 'Humans', 'Hypertension', 'Hypertrophy, Left Ventricular', 'Male', 'Middle Aged', 'Photoperiod', 'White Coat Hypertension']
| 29,240,564
|
[['M01.060.116.100'], ['E01.370.600.875.249', 'G09.330.380.076'], ['E01.370.370.140.100', 'E01.370.520.500.100'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['C14.907.489'], ['C14.280.195.400', 'C23.300.775.250.400'], ['M01.060.116.630'], ['G01.910.675'], ['C14.907.489.907']]
|
['Named Groups [M]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Phenomena and Processes [G]', 'Organisms [B]', 'Diseases [C]']
| 0
| 1
| 1
| 0
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 1
| 0
| 0
|
Restoration of resistance to osmotic swelling of vitrified mouse embryos by short-term culture.
|
In cryopreservation of mammalian embryos, embryos can be injured by osmotic swelling during removal of the cryoprotectant after warming. We have shown that vitrified embryos are more sensitive to osmotic swelling than fresh cells but that sensitivity is reduced or abolished if vitrified cells are cultured for a short period before subjecting them to hypotonic stress. In the present study, we examined the mechanism by which vitrified two-cell mouse embryos regain their resistance to osmotic swelling by culturing the embryos in the presence of various inhibitors before hypotonic treatment. New synthesis of RNA and proteins during culture was not required for regaining resistance to osmotic swelling because actinomycin D and cycloheximide failed to inhibit restoration. Inhibitors of polymerization of microfilaments and microtubules (cytochalasin B and demecolcine, respectively) also did not affect restoration of resistance to osmotic swelling, suggesting that rearrangement or repolymerization of cytoskeletal components is not involved in this process. On the other hand, brefeldin A and concanamycin A, which inhibit intracellular vesicular transport, strongly suppressed restoration of resistance. These results suggest that the intracellular vesicular transport system plays a crucial role in restoration of resistance of vitrified embryos to osmotic swelling during short-term culture.
|
['Animals', 'Anti-Bacterial Agents', 'Brefeldin A', 'Cryopreservation', 'Cycloheximide', 'Cytochalasin B', 'Dactinomycin', 'Demecolcine', 'Embryo Transfer', 'Embryo, Mammalian', 'Macrolides', 'Mice', 'Osmotic Pressure', 'Protein Synthesis Inhibitors']
| 10,413,570
|
[['B01.050'], ['D27.505.954.122.085'], ['D02.540.576.500.875'], ['E01.370.225.500.620.760.160', 'E01.370.225.750.600.760.160', 'E02.792.156', 'E05.200.500.620.760.160', 'E05.200.750.600.760.160', 'E05.760.156'], ['D03.383.621.808.240'], ['D03.633.100.473.231.370', 'D23.946.587.370.370'], ['D03.633.300.200', 'D04.345.566.252', 'D12.644.641.252'], ['D03.132.225.374'], ['E02.875.800.500', 'E05.820.800.500'], ['A16.254'], ['D02.540.505', 'D02.540.576.500', 'D04.345.674.500'], ['B01.050.150.900.649.313.992.635.505.500'], ['G01.374.715.578', 'G02.640.249', 'G02.723.661'], ['D27.505.519.389.760']]
|
['Organisms [B]', 'Chemicals and Drugs [D]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Anatomy [A]', 'Phenomena and Processes [G]']
| 1
| 1
| 0
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 0
|
[Study on the knowledge of and attitude to sexual dysfunction in aged men].
|
OBJECTIVE: To investigate the knowledge of and attitude to sexual dysfunction in aged men, and to discuss the status and needs of male healthcare.METHODS: Two thousand seven hundred and twenty-eight men (40-70 years old) were surveyed on sexual dysfunction using the randomized questionnaire in Xicheng District, Beijing.RESULTS: The prevalence of erectile dysfunction (ED) was 41.2%, and only 12.1% ED patients were to see the doctor. 52.4% aged men thought the sexual life was important or very important during the life, and 55.6% thought ED would exert negative impact on the quality of life and the partner relationship. Although 27.4% knew that ED was a kind of disease, 49.0% thought ED was a nature rule. Compare to the 41.2% ED prevalence, only 9.7% male were dissatisfied with their sexual life, and later ratio was 14.1% among the partner.CONCLUSION: In China, the status of the knowledge of and attitude to sexual dysfunction in aged men was unsatisfactory to some extent. There is a lot of work to do especially in sexual healthcare education and improvement on diagnostic and treatment of sexual dysfunction.
|
['Adult', 'Aged', 'China', 'Coitus', 'Erectile Dysfunction', 'Health Knowledge, Attitudes, Practice', 'Humans', 'Male', 'Middle Aged', 'Prevalence', 'Quality of Life', 'Surveys and Questionnaires']
| 16,281,508
|
[['M01.060.116'], ['M01.060.116.100'], ['Z01.252.474.164'], ['F01.145.802.188', 'G08.686.784.041'], ['C12.294.644.486', 'F03.835.400'], ['F01.100.150.500', 'N05.300.150.410'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['M01.060.116.630'], ['E05.318.308.985.525.750', 'N01.224.935.597.750', 'N06.850.505.400.975.525.750', 'N06.850.520.308.985.525.750'], ['I01.800', 'K01.752.400.750', 'N06.850.505.400.425.837'], ['E05.318.308.980', 'N05.715.360.300.800', 'N06.850.520.308.980']]
|
['Named Groups [M]', 'Geographicals [Z]', 'Psychiatry and Psychology [F]', 'Phenomena and Processes [G]', 'Diseases [C]', 'Health Care [N]', 'Organisms [B]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Anthropology, Education, Sociology, and Social Phenomena [I]', 'Humanities [K]']
| 0
| 1
| 1
| 0
| 1
| 1
| 1
| 0
| 1
| 0
| 0
| 1
| 1
| 1
|
PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease.
|
UNLABELLED: Early identification of chemotherapy-refractory lymphoma patients provides a basis for alternative treatment strategies. Metabolic imaging with (18)F-FDG PET offers functional tissue characterization that is useful for assessing response to therapy. Our objective was to determine the predictive value of (18)F-FDG PET early during chemotherapy (after 1 cycle) and at the completion of chemotherapy for subsequent progression-free survival (PFS) in patients with aggressive non-Hodgkin's lymphoma (NHL) or Hodgkin's disease (HD).METHODS: (18)F-FDG PET (dual-head coincidence camera with attenuation correction) was performed before and after 1 cycle of chemotherapy on 30 patients (17 NHL, 13 HD; mean age, 52.3 +/- 16.0 y). For 23 of the 30 patients, (18)F-FDG PET data were also obtained after the completion of chemotherapy. The patients had a median follow-up of 19 mo (range, 18-24 mo). Follow-up of PFS was compared between patients with positive and negative (18)F-FDG PET results obtained after the first cycle of chemotherapy and at the completion of chemotherapy.RESULTS: Positive (18)F-FDG PET results obtained both after the first cycle and at the completion of therapy were associated with a shorter PFS (median, 5 and 0 mo, respectively) than were negative (18)F-FDG PET results (PFS medians not reached). A statistically significant difference in PFS between positive and negative (18)F-FDG PET results was obtained both after the first cycle and at the completion of chemotherapy (P < or = 0.001). The PFS and (18)F-FDG PET results obtained after the first cycle correlated better than those obtained after the completion of chemotherapy (r(2) = 0.45 vs. 0.17). (18)F-FDG PET had more false-negative results after the last cycle (6/17 cases, or 35%) than after the first cycle (2/13 cases, or 15%). Thus, (18)F-FDG PET had greater sensitivity and positive predictive values after the first cycle (82% vs. 45.5% and 90% vs. 83%, respectively) than after the last cycle.CONCLUSION: (18)F-FDG PET after 1 cycle of chemotherapy is predictive of 18-mo outcome in patients with aggressive NHL and HD and may earlier identify patients who would benefit from more intensive treatment programs.
|
['Antineoplastic Combined Chemotherapy Protocols', 'Female', 'Fluorodeoxyglucose F18', 'Follow-Up Studies', 'Hodgkin Disease', 'Humans', 'Lymphoma, Non-Hodgkin', 'Male', 'Middle Aged', 'Predictive Value of Tests', 'Prognosis', 'Radiopharmaceuticals', 'Sensitivity and Specificity', 'Time Factors', 'Tomography, Emission-Computed', 'Treatment Outcome']
| 12,163,626
|
[['E02.183.750.500', 'E02.319.077.500', 'E02.319.310.037'], ['D09.254.229.500'], ['E05.318.372.500.750.249', 'N05.715.360.330.500.750.350', 'N06.850.520.450.500.750.350'], ['C04.557.386.355', 'C15.604.515.569.355', 'C20.683.515.761.355'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['C04.557.386.480', 'C15.604.515.569.480', 'C20.683.515.761.480'], ['M01.060.116.630'], ['E05.318.370.800.650', 'N05.715.360.325.700.640', 'N06.850.520.445.800.650'], ['E01.789'], ['D27.505.259.843', 'D27.505.519.871', 'D27.720.470.410.650'], ['E05.318.370.800', 'E05.318.740.872', 'G17.800', 'N05.715.360.325.700', 'N05.715.360.750.725', 'N06.850.520.445.800', 'N06.850.520.830.872'], ['G01.910.857'], ['E01.370.350.350.800', 'E01.370.350.600.350.800', 'E01.370.350.710.800', 'E01.370.350.825.800', 'E01.370.384.730.800'], ['E01.789.800', 'N04.761.559.590.800', 'N05.715.360.575.575.800']]
|
['Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Chemicals and Drugs [D]', 'Health Care [N]', 'Diseases [C]', 'Organisms [B]', 'Named Groups [M]', 'Phenomena and Processes [G]']
| 0
| 1
| 1
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 1
| 1
| 0
|
Electrostatic and lipid anchor contributions to the interaction of transducin with membranes: mechanistic implications for activation and translocation.
|
The heterotrimeric G protein transducin is a key component of the vertebrate phototransduction cascade. Transducin is peripherally attached to membranes of the rod outer segment, where it interacts with other proteins at the membrane-cytosol interface. However, upon sustained activation by light, the dissociated G(t)alpha and Gbeta(1)gamma(1) subunits of transducin translocate from the outer segment to other parts of the rod cell. Here we used a computational approach to analyze the interaction strength of transducin and its subunits with acidic lipid bilayers, as well as the range of orientations that they are allowed to occupy on the membrane surface. Our results suggest that the combined constraints of electrostatics and lipid anchors substantially limit the rotational degrees of freedom of the membrane-bound transducin heterotrimer. This may contribute to a faster transducin activation rate by accelerating transducin-rhodopsin complex formation. Notably, the membrane interactions of the dissociated transducin subunits are very different from those of the heterotrimer. As shown previously, Gbeta(1)gamma(1) experiences significant attractive interactions with negatively charged membranes, whereas our new results suggest that G(t)alpha is electrostatically repelled by such membranes. We suggest that this repulsion could facilitate the membrane dissociation and intracellular translocation of G(t)alpha. Moreover, based on similarities in sequence and electrostatic properties, we propose that the properties described for transducin are common to its homologs within the G(i) subfamily. In a broader view, this work exemplifies how the activity-dependent association and dissociation of a G protein can change both the affinity for membranes and the range of allowed orientations, thereby modulating G protein function.
|
['Animals', 'Humans', 'Lipid Bilayers', 'Models, Biological', 'Models, Molecular', 'Protein Structure, Quaternary', 'Protein Subunits', 'Protein Transport', 'Retinal Rod Photoreceptor Cells', 'Rhodopsin', 'Transducin']
| 18,782,760
|
[['B01.050'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['D10.570.510', 'J01.637.087.500.510'], ['E05.599.395'], ['E05.599.595'], ['G02.111.570.820.709.550'], ['D12.776.813'], ['G03.143.700'], ['A08.675.650.850.625.670.650', 'A08.675.650.915.937.670.650', 'A08.800.950.937.670.650', 'A09.371.729.831.625.670.650', 'A11.671.650.850.625.670.650', 'A11.671.650.915.937.670.650'], ['D12.776.543.750.695.955', 'D23.767.930.750.500.500'], ['D08.811.277.040.330.300.200.800', 'D12.644.360.360.940', 'D12.776.157.325.332.940', 'D12.776.476.375.940', 'D12.776.543.325.800']]
|
['Organisms [B]', 'Chemicals and Drugs [D]', 'Technology, Industry, and Agriculture [J]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Phenomena and Processes [G]', 'Anatomy [A]']
| 1
| 1
| 0
| 1
| 1
| 0
| 1
| 0
| 0
| 1
| 0
| 0
| 0
| 0
|
Coronary artery disease alters ventricular repolarization dynamics in type 2 diabetes.
|
Ventricular repolarization dynamics (VRD) is an important predictor of outcome in diabetes. We examined the potential impact of coronary artery disease (CAD) on VRD in type 2 diabetic patients. We recorded 5-minute high-resolution resting electrocardiograms in 38 diabetic patients undergoing elective coronary angiography, and in 38 age- and gender-matched apparently healthy subjects (controls). Using leads-I and -II, time-domain indices of VRD were calculated. Coronary angiography was regarded as positive if >/= 50% stenosis was found. Angiography was positive in 21 diabetic patients (55%). Patients with CAD had a significantly higher degree of VRD than controls (SDNN(QT): 15.81 +/- 7.22 ms versus 8.94 +/- 6.04 ms; P < 0.001, rMSSD(QT): 21.02 +/- 7.07 ms versus 11.18 +/- 7.45 ms; P < 0.001). Ventricular repolarization dynamics in diabetic patients with negative angiograms did not differ from VRD in controls (SDNN(QT): 8.94 +/- 6.04 ms versus 7.44 +/- 5.72 ms; P = 0.67, rMSSD(QT): 11.18 +/- 7.45 ms versus 10.22 +/- 5.35 ms; P = 0.82). CAD increases VRD in patients with type 2 diabetes. Therefore, changes in ventricular repolarization in diabetic patients may be due to silent CAD rather than due to diabetes per se.
|
['Case-Control Studies', 'Coronary Artery Disease', 'Diabetes Mellitus, Type 2', 'Diabetic Angiopathies', 'Double-Blind Method', 'Electrophysiology', 'Female', 'Heart Ventricles', 'Humans', 'Male', 'Middle Aged']
| 15,683,491
|
[['E05.318.372.500.500', 'N05.715.360.330.500.500', 'N06.850.520.450.500.500'], ['C14.280.647.250.260', 'C14.907.137.126.339', 'C14.907.585.250.260'], ['C18.452.394.750.149', 'C19.246.300'], ['C14.907.320', 'C19.246.099.500'], ['E05.318.370.300', 'E05.581.500.300', 'N05.715.360.325.320', 'N06.850.520.445.300'], ['H01.158.344.528', 'H01.158.782.236'], ['A07.541.560'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['M01.060.116.630']]
|
['Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Health Care [N]', 'Diseases [C]', 'Disciplines and Occupations [H]', 'Anatomy [A]', 'Organisms [B]', 'Named Groups [M]']
| 1
| 1
| 1
| 0
| 1
| 0
| 0
| 1
| 0
| 0
| 0
| 1
| 1
| 0
|
Bilateral subthalamic deep brain stimulation initial impact on nonmotor and motor symptoms in Parkinson's disease: An open prospective single institution study.
|
Numerous studies document significant improvement in motor symptoms in patients with Parkinson's disease (PD) after deep brain stimulation of the subthalamic nucleus (STN-DBS). However, little is known about the initial effects of STN-DBS on nonmotor domains.Our objective was to elucidate the initial effects of STN-DBS on non-motor and motor symptoms in PD patients in a 4-month follow-up.This open prospective study followed 24 patients with PD who underwent STN-DBS. The patients were examined using dedicated rating scales preoperatively and at 1 and 4 months following STN-DBS to determine initial changes in motor and nonmotor symptoms. Patients at month 1 after STN-DBS had significantly reduced the Parkinson's disease Questionnaire scores (P = .018) and Scales for Outcomes in Parkinson's disease - Autonomic scores (P = .002); these scores had increased at Month 4 after DBS-STN. Nonmotor Symptoms Scale for Parkinson's Disease had improved significantly at Month 1 (P < .001); at Month 4, it remained significantly lower than before stimulation (P = .036). There was no significant difference in The Parkinson's Disease Sleep Scaleat Month 1 and significant improvement at Month 4 (P = .026). There were no significant changes in The Female Sexual Function Index or International Index of Erectile Function. Movement Disorder Society Unified Parkinson's Disease Rating Scale, Part III scores show significant improvements at Month 1 (P < .001) and at Month 4 (P < .001).STN-DBS in patients with advanced PD clearly improves not only motor symptoms, but also several domains of nonmotor functions, namely sleep, autonomic functions and quality of life quickly following the start of stimulation.
|
['Adult', 'Aged', 'Deep Brain Stimulation', 'Female', 'Follow-Up Studies', 'Humans', 'Male', 'Middle Aged', 'Motor Activity', 'Parkinson Disease', 'Prospective Studies', 'Subthalamic Nucleus', 'Time Factors', 'Treatment Outcome']
| 29,384,860
|
[['M01.060.116'], ['M01.060.116.100'], ['E02.331.300', 'E04.190'], ['E05.318.372.500.750.249', 'N05.715.360.330.500.750.350', 'N06.850.520.450.500.750.350'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['M01.060.116.630'], ['F01.145.632', 'G11.427.410.698'], ['C10.228.140.079.862.500', 'C10.228.662.600.400', 'C10.574.928.750'], ['E05.318.372.500.750.625', 'N05.715.360.330.500.750.650', 'N06.850.520.450.500.750.650'], ['A08.186.211.200.317.800.800'], ['G01.910.857'], ['E01.789.800', 'N04.761.559.590.800', 'N05.715.360.575.575.800']]
|
['Named Groups [M]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Health Care [N]', 'Organisms [B]', 'Psychiatry and Psychology [F]', 'Phenomena and Processes [G]', 'Diseases [C]', 'Anatomy [A]']
| 1
| 1
| 1
| 0
| 1
| 1
| 1
| 0
| 0
| 0
| 0
| 1
| 1
| 0
|
Antiviral activity of bacteria-derived human alpha interferons against encephalomyocarditis virus infection of mice.
|
Bacteria-derived human leukocyte interferon (IFN) subtypes, IFN-alpha A, -alpha B, and -alpha D, and two hybrid IFNs, IFN-alpha AD and -alpha DA, were examined for both in vitro and in vivo antiviral activity. Two of these materials in highly purified form (IFN-alpha D and -alpha D) protect mice against lethal doses of encephalomyocarditis virus infection. A single dose of 1 microgram of protein of IFN-alpha D 3 h before infection conferred protection in both BDF1 and CD-1 mice against encephalomyocarditis virus infection, and multiple treatments with IFN-alpha D or IFN-alpha AD extend the mean survival time of infected mice. On a weight basis, IFN-alpha AD was approximately 100-fold more effective than IFN-alpha D. There is a direct correlation between the antiviral activity of the various human IFN species in L-929 cells and in mice for both single and multiple treatments before infection, but none of the cloned human IFN subtypes were effective when administered 24 h after infection. Mixtures of the two parental materials, IFN-alpha A and -alpha D, were not as protective as the hybrid molecule IFN-alpha AD, suggesting that IFNs with unique and altered species specificity can be produced by recombinant DNA methods.
|
['Animals', 'Cattle', 'Cell Line', 'Cloning, Molecular', 'Encephalomyocarditis virus', 'Enterovirus Infections', 'Escherichia coli', 'Female', 'Humans', 'Interferons', 'Mice', 'Plasmids', 'Time Factors']
| 6,173,327
|
[['B01.050'], ['B01.050.150.900.649.313.500.380.271'], ['A11.251.210'], ['E05.393.220'], ['B04.820.578.750.170.200'], ['C01.925.782.687.359'], ['B03.440.450.425.325.300', 'B03.660.250.150.180.100'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['D12.644.276.374.440', 'D12.776.467.374.440', 'D23.529.374.440'], ['B01.050.150.900.649.313.992.635.505.500'], ['G05.360.600'], ['G01.910.857']]
|
['Organisms [B]', 'Anatomy [A]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Diseases [C]', 'Chemicals and Drugs [D]', 'Phenomena and Processes [G]']
| 1
| 1
| 1
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 0
|
Olfactory impairment is more marked in patients with mild dementia with Lewy bodies than those with mild Alzheimer disease.
|
BACKGROUND: Dementia patients with anosmia are more likely to have Lewy body pathology at postmortem, but clinicopathological studies have only assessed olfaction in moderate dementia or an average of 5 years before death. It is not known whether, in patients with mild dementia (MMSE score over 20), olfactory function is more impaired in Alzheimer disease (AD) than dementia with Lewy bodies (DLB).METHODS: Patients with mild DLB (n = 21), mild AD (n = 27), mild cognitive impairment (MCI) (n = 21) and controls (n = 47) were assessed using a 16-item olfactory identification test and an olfactory threshold test which used sticks impregnated with differing concentrations of butanol.RESULTS: Patients with mild DLB had impaired olfactory identification ability compared with those with mild AD or MCI, independent of age, cognitive function and sex. The sensitivity of a cutoff score of seven correct responses out of 16 was 0.81 for distinguishing mild DLB from mild AD (AUC 0.682). The specificity, positive predictive value and negative predictive value for the same cut-off score were 0.41, 0.48 and 0.73, respectively. The olfactory threshold was not different in the AD and DLB groups.CONCLUSIONS: Simple bedside tests of olfactory identification merit further examination for their potential to improve the identification of patients with DLB when used alongside existing criteria. They are insufficiently specific for use in screening.
|
['Aged', 'Aged, 80 and over', 'Alzheimer Disease', 'Cognition Disorders', 'Diagnosis, Differential', 'Female', 'Humans', 'Lewy Body Disease', 'Male', 'Mental Status Schedule', 'Olfaction Disorders', 'Point-of-Care Systems', 'ROC Curve', 'Sensory Thresholds']
| 19,448,090
|
[['M01.060.116.100'], ['M01.060.116.100.080'], ['C10.228.140.380.100', 'C10.574.945.249', 'F03.615.400.100'], ['F03.615.250'], ['E01.171'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['C10.228.140.079.862.400', 'C10.228.140.380.422', 'C10.228.662.600.200', 'C10.574.928.500', 'F03.615.400.512'], ['F04.711.513.603.500', 'F04.711.513.653.574'], ['C10.597.751.600', 'C23.888.592.763.550'], ['N04.452.442.452.452.680', 'N04.452.515.360.652', 'N04.590.874'], ['E05.318.370.800.750', 'E05.318.740.872.750', 'N05.715.360.325.700.680', 'N06.850.520.445.800.750'], ['F02.463.593.710']]
|
['Named Groups [M]', 'Diseases [C]', 'Psychiatry and Psychology [F]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Organisms [B]', 'Health Care [N]']
| 0
| 1
| 1
| 0
| 1
| 1
| 0
| 0
| 0
| 0
| 0
| 1
| 1
| 0
|
The diagnosis of pelviureteric junction obstruction.
|
The distinction between a dilated upper urinary tract which is obstructed and a dilated but unobstructed system is of fundamental importance. This differentiation may be difficult to make with methods of diagnosis currently available. Standard intravenous urography provides good morphological information about the collecting system but is unreliable in the assessment of urodynamic upper tract function and renal parenchymal function. Pressure/flow studies may provide useful urodynamic information but the method has certain disadvantages. Standard probe renography is unreliable in differentiating upper urinary tract stasis from obstruction. A quantitative method of diuretic urography and a new quantitative gamma-camera renal radionuclide investigation are described and the results of these investigations are compared with urodynamic studies in patients with upper urinary tract obstruction at the level of the pelviureteric junction.
|
['Follow-Up Studies', 'Humans', 'Kidney', 'Kidney Pelvis', 'Postoperative Period', 'Radiography', 'Radionuclide Imaging', 'Ureteral Obstruction', 'Urinary Bladder', 'Urodynamics']
| 7,436,292
|
[['E05.318.372.500.750.249', 'N05.715.360.330.500.750.350', 'N06.850.520.450.500.750.350'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['A05.810.453'], ['A05.810.453.537'], ['E04.614.750', 'N02.421.585.753.750'], ['E01.370.350.700'], ['E01.370.350.710', 'E01.370.384.730'], ['C12.777.725.776', 'C13.351.968.725.776'], ['A05.810.890'], ['G08.852.898']]
|
['Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Health Care [N]', 'Organisms [B]', 'Anatomy [A]', 'Diseases [C]', 'Phenomena and Processes [G]']
| 1
| 1
| 1
| 0
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 0
| 1
| 0
|
Risk factors for community-acquired pneumonia in immunocompetent seniors.
|
OBJECTIVES: To identify risk factors for developing community-acquired pneumonia (CAP) in seniors.DESIGN: Nested case-control study.SETTING: Group Health, a health maintenance organization in Washington state.PARTICIPANTS: One thousand one hundred seventy-three immunocompetent seniors with CAP and 2,346 age- and sex-matched controls, sampled during influenza seasons and pre-influenza periods of 2000/01 and 2002/03. CAP cases were presumptively identified according to diagnosis codes assigned to outpatient and inpatient encounters and validated according to review of chest radiograph reports or medical records.MEASUREMENTS: Medical records were used to assess body mass, the presence and severity of cardiopulmonary and other chronic diseases, and the presence of functional or cognitive impairments. Use of prescription medications and inpatient, outpatient, and home medical services were identified from administrative databases.RESULTS: Independent predictors of CAP include the presence and severity of cardiopulmonary disease, low weight and recent weight loss, and poor functional status; 42.0% of pneumonia cases can be attributed to underlying cardiopulmonary disease.CONCLUSION: Seniors with cardiopulmonary disease, poor functional status, low weight, or recent weight loss have a greater risk of developing CAP. Preventative efforts should be targeted toward these individuals.
|
['Aged', 'Aged, 80 and over', 'Body Weight', 'Cardiovascular Diseases', 'Case-Control Studies', 'Community-Acquired Infections', 'Female', 'Frail Elderly', 'Humans', 'Influenza, Human', 'Logistic Models', 'Male', 'Pneumonia', 'Risk Assessment', 'Risk Factors', 'Washington', 'Weight Loss']
| 19,453,307
|
[['M01.060.116.100'], ['M01.060.116.100.080'], ['C23.888.144', 'E01.370.600.115.100.160.120', 'E05.041.124.160.750', 'G07.100.100.160.120', 'G07.345.249.314.120'], ['C14'], ['E05.318.372.500.500', 'N05.715.360.330.500.500', 'N06.850.520.450.500.500'], ['C01.234'], ['M01.060.116.100.540'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['C01.748.310', 'C01.925.782.620.365', 'C08.730.310'], ['E05.318.740.500.525', 'E05.318.740.600.800.450', 'E05.318.740.750.450', 'E05.599.835.875', 'N05.715.360.750.530.480', 'N05.715.360.750.625.700.450', 'N05.715.360.750.695.470', 'N06.850.520.830.500.525', 'N06.850.520.830.600.800.450', 'N06.850.520.830.750.450'], ['C01.748.610', 'C08.381.677', 'C08.730.610'], ['E05.318.740.600.800.715', 'N04.452.871.715', 'N05.715.360.750.625.700.690', 'N06.850.505.715', 'N06.850.520.830.600.800.715'], ['E05.318.740.600.800.725', 'N05.715.350.200.700', 'N05.715.360.750.625.700.700', 'N06.850.490.625.750', 'N06.850.520.830.600.800.725'], ['Z01.107.567.875.560.900', 'Z01.107.567.875.580.900'], ['C23.888.144.243.963', 'G07.345.249.314.120.200.963']]
|
['Named Groups [M]', 'Diseases [C]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Phenomena and Processes [G]', 'Health Care [N]', 'Organisms [B]', 'Geographicals [Z]']
| 0
| 1
| 1
| 0
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 1
| 1
| 1
|
Pro inflammatory interleukins and thyroid function in Naswar (dipping tobacco) users: a case control study.
|
BACKGROUND: Naswar is a type of finely ground, moistened smokeless dipping tobacco product being commonly used in Pakistan. Although, nicotine is the most important psychoactive agent present in Naswar, it also exerts immunosuppressive effects and could alter the levels of cytokines. Additionally, the effects of Naswar consumption on thyroid hormones are not known.METHODS: Eighty healthy males aged 16-43 years were selected for the study and were divided into a control group comprising 31 healthy subjects with no history of tobacco use in any form, with age matched test group comprising 49 exclusive Naswar users who were consuming Naswar for at least 1 year. Estimation of serum interleukin (IL)-1â, IL-6, free thyroxine (FT4), free triiodothyronine (FT3) and thyroid stimulating hormone (TSH) was carried out. The data was analyzed by statistical programme (SPSS) using student's independent samples t-test. One way Anova followed by post hoc Tukey test was applied to assess parameters in Naswar users grouped according to duration of Naswar usage. Pearson's correlation coefficient was applied to assess correlations between parameters.RESULTS: IL-1â was found to be significantly lowered in Naswar users compared to the control group whereas serum FT3 and FT4 levels in Naswar users were significantly raised compared to the control group. However, no differences in the levels of serum IL-6 and TSH between Naswar users and the control group were found. Also, serum FT3 and FT4 were consistently raised whereas IL-1â was lowered in Naswar users irrespective of duration of Naswar consumption. IL-1â was negatively correlated with FT3 in Naswar users.CONCLUSION: The findings suggest that Naswar users might be in an immune suppressive state as evident by the lowered levels of interleukin 1â. Additionally, alterations in the levels of thyroid hormones signify the impact of Naswar consumption on thyroid function.
|
['Adolescent', 'Adult', 'Humans', 'Interleukin-1beta', 'Interleukin-6', 'Male', 'Pakistan', 'Thyroid Function Tests', 'Thyroid Gland', 'Thyrotropin', 'Thyroxine', 'Tobacco Use', 'Triiodothyronine']
| 27,515,932
|
[['M01.060.057'], ['M01.060.116'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['D12.644.276.374.465.010.600', 'D12.644.276.374.500.400.600', 'D12.776.467.374.465.010.600', 'D12.776.467.374.500.400.600', 'D23.529.374.465.131.600', 'D23.529.374.500.400.600'], ['D12.644.276.374.465.224', 'D12.776.467.374.465.202', 'D23.529.374.465.224'], ['Z01.252.245.723'], ['E01.370.374.750'], ['A06.300.900'], ['D06.472.699.631.525.883', 'D12.644.548.691.525.883'], ['D06.472.931.812', 'D12.125.072.050.767'], ['F01.145.958'], ['D06.472.931.740.385', 'D12.125.072.050.767.741.894']]
|
['Named Groups [M]', 'Organisms [B]', 'Chemicals and Drugs [D]', 'Geographicals [Z]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Anatomy [A]', 'Psychiatry and Psychology [F]']
| 1
| 1
| 0
| 1
| 1
| 1
| 0
| 0
| 0
| 0
| 0
| 1
| 0
| 1
|
Impact of Sarcopenic Obesity on Failure to Rescue from Major Complications Following Pancreaticoduodenectomy for Cancer: Results from a Multicenter Study.
|
BACKGROUND: Failure to rescue (FTR) is a quality-of-care indicator in pancreatic surgery, but may also identify patients who may not tolerate major postoperative complications despite being treated with best available care. Previous studies found that high visceral adipose tissue-to-skeletal muscle ratio is associated with poor outcomes following pancreaticoduodenectomy (PD). The aim of the study is to assess the impact of sarcopenic obesity on occurrence of FTR from major complications in cancer patients undergoing PD.METHODS: Prospectively collected data from three high-volume hospitals were reviewed. Total abdominal muscle area (TAMA) and visceral fat area (VFA) were assessed at preoperative staging computed tomography scan. Sarcopenic obesity was defined as high VFA/TAMA ratio. FTR was defined as postoperative mortality following major complication.RESULTS: 120 patients with major complications were included. FTR occurred in 23 (19.2%) patients. The "seminal" complications leading to FTR were pancreatic or biliary fistula-related sepsis (n = 14), postoperative pancreatic fistula (POPF)-related hemorrhage (n = 5), and duodenojejunal anastomosis leak-related sepsis (n = 1). On univariate analysis, older age [odds ratio (OR) 3.5, p = 0.034], American Society of Anesthesiologists (ASA) score 3+ (OR 4.2, p = 0.005), cardiovascular disease (OR 3.3, p = 0.013), low serum albumin (OR 2.6, p = 0.042), sarcopenic obesity (OR 4.2, p = 0.009), POPF (OR 3.1, p = 0.027), and cardiorespiratory complications (OR 3.7, p = 0.011) were significantly associated with FTR. On multivariate analysis, sarcopenic obesity [OR 5.7, 95% confidence interval (CI) 1.6-20.7, p = 0.008], ASA score 3+ (OR 4.1, 95% CI 1.2-14.3, p = 0.025), and pancreatic fistula (OR 3.2, 95% CI 1.0-10.2, p = 0.045) were independently associated with FTR.CONCLUSION: Sarcopenic obesity, low preoperative physical status, and occurrence of pancreatic fistula are associated with significantly higher risk of FTR from major complications after PD.
|
['Abdominal Muscles', 'Aged', 'Aged, 80 and over', 'Anastomotic Leak', 'Failure to Rescue, Health Care', 'Female', 'Health Status', 'Humans', 'Intra-Abdominal Fat', 'Male', 'Obesity', 'Pancreatic Fistula', 'Pancreatic Neoplasms', 'Pancreaticoduodenectomy', 'Postoperative Hemorrhage', 'Preoperative Period', 'Retrospective Studies', 'Sarcopenia', 'Sepsis', 'Tomography, X-Ray Computed']
| 29,116,490
|
[['A02.633.567.050'], ['M01.060.116.100'], ['M01.060.116.100.080'], ['C23.550.767.071'], ['E01.789.800.760.500', 'H01.770.644.145.431.500', 'N04.761.559.590.800.760.500', 'N05.715.360.575.575.800.760.500'], ['I01.240.425', 'N01.224.425', 'N06.850.505.400.425'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['A10.165.114.830.500.500'], ['C18.654.726.500', 'C23.888.144.699.500', 'E01.370.600.115.100.160.120.699.500', 'G07.100.100.160.120.699.500'], ['C06.267.775', 'C06.689.583', 'C23.300.575.185.775'], ['C04.588.274.761', 'C04.588.322.475', 'C06.301.761', 'C06.689.667', 'C19.344.421'], ['E04.210.760'], ['C23.550.414.941', 'C23.550.767.850'], ['E04.614.937', 'N02.421.585.753.937'], ['E05.318.372.500.500.500', 'E05.318.372.500.750.750', 'N05.715.360.330.500.500.500', 'N05.715.360.330.500.750.825', 'N06.850.520.450.500.500.500', 'N06.850.520.450.500.750.825'], ['C10.597.613.612.500', 'C23.300.070.500.500', 'C23.888.592.608.612.500'], ['C01.757', 'C23.550.470.790.500'], ['E01.370.350.350.810', 'E01.370.350.600.350.700.810', 'E01.370.350.700.700.810', 'E01.370.350.700.810.810', 'E01.370.350.825.810.810']]
|
['Anatomy [A]', 'Named Groups [M]', 'Diseases [C]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Disciplines and Occupations [H]', 'Health Care [N]', 'Anthropology, Education, Sociology, and Social Phenomena [I]', 'Organisms [B]', 'Phenomena and Processes [G]']
| 1
| 1
| 1
| 0
| 1
| 0
| 1
| 1
| 1
| 0
| 0
| 1
| 1
| 0
|
mda-7/IL-24 expression inhibits breast cancer through upregulation of growth arrest-specific gene 3 (gas3) and disruption of â1 integrin function.
|
Melanoma differentiation-associated gene (MDA)-7)/interleukin (IL)-24, a member of the IL-10 family of cytokines, inhibits growth of various human cancer cells, yet the underlying mechanism is largely unknown. Here, we report that mda-7/IL-24 efficiently suppresses the development of rat mammary tumors in vivo. Microarray analysis for genes differentially expressed in rat mammary tumor cells overexpressing MDA-7/IL-24 compared with those that do not express this cytokine identified growth arrest-specific gene-3 (gas3) as a target for mda-7/IL-24. Upregulation of gas3 by mda-7/IL-24 was STAT3 dependent. Induction of gas3 inhibited attachment and proliferation of tumor cells in vitro and in vivo by inhibiting the interaction of â1 integrin with fibronectin. A mutated GAS3, which is unable to bind â1 integrin, was also unable to inhibit fibronectin-mediated attachment and cell growth both in adherent and suspension cultures, suggesting that GAS3 exerts its effects through interaction with and regulation of â1 integrin. Thus, mda-7/IL-24 inhibits breast cancer growth, at least in part, through upregulation of GAS3 and disruption of â1 integrin function. Importantly, the expression of the mda-7/IL-24 receptor, IL-20R1, is highly correlated with GAS3 expression in human breast cancer (P = 1.02 ? 10(-9)), and the incidence of metastases is significantly reduced in patients with HER2(+) breast cancer expressing high-levels of IL-20R1. Together, our results identify a novel MDA-7/IL-24-GAS3-â1integrin-fibronectin signaling pathway that suppresses breast cancer growth and can be targeted for therapy.
|
['Adenoviridae', 'Animals', 'Breast Neoplasms', 'Carcinogenesis', 'Cell Adhesion', 'Cell Line, Tumor', 'Cell Proliferation', 'Female', 'Fibronectins', 'Gene Expression Regulation, Neoplastic', 'Glycosylation', 'Humans', 'Integrin beta1', 'Interleukins', 'Ligands', 'Mammary Neoplasms, Animal', 'Mice', 'Mice, Nude', 'Mutation', 'Myelin Proteins', 'Protein Binding', 'Rats', 'Receptors, Interleukin', 'Treatment Outcome', 'Up-Regulation']
| 23,468,528
|
[['B04.280.030'], ['B01.050'], ['C04.588.180', 'C17.800.090.500'], ['C04.697.098', 'C23.550.727.098'], ['G04.022'], ['A11.251.210.190', 'A11.251.860.180'], ['G04.161.750', 'G07.345.249.410.750'], ['D12.776.377.715.390', 'D12.776.395.550.350', 'D12.776.543.550.350', 'D12.776.860.300.450'], ['G05.308.370'], ['G02.111.158.812', 'G02.607.299', 'G03.191.812'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['D12.776.543.750.705.408.200.500'], ['D12.644.276.374.465', 'D12.776.467.374.465', 'D23.529.374.465'], ['D27.720.470.480'], ['C04.588.531', 'C22.520'], ['B01.050.150.900.649.313.992.635.505.500'], ['B01.050.150.900.649.313.992.635.505.500.550.500'], ['G05.365.590'], ['D12.776.543.620', 'D12.776.631.580'], ['G02.111.679', 'G03.808'], ['B01.050.150.900.649.313.992.635.505.700'], ['D12.776.543.750.705.852.420'], ['E01.789.800', 'N04.761.559.590.800', 'N05.715.360.575.575.800'], ['G02.111.905', 'G05.308.850', 'G07.690.773.998']]
|
['Organisms [B]', 'Diseases [C]', 'Phenomena and Processes [G]', 'Anatomy [A]', 'Chemicals and Drugs [D]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Health Care [N]']
| 1
| 1
| 1
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 0
| 1
| 0
|
Electron spin resonance and electron-spin-echo study of oriented multilayers of L alpha-dipalmitoylphosphatidylcholine water systems.
|
A detailed electron spin resonance (ESR) study of spin-labeled-oriented multilayers of L alpha-dipalmitoylphosphatidylcholine (DPPC) water systems for low water content (2-10% by weight) is reported with the purpose of characterizing the dynamical and structural properties of model membrane systems. Emphasis is placed on the value of combining such experiments with detailed simulations based on current slow-motional theories. Information is obtained regarding ordering and anisotropic rotational diffusion rates via ESR lineshape analysis over the entire motional range, from the fast motional region through the moderately slow and slow to the rigid limit. This includes the low-temperature gel phase, the liquid crystalline L alpha (1) phase and what appears to be a third high-temperature phase above the L alpha phase. Cholestane (CSL) and spin-labeled DPPC (5-PC, 8-PC, and 16-PC) have been used to probe different depths of the bilayer. While CSL and 5-PC both reflect the high ordering of the bilayer close to the lipid-water interface, CSL appears to be located close enough to the water for the nitroxide to be involved in hydrogen bonding with water molecules. 16-PC reflects the relatively low ordering near the tail of the hydrocarbon chain in the bilayer. Quantitative estimates of ordering and motion are obtained for these cases. The results from CSL indicate that close to the lipid-water interface the DPPC molecule is oriented approximately perpendicular to the bilayer in these low water-content systems. However, all three labeled lipid probes indicate that the hydrocarbon chain of DPPC may be bent away from the bilayer normal by as much as 30 degrees and this evidence is stronger at low temperatures. When cholesterol is added to the DPPC-water system at a concentration greater than or equal to 2.5 mol %, the ordering is greatly increased although the rotational diffusion rate remains almost unaffected in the gel phase. Electron spin echoes (ESE) are observed for the first time from oriented lipid-water multilayers. Results obtained from cw ESR lineshape analysis are correlated with data from ESE experiments, which give a more direct measurement of relaxation times. These results indicate that for detection of very slow motions (close to the rigid limit) ESE experiments are more sensitive to dynamics than continuous wave ESR for which inhomogeneous broadening becomes a major problem.
|
['Electron Spin Resonance Spectroscopy', 'Liposomes', 'Molecular Conformation', 'Pulmonary Surfactants', 'Thermodynamics', 'Water']
| 2,996,648
|
[['E05.196.867.519.274'], ['D25.479.517', 'D26.255.260.517', 'J01.637.051.479.517', 'J01.637.087.500.517'], ['G02.111.570.820'], ['D27.505.954.796.600'], ['G01.906'], ['D01.045.250.875', 'D01.248.497.158.459.650', 'D01.650.550.925']]
|
['Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Chemicals and Drugs [D]', 'Technology, Industry, and Agriculture [J]', 'Phenomena and Processes [G]']
| 0
| 0
| 0
| 1
| 1
| 0
| 1
| 0
| 0
| 1
| 0
| 0
| 0
| 0
|
Effect of intravenous methylprednisolone on the number, size and confluence of plaques in relapsing-remitting multiple sclerosis.
|
The aim of the present study was to evaluate whether intravenous methylprednisolone (IVMP) pulses affect the confluence and enlargement of T2 lesions in the long term in patients with relapsing-remitting (RR) multiple sclerosis (MS). Of 88 RR MS patients, randomly assigned to regular pulses of IVMP (1 g/day for 5 days with an oral prednisone taper) or IVMP on the same dose schedule only for relapses, and followed up without other disease-modifying drug therapy for 5 years, 81 patients completed the trial as planned. Pulsed IVMP was given every 4 months for 3 years, and then every 6 months for the subsequent 2 years. Calculations were performed for number, size and lesion volume (LV) of T2- and confluent T2-lesions. At study entry, the number, size and LV of T2- and confluent T2-lesions were well matched in the two study arms. At the end of the study, patients who received IVMP pulses every 4-6 months for 5 years had significantly fewer confluent T2 lesions (105 vs. 270, p<0.0001), lower confluent T2-LV (5.4 ml vs. 17.4 ml, p<0.00001), fewer large T2 lesions (>10 mm) (165 vs. 541, p<0.00001), and lower T2-LV/N degrees T2 lesion index (0.52 vs. 1.1, p=0.007) when compared to patients who received IVMP only for relapses. There were more small T2 lesions (1082 vs. 288, p<0.000001) in the IVMP pulsed arm. Patients who received higher total doses of IVMP showed the smallest changes in confluent T2-LV during the study. This study suggests that treatment with pulses of IVMP may prevent the confluence of T2 lesions, which may in turn contribute to slower progression of disability in the long term. However, pulsed IVMP treatment did not significantly slow down accumulation of overall T2-LV and there were more smaller T2 lesions in the IVMP pulsed arm at the end of the study.
|
['Adolescent', 'Adult', 'Anti-Inflammatory Agents', 'Central Nervous System', 'Disease Progression', 'Dose-Response Relationship, Drug', 'Drug Administration Schedule', 'Female', 'Humans', 'Injections, Intravenous', 'Magnetic Resonance Imaging', 'Male', 'Methylprednisolone', 'Middle Aged', 'Multiple Sclerosis, Relapsing-Remitting', 'Nerve Fibers, Myelinated', 'Recurrence', 'Severity of Illness Index', 'Treatment Outcome']
| 17,945,260
|
[['M01.060.057'], ['M01.060.116'], ['D27.505.954.158'], ['A08.186'], ['C23.550.291.656'], ['G07.690.773.875', 'G07.690.936.500'], ['E02.319.283'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['E02.319.267.082.750', 'E02.319.267.530.540'], ['E01.370.350.825.500'], ['D04.210.500.745.432.769.795.539'], ['M01.060.116.630'], ['C10.114.375.500.600', 'C10.314.350.500.600', 'C20.111.258.250.500.600'], ['A08.675.542.512', 'A11.671.501.512', 'A11.671.514'], ['C23.550.291.937'], ['E05.318.308.980.438.475.456.500', 'N05.715.360.300.800.438.375.364.500', 'N06.850.520.308.980.438.475.364.500'], ['E01.789.800', 'N04.761.559.590.800', 'N05.715.360.575.575.800']]
|
['Named Groups [M]', 'Chemicals and Drugs [D]', 'Anatomy [A]', 'Diseases [C]', 'Phenomena and Processes [G]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Organisms [B]', 'Health Care [N]']
| 1
| 1
| 1
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 1
| 1
| 0
|
Validation of the HEM-780REL with easy wrap cuff for self-measurement of blood pressure according to the European Society of Hypertension International Protocol.
|
OBJECTIVE: We tested the accuracy of the HEM-780REL automatic blood pressure monitor with Easy Wrap Cuff.METHODS: We used the International Protocol for validation of blood pressure measuring devices developed by the Working Group on Blood Pressure Monitoring of the European Society of Hypertension. Thirty-three adults over the age of 30 years participated to have 11 total participants in each of the three required blood pressure ranges for systolic and diastolic blood pressure. Sequential blood pressure readings were taken independently by trained observers using a mercury standard with appropriate size cuff. A third observer performed measurements with the test device. Analyses were performed according to International Protocol specifications for the 99 pairs of measurements. The device was given a pass/fail recommendation based on bands of accuracy compared with the mercury standard (within 5, 10, or 15 mmHg), as well as number of readings per participant within 5 mmHg.RESULTS: The mean blood pressure difference was 0.52+/-7.7 mmHg for systolic blood pressure and 0.39+/-4.7 mmHg for diastolic blood pressure. Twenty-four out of 33 participants had two out of three readings within 5 mmHg of the mercury standard for systolic blood pressure. Twenty-seven out of 33 participants had two out of three readings within 5 mmHg of the mercury standard for diastolic blood pressure. The device received a passing grade both for accuracy of individual measurements and for accuracy for individuals.CONCLUSION: The HEM-780REL with Easy Wrap Cuff performs accurately according to the standards of the International Protocol.
|
['Adult', 'Blood Pressure', 'Blood Pressure Determination', 'Blood Pressure Monitoring, Ambulatory', 'Blood Pressure Monitors', 'Diastole', 'Europe', 'Female', 'Humans', 'Hypertension', 'Male', 'Middle Aged', 'Reference Values', 'Reproducibility of Results', 'Societies, Medical', 'Systole']
| 17,890,973
|
[['M01.060.116'], ['E01.370.600.875.249', 'G09.330.380.076'], ['E01.370.370.140', 'E01.370.600.100'], ['E01.370.370.140.100', 'E01.370.520.500.100'], ['E07.230.740.100'], ['G09.330.580.295', 'G11.427.494.554.250', 'G11.427.494.570.295'], ['Z01.542'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['C14.907.489'], ['M01.060.116.630'], ['E05.978.810'], ['E05.318.370.725', 'E05.337.851', 'N05.715.360.325.685', 'N06.850.520.445.725'], ['N03.540.828.589'], ['G09.330.580.880', 'G11.427.494.570.880']]
|
['Named Groups [M]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Phenomena and Processes [G]', 'Geographicals [Z]', 'Organisms [B]', 'Diseases [C]', 'Health Care [N]']
| 0
| 1
| 1
| 0
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 1
| 1
| 1
|
An AFLP estimation of the outcrossing rate of Spondias tuberosa (Anacardiaceae), an endemic species to the Brazilian semiarid region.
|
The umbu tree (Spondias tuberosa) is one of the most important endemic species to the Brazilian tropical semiarid region. The umbu tree has edible fruits with a peculiar flavor that are consumed in natura or in a semi-industrialized form, such as jams, candies and juices. The majority of endemic species to Brazilian semiarid region have not been studied or sampled to form germ-plasm collections, which increases the risk of losing genetic variability of the adapted species to xerophytic conditions. The aim of this study was to estimate outcrossing rates in S. tuberosa using a multilocus mixed model in order to guide genetic resources and breeding programs of this species. DNA samples were extracted from 92 progenies of umbu trees, which were distributed among 12 families. These trees were planted by seed in 1991 in Petrolina, PE, Brazil. The experimental design was a randomized block, with a total of 42 progenies sampled in three regions. The experimental units were composed by five plants and five replications. The outcrossing rate was estimated by the multilocus model, which is available in the MLTR software, and was based on 17 polymorphic AFLP bands obtained from AAA_CTG and AAA_CTC primer combinations. The observed heterozygotes ranged from 0.147 to 0.499, with a maximum frequency estimated for the AAA_CTC 10 amplicon. The multilocus outcrossing estimation (t(m)) was 0.804 +/- 0.072, while the single-locus (t(s)) was 0.841 +/- 0.079, which suggests that S. tuberosa is predominantly an outcrossing species. The difference between t(m) and t(s) was -0.037 +/- 0.029, which indicates that biparental inbreeding was nearly absent. The mean inbreeding coefficient or fixation index (F) among maternal plants was--0.103 +/- 0.045, and the expected F was 0.108, which indicates that there was no excess of heterozygotes in the maternal population. The outcrossing estimates obtained in the present study indicate that S. tuberosa is an open-pollinated species. Biometrical models applied to this species should therefore take into account the deviation from random outcrossing to estimate genetic parameters and the constitution of broad germplasm samples to preserve the genetic variability of the species. Outcrossing rates based on AFLP and the mixed-mating model should be applied to other studies of plant species in the Brazilian semiarid region.
|
['Amplified Fragment Length Polymorphism Analysis', 'Anacardiaceae', 'Brazil', 'Crosses, Genetic', 'Inbreeding']
| 23,885,576
|
[['E05.393.290.382', 'E05.393.620.500.324'], ['B01.650.940.800.575.912.250.044'], ['Z01.107.757.176'], ['E05.393.281'], ['E05.820.150.520', 'G05.090.403']]
|
['Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Organisms [B]', 'Geographicals [Z]', 'Phenomena and Processes [G]']
| 0
| 1
| 0
| 0
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 1
|
Innovative Nanosensor for Disease Diagnosis.
|
As a futuristic diagnosis platform, breath analysis is gaining much attention because it is a noninvasive, simple, and low cost diagnostic method. Very promising clinical applications have been demonstrated for diagnostic purposes by correlation analysis between exhaled breath components and specific diseases. In addition, diverse breath molecules, which serve as biomarkers for specific diseases, are precisely identified by statistical pattern recognition studies. To further improve the accuracy of breath analysis as a diagnostic tool, breath sampling, biomarker sensing, and data analysis should be optimized. In particular, development of high performance breath sensors, which can detect biomarkers at the ppb-level in exhaled breath, is one of the most critical challenges. Due to the presence of numerous interfering gas species in exhaled breath, selective detection of specific biomarkers is also important. This Account focuses on chemiresistive type breath sensors with exceptionally high sensitivity and selectivity that were developed by combining hollow protein templated nanocatalysts with electrospun metal oxide nanostructures. Nanostructures with high surface areas are advantageous in achieving high sensitivity because the sensing signal is dominated by the surface reaction between the sensing layers and the target biomarkers. Furthermore, macroscale pores between one-dimensional (1D) nanostructures can facilitate fast gas diffusion into the sensing layers. To further enhance the selectivity, catalytic functionalization of the 1D metal oxide nanostructure is essential. However, the majority of conventional techniques for catalytic functionalization have failed to achieve a high degree of dispersion of nanoscale catalysts due to aggregation on the surface of the metal oxide, which severely deteriorates the sensing properties by lowering catalytic activity. This issue has led to extensive studies on monolithically dispersed nanoscale particles on metal oxides to maximize the catalytic performances. As a pioneering technique, a bioinspired templating route using apoferritin, that is, a hollow protein cage, has been proposed to obtain nanoscale (?2 nm) catalyst particles with high dispersity. Nanocatalysts encapsulated by a protein shell were first used in chemiresistive type breath sensors for catalyst functionalization on 1D metal oxide structures. We discuss the robustness and versatility of the apoferrtin templating route for creating highly dispersive catalytic NPs including single components (Au, Pt, Pd, Rh, Ag, Ru, Cu, and La) and bimetallic catalysts (PtY and PtCo), as well as the core-shell structure of Au-Pd (Au-core@Pd-shell). The use of these catalysts is essential to establish high performance sensors arrays for the pattern recognition of biomarkers. In addition, novel multicomponent catalysts provide unprecedented sensitivity and selectivity. With this in mind, we discuss diverse synthetic routes for nanocatalysts using apoferritin and the formation of various catalyst-1D metal oxide composite nanostructures. Furthermore, we discuss detection capability of a simulated biomarker gas using the breath sensor arrays and principal component analysis. Finally, future prospects with the portable breath analysis platform are presented by demonstrating the potential feasibility of real-time and on-site breath analysis using chemiresistive sensors.
|
['Biosensing Techniques', 'Breath Tests', 'Catalysis', 'Diagnosis', 'Humans', 'Nanotechnology']
| 28,481,075
|
[['E05.601.043'], ['E01.370.100'], ['G02.130'], ['E01'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['H01.603', 'J01.897.520.600']]
|
['Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Phenomena and Processes [G]', 'Organisms [B]', 'Disciplines and Occupations [H]', 'Technology, Industry, and Agriculture [J]']
| 0
| 1
| 0
| 0
| 1
| 0
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 0
|
Coronavirus (COVID-19) outbreak: what the department of endoscopy should know.
|
Italy recorded its first case of confirmed acute respiratory illness because of coronavirus on February 18, 2020, soon after the initial reports in China. Since that time, Italy and nations throughout the world have adopted very stringent and severe measures to protect populations from spread of infection. Despite these measures, the number of infected people is growing exponentially, with a significant number of patients developing acute respiratory insufficiency. Endoscopy departments face significant risk for diffusion of respiratory diseases that can be spread via an airborne route, including aspiration of oral and fecal material via endoscopes. The purpose of this article is to discuss the measures, with specific focus on personal protection equipment and dress code modalities, implemented in our hospital to prevent further dissemination of COVID-19 infection.
|
['Betacoronavirus', 'COVID-19', 'Coronavirus Infections', 'Endoscopy', 'Humans', 'Infection Control', 'Infectious Disease Transmission, Patient-to-Professional', 'Pandemics', 'Personal Protective Equipment', 'Pneumonia, Viral', 'SARS-CoV-2']
| 32,179,106
|
[['B04.820.578.500.540.150.113'], ['C01.748.214', 'C01.748.610.763.500', 'C01.925.705.500', 'C01.925.782.600.550.200.163', 'C08.381.677.807.500', 'C08.730.214', 'C08.730.610.763.500'], ['C01.925.782.600.550.200'], ['E01.370.388.250', 'E04.502.250'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['N06.850.780.200.450'], ['N06.850.335.500'], ['N06.850.290.200.600'], ['E07.700.560', 'J01.637.708.560'], ['C01.748.610.763', 'C01.925.705', 'C08.381.677.807', 'C08.730.610.763'], ['B04.820.578.500.540.150.113.968']]
|
['Organisms [B]', 'Diseases [C]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Health Care [N]', 'Technology, Industry, and Agriculture [J]']
| 0
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 1
| 0
| 0
| 1
| 0
|
Structural investigations of neuromelanin by pyrolysis-gas chromatography/mass spectrometry.
|
Pyrolysis combined with gas chromatography and mass spectrometry (Py-GC/MS) was applied for structural investigations of the human substantia nigra neuromelanin. Using synthetic neuromelanins, we have demonstrated that Py-GC/MS is suitable for identification and differentiation of both eumelanin (dopamine-derived) and pheomelanin (cysteinyldopamine-derived) component of the pigment. Structural information on melanin monomers was inferred from their pyrolytic markers. When the human neuromelanin was subjected to pyrolysis, none of the heterocyclic, sulfur-containing markers of pheomelanin component was detected among the thermal degradation products. We have concluded that nigral pigment isolated from normal brain tissue does not contain benzothiazine-type monomers, and that cysteinyldopamine-originated units may be incorporated into the polymer in uncyclized form. The most abundant pyrolysis product was identified as limonene, which indicates that nigral pigment is tightly associated with an isoprenoid-type compound. Pyrolysis in the presence of the methylating reagent allowed identification of high levels of saturated and monounsaturated straight-chain C14-C18 fatty acid species chemically bound to the pigment macromolecule.
|
['Gas Chromatography-Mass Spectrometry', 'Humans', 'Melanins', 'Pigments, Biological', 'Substantia Nigra']
| 16,755,376
|
[['E05.196.181.349.500', 'E05.196.566.500'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['D12.125.072.050.875.379', 'D23.767.620'], ['D23.767'], ['A08.186.211.132.659.413.656']]
|
['Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Organisms [B]', 'Chemicals and Drugs [D]', 'Anatomy [A]']
| 1
| 1
| 0
| 1
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 0
| 0
| 0
|
Sequence and comparative genomic analysis of actin-related proteins.
|
Actin-related proteins (ARPs) are key players in cytoskeleton activities and nuclear functions. Two complexes, ARP2/3 and ARP1/11, also known as dynactin, are implicated in actin dynamics and in microtubule-based trafficking, respectively. ARP4 to ARP9 are components of many chromatin-modulating complexes. Conventional actins and ARPs codefine a large family of homologous proteins, the actin superfamily, with a tertiary structure known as the actin fold. Because ARPs and actin share high sequence conservation, clear family definition requires distinct features to easily and systematically identify each subfamily. In this study we performed an in depth sequence and comparative genomic analysis of ARP subfamilies. A high-quality multiple alignment of approximately 700 complete protein sequences homologous to actin, including 148 ARP sequences, allowed us to extend the ARP classification to new organisms. Sequence alignments revealed conserved residues, motifs, and inserted sequence signatures to define each ARP subfamily. These discriminative characteristics allowed us to develop ARPAnno (http://bips.u-strasbg.fr/ARPAnno), a new web server dedicated to the annotation of ARP sequences. Analyses of sequence conservation among actins and ARPs highlight part of the actin fold and suggest interactions between ARPs and actin-binding proteins. Finally, analysis of ARP distribution across eukaryotic phyla emphasizes the central importance of nuclear ARPs, particularly the multifunctional ARP4.
|
['Actins', 'Animals', 'Conserved Sequence', 'Genome', 'Internet', 'Mice', 'Models, Molecular', 'Mutagenesis, Insertional', 'Nucleic Acid Hybridization', 'Phylogeny', 'Protein Conformation', 'Protein Folding', 'Protein Structure, Secondary', 'Sequence Deletion']
| 16,195,354
|
[['D05.750.078.730.250', 'D12.776.210.500.100', 'D12.776.220.525.255'], ['B01.050'], ['G02.111.570.580'], ['G05.360.340'], ['L01.224.230.110.500'], ['B01.050.150.900.649.313.992.635.505.500'], ['E05.599.595'], ['E05.393.420.601.550', 'G05.365.590.575', 'G05.558.550'], ['E05.393.661', 'G02.111.611'], ['G05.697', 'G16.075.605', 'L01.100.697'], ['G02.111.570.820.709'], ['G01.154.651', 'G02.111.688'], ['G02.111.570.820.709.600'], ['G05.365.590.762', 'G05.558.800']]
|
['Chemicals and Drugs [D]', 'Organisms [B]', 'Phenomena and Processes [G]', 'Information Science [L]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]']
| 0
| 1
| 0
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 1
| 0
| 0
| 0
|
In Vitro Description of Macroscopic Changes of Dental Amalgam Discs Subject to High Temperatures to Forensic Purposes.
|
OBJECTIVE: To describe the behavior of 45 discs of dental amalgam of known dimension prepared from three commercially available brands of dental amalgam (Contour® Kerr®-USA, Admix® SDI®-Australia and Nu Alloy® Newstethic®-Colombia) when subjected to the action of high temperatures (200 °C, 400 °C, 600 °C, 800 °C, 1000 °C). It was hoped to establish parameters that could be used for human dental identification in cases of charred, burned or incinerated human remains.MATERIALS AND METHODS: A pseudo-experimental descriptive in-vitro study was designed to describe the macroscopic physical changes to the surface of 45 discs of pre-prepared amalgam of three commercially available brands exposed to a range of high temperatures.RESULTS: Characteristic and repetitive physical changes were a noticeable feature of the discs of amalgam of each brand of amalgam subjected to the different temperature ranges. These physical changes included changes in dimensional stability, changes in texture, changes in colour, changes in the appearance of fissures and cracks and changes in the fracture and fragmentation of the sample.CONCLUSIONS: The characteristics of dental amalgam may be of assistance in cases of human identification where charred, burned or incinerated human remains are a feature and where fingerprints or other soft tissue features are unavailable.
|
['Cross-Sectional Studies', 'Dental Amalgam', 'Forensic Dentistry', 'Hot Temperature', 'Humans', 'In Vitro Techniques', 'Materials Testing', 'Microscopy']
| 26,851,445
|
[['E05.318.372.500.875', 'N05.715.360.330.500.875', 'N06.850.520.450.500.875'], ['D25.339.208.291', 'J01.637.051.339.208.291'], ['H02.163.285', 'I01.198.780.875'], ['G01.906.595.543', 'G16.500.275.063.725.710.380', 'G16.500.750.775.710.380', 'N06.230.300.100.725.232', 'N06.230.300.100.725.710.380'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['E05.481'], ['E05.570'], ['E01.370.350.515', 'E05.595', 'H01.671.617.562']]
|
['Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Health Care [N]', 'Chemicals and Drugs [D]', 'Technology, Industry, and Agriculture [J]', 'Disciplines and Occupations [H]', 'Anthropology, Education, Sociology, and Social Phenomena [I]', 'Phenomena and Processes [G]', 'Organisms [B]']
| 0
| 1
| 0
| 1
| 1
| 0
| 1
| 1
| 1
| 1
| 0
| 0
| 1
| 0
|
Color vision in attention-deficit/hyperactivity disorder: a pilot visual evoked potential study.
|
BACKGROUND: Individuals with attention-deficit/hyperactivity disorder (ADHD) are reported to manifest visual problems (including ophthalmological and color perception, particularly for blue-yellow stimuli), but findings are inconsistent. Accordingly, this study investigated visual function and color perception in adolescents with ADHD using color Visual Evoked Potentials (cVEP), which provides an objective measure of color perception.METHOD: Thirty-one adolescents (aged 13-18), 16 with a confirmed diagnosis of ADHD, and 15 healthy peers, matched for age, gender, and IQ participated in the study. All underwent an ophthalmological exam, as well as electrophysiological testing color Visual Evoked Potentials (cVEP), which measured the latency and amplitude of the neural P1 response to chromatic (blue-yellow, red-green) and achromatic stimuli.RESULT: No intergroup differences were found in the ophthalmological exam. However, significantly larger P1 amplitude was found for blue and yellow stimuli, but not red/green or achromatic stimuli, in the ADHD group (particularly in the medicated group) compared to controls.CONCLUSION: Larger amplitude in the P1 component for blue-yellow in the ADHD group compared to controls may account for the lack of difference in color perception tasks. We speculate that the larger amplitude for blue-yellow stimuli in early sensory processing (P1) might reflect a compensatory strategy for underlying problems including compromised retinal input of s-cones due to hypo-dopaminergic tone.
|
['Adolescent', 'Analysis of Variance', 'Attention Deficit Disorder with Hyperactivity', 'Case-Control Studies', 'Color Perception', 'Contrast Sensitivity', 'Evoked Potentials, Visual', 'Female', 'Humans', 'Male', 'Photic Stimulation', 'Pilot Projects', 'Refraction, Ocular', 'Visual Acuity']
| 25,435,188
|
[['M01.060.057'], ['E05.318.740.150', 'N05.715.360.750.125', 'N06.850.520.830.150'], ['F03.625.094.150'], ['E05.318.372.500.500', 'N05.715.360.330.500.500', 'N06.850.520.450.500.500'], ['F02.463.593.932.217'], ['E01.370.380.850.950.500', 'F02.463.593.778.435.110', 'F02.463.593.932.281', 'F02.463.593.932.901.500', 'G14.940.500'], ['G07.265.216.500.425', 'G11.561.200.500.425', 'G14.330'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['E05.723.729'], ['E05.318.372.750', 'E05.337.737', 'N05.715.360.330.720', 'N06.850.520.450.720'], ['E01.370.380.850.700', 'G01.590.775', 'G14.760'], ['E01.370.380.850.950', 'F02.463.593.932.901', 'G14.940']]
|
['Named Groups [M]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Health Care [N]', 'Psychiatry and Psychology [F]', 'Phenomena and Processes [G]', 'Organisms [B]']
| 0
| 1
| 0
| 0
| 1
| 1
| 1
| 0
| 0
| 0
| 0
| 1
| 1
| 0
|
ZUFSP Deubiquitylates K63-Linked Polyubiquitin Chains to Promote Genome Stability.
|
Deubiquitylating enzymes (DUBs) enhance the dynamics of the versatile ubiquitin (Ub) code by reversing and regulating cellular ubiquitylation processes at multiple levels. Here we discovered that the uncharacterized human protein ZUFSP (zinc finger with UFM1-specific peptidase domain protein/C6orf113/ZUP1), which has been annotated as a potentially inactive UFM1 protease, and its fission yeast homolog Mug105 define a previously unrecognized class of evolutionarily conserved cysteine protease DUBs. Human ZUFSP selectively interacts with and cleaves long K63-linked poly-Ub chains by means of tandem Ub-binding domains, whereas it displays poor activity toward mono- or di-Ub substrates. In cells, ZUFSP is recruited to and regulates K63-Ub conjugates at genotoxic stress sites, promoting chromosome stability upon replication stress in a manner dependent on its catalytic activity. Our findings establish ZUFSP as a new type of linkage-selective cysteine peptidase DUB with a role in genome maintenance pathways.
|
['Binding Sites', 'Bone Neoplasms', 'Cell Line, Tumor', 'DNA Damage', 'Deubiquitinating Enzymes', 'Genomic Instability', 'HEK293 Cells', 'Humans', 'Lysine', 'Osteosarcoma', 'Polyubiquitin', 'Protein Binding', 'Protein Interaction Domains and Motifs', 'Retinal Pigment Epithelium', 'Substrate Specificity', 'Ubiquitination']
| 29,576,528
|
[['G02.111.570.120'], ['C04.588.149', 'C05.116.231'], ['A11.251.210.190', 'A11.251.860.180'], ['G05.200'], ['D08.811.037'], ['C23.550.362', 'G05.365.590.335', 'G05.370'], ['A11.251.210.172.750', 'A11.436.334'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['D12.125.068.555', 'D12.125.095.647', 'D12.125.142.497'], ['C04.557.450.565.575.650', 'C04.557.450.795.620'], ['D12.776.947.500.500'], ['G02.111.679', 'G03.808'], ['G02.111.570.820.709.275.750.500'], ['A09.371.670.500', 'A09.371.729.887'], ['G02.111.835'], ['G02.111.660.871.790.600.925', 'G02.111.691.600.775', 'G03.734.871.790.600.831', 'G05.308.670.600.831']]
|
['Phenomena and Processes [G]', 'Diseases [C]', 'Anatomy [A]', 'Chemicals and Drugs [D]', 'Organisms [B]']
| 1
| 1
| 1
| 1
| 0
| 0
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 0
|
Pneumonia associated with aspiration following stroke.
|
OBJECTIVE: To determine the association between demonstrated aspiration and pneumonia in stroke patients.METHODS: Chart review of 441 consecutive stroke patients admitted to a stroke rehabilitation unit within 4 months of their stroke over an 8-year period. Videofluoroscopic modified barium swallow (VMBS) was performed on all patients suspected of aspirating. In all patients, the presence or absence of pneumonia was noted.RESULTS: Eighty-four of the 441 (19.0%) stroke patients transferred for rehabilitation demonstrated aspiration of thin liquids on VMBS. Twelve of the 441 (2.7%) developed pneumonia while in hospital, either in the acute or rehabilitation phases. The incidence of pneumonia among proven aspirators on VMBS was 10 of 84 (11.9%) patients. Two of the 357 (0.6%) patients who were presumed nonaspirators developed pneumonia. Brain stem and right hemispheric stroke patients had a higher incidence of pneumonia.CONCLUSIONS: Pneumonia is an uncommon complication of stroke. However, approximately 12% of stroke rehabilitation patients diagnosed as aspirators on VMBS developed pneumonia, a 20-fold increase over presumed nonaspirators. VMBS is a potentially valuable tool in determining those patients at risk of aspiration pneumonia.
|
['Acute Disease', 'Barium Sulfate', 'Cerebrovascular Disorders', 'Fluoroscopy', 'Humans', 'Incidence', 'Pneumonia, Aspiration', 'Retrospective Studies', 'Risk Factors', 'Videotape Recording']
| 8,669,999
|
[['C23.550.291.125'], ['D01.103.075', 'D01.875.800.800.850.075'], ['C10.228.140.300', 'C14.907.253'], ['E01.370.350.700.225'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['E05.318.308.985.525.375', 'N01.224.935.597.500', 'N06.850.505.400.975.525.375', 'N06.850.520.308.985.525.375'], ['C01.748.610.529', 'C08.381.677.529', 'C08.730.610.529'], ['E05.318.372.500.500.500', 'E05.318.372.500.750.750', 'N05.715.360.330.500.500.500', 'N05.715.360.330.500.750.825', 'N06.850.520.450.500.500.500', 'N06.850.520.450.500.750.825'], ['E05.318.740.600.800.725', 'N05.715.350.200.700', 'N05.715.360.750.625.700.700', 'N06.850.490.625.750', 'N06.850.520.830.600.800.725'], ['J01.897.280.500.846.734', 'J01.897.280.500.898.840', 'L01.178.590.875.840', 'L01.178.820.090.846.734', 'L01.178.820.090.898.840', 'L01.280.940.840', 'L01.280.960.880']]
|
['Diseases [C]', 'Chemicals and Drugs [D]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Organisms [B]', 'Health Care [N]', 'Technology, Industry, and Agriculture [J]', 'Information Science [L]']
| 0
| 1
| 1
| 1
| 1
| 0
| 0
| 0
| 0
| 1
| 1
| 0
| 1
| 0
|
Internal Structure Analysis of a Tobacco Control Network on the U.S.-M?xico Border.
|
Tobacco control (TC) networks (in which multiple agencies collaborate) are essential components within comprehensive TC efforts. The aim of this study was to assess the internal coalition outcomes hierarchy model (via the Internal Coalition Effectiveness [ICE] scale) in the present sample. Participants (members of a TC Network on the U.S.-M?xico border; independent Waves 1 [N = 30] and 2 [N = 33; at a 1-year subsequent assessment]) completed a background questionnaire and an adapted version of the ICE scale. Mean values for ICE subscales suggested a strong enthusiasm of Network members and recognition of the importance of a cohesive social vision, employment of efficient practices, a need for improved and maintained knowledge/training, and stable social relationships among members. However, no significant differences were observed between data waves in the ICE subscales, multivariate analysis of variance: ë = .97, F(4, 43) = 0.31, p > .86. Considering a multifaceted assessment may enhance the understanding of the dynamics and strengths of the Network. Finally, including an assessment of the leadership's perspective regarding internal coalition outcome hierarchy model constructs to compare them with members' perspective is warranted.
|
['Analysis of Variance', 'Cooperative Behavior', 'Health Promotion', 'Humans', 'Interinstitutional Relations', 'Mexico', 'Surveys and Questionnaires', 'Texas', 'Tobacco Industry', 'Tobacco Use Cessation', 'United States']
| 25,384,580
|
[['E05.318.740.150', 'N05.715.360.750.125', 'N06.850.520.830.150'], ['F01.145.813.115'], ['I02.233.332.445', 'N02.421.726.407.579'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['N04.452.822.400'], ['Z01.107.567.589'], ['E05.318.308.980', 'N05.715.360.300.800', 'N06.850.520.308.980'], ['Z01.107.567.875.760.750'], ['J01.576.655.968'], ['F01.145.488.750'], ['Z01.107.567.875']]
|
['Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Health Care [N]', 'Psychiatry and Psychology [F]', 'Anthropology, Education, Sociology, and Social Phenomena [I]', 'Organisms [B]', 'Geographicals [Z]', 'Technology, Industry, and Agriculture [J]']
| 0
| 1
| 0
| 0
| 1
| 1
| 0
| 0
| 1
| 1
| 0
| 0
| 1
| 1
|
Immunosuppressive therapies after intestinal transplant modulate the expression of Th1 signature genes during acute cellular rejection. Implications in the search for rejection biomarkers.
|
BACKGROUND AND AIMS: Acute cellular rejection (ACR) and infections are leading causes of graft loss and death in intestinal transplant patients. Our aim was to evaluate the impact of maintenance immunosuppressive therapies on the expression of pro-inflammatory mediators in small bowel at ACR diagnosis.MATERIALS AND METHODS: We analyzed expression levels of Th1-associated genes, IFNG, CXCL10, and CXCL11 by qPCR in 46 selected graft biopsies unequivocally assigned to mild ACR (n = 14) or normal histopathology and clinical condition (n = 32) from 15 patients receiving two different immunosuppressive (IS) schemes. Double treatment: corticosteroids and tacrolimus (n = 17) and triple treatment: sirolimus or mycophenolate mofetil in addition to the basal therapy (n = 29).RESULTS: IFNG, CXCL10, and CXCL11 were induced during rejection (p < 0.05; p < 0.005, and p < 0.05, respectively). However, when rejection and control groups were classified according to immunosuppressive treatment, in the rejection group, significant differences of IFNG, CXCL10, and CXCL11 expression (p < 0.001; p < 0.005, and 0.01, respectively) were detected, whereas no differences were observed in the control group.CONCLUSION: Gene expression of Th1 response mediators is higher during ACR. Triple IS group showed significantly lower expression of pro-inflammatory Th1 mediators during mild ACR indicating that use of these markers to monitor rejection can be affected by the IS treatment used.
|
['Adult', 'Biomarkers', 'Case-Control Studies', 'Chemokine CXCL10', 'Chemokine CXCL11', 'Female', 'Follow-Up Studies', 'Graft Rejection', 'Humans', 'Immunosuppressive Agents', 'Interferon-gamma', 'Intestinal Diseases', 'Intestine, Small', 'Male', 'Postoperative Complications', 'Prognosis', 'Real-Time Polymerase Chain Reaction', 'Risk Factors', 'Th1 Cells']
| 25,251,331
|
[['M01.060.116'], ['D23.101'], ['E05.318.372.500.500', 'N05.715.360.330.500.500', 'N06.850.520.450.500.500'], ['D12.644.276.374.200.120.500', 'D12.776.467.374.200.120.500', 'D23.125.300.120.500', 'D23.469.200.120.500', 'D23.529.374.200.120.500'], ['D12.644.276.374.200.120.550', 'D12.776.467.374.200.120.550', 'D23.125.300.120.550', 'D23.469.200.120.550', 'D23.529.374.200.120.550'], ['E05.318.372.500.750.249', 'N05.715.360.330.500.750.350', 'N06.850.520.450.500.750.350'], ['G12.875.545.328'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['D27.505.696.477.656'], ['D12.644.276.374.440.893', 'D12.644.276.374.480.615.350', 'D12.776.467.374.440.893', 'D12.776.467.374.480.615.350', 'D23.529.374.440.893', 'D23.529.374.480.615.350'], ['C06.405.469'], ['A03.556.124.684'], ['C23.550.767'], ['E01.789'], ['E05.393.620.500.706'], ['E05.318.740.600.800.725', 'N05.715.350.200.700', 'N05.715.360.750.625.700.700', 'N06.850.490.625.750', 'N06.850.520.830.600.800.725'], ['A11.118.637.555.567.550.500.400.900', 'A11.118.637.555.567.569.200.400.900', 'A11.118.637.555.567.569.500.400.900', 'A15.145.229.637.555.567.550.500.400.500', 'A15.145.229.637.555.567.569.200.400.500', 'A15.145.229.637.555.567.569.500.400.500', 'A15.382.490.555.567.550.500.400.900', 'A15.382.490.555.567.569.200.400.900', 'A15.382.490.555.567.569.500.400.900']]
|
['Named Groups [M]', 'Chemicals and Drugs [D]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Health Care [N]', 'Phenomena and Processes [G]', 'Organisms [B]', 'Diseases [C]', 'Anatomy [A]']
| 1
| 1
| 1
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 1
| 1
| 0
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.